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1.2 Abbreviations 
Frequently used abbreviations are listed below. Other abbreviations are indicated in the text when appropriate 
 
5-FU   5-fluorouracil 
CEA   Carcinoembryonic antigen 
CTC   Circulating tumor cells 
CRC   Colorectal cancer 
CRM   Circumferential resection margin 
CRT   Chemoradiotherapy 
CT   Computer tomography 
DFS   Disease-free survival 
DLT   Dose-limiting toxicity 
DTC   Disseminated tumor cells 
HAT   Histone acetyl transferase 
HIF-1α   Hypoxia-inducible factor type 1α 
HDAC   Histone deacetylase 
IR   Irradiation 
LARC   Locally advanced rectal cancer 
LARC-RRP  Locally advanced rectal cancer – radiation response prediction  
MFS   Metastasis-free survival 
MRI   Magnetic resonance imaging 
MRF   Mesorectal fascia 
MTD   Maximum-tolerated dose 
NACT   Neoadjuvant chemotherapy 
pCR   Pathological complete response 
OS   Overall survival  
OXA   Oxaliplatin        
PBMC   Peripheral blood mononuclear cells 
PDGFRB  PDGF receptor type β 
PRAVO   Pelvic radiation and vorinostat  
RT-qPCR  Realtime quantitative polymerase chain reaction 
TGD   Tumor growth delay 
TNM   Tumor Node Metastasis 
TRG   Tumor regression grade 
VEGF   Vascular endothelial growth factor A 
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2 Introduction 
Rectal cancer is common in both genders and among all adult age groups, with the highest 
incidence in elderly people. In Europe it has been estimated that nearly 447,000 were diagnosed 
with colorectal cancer (CRC) in 2012; of these cases, about 30% were in the rectal anatomic 
site1. The management of rectal cancer is multidisciplinary, involving precision diagnostics 
within pathology and radiology, along with highly specialized knowledge within oncology and 
surgery (Figure 2.1). The therapy is multimodal; while surgery remains the principal treatment 
modality in achieving tumor clearance, the introduction of neoadjuvant radiotherapy 
administered with radiosensitizing chemotherapeutics has significantly reduced local recurrences 
in patients with locally advanced rectal cancer (LARC) 2,3. The response to neoadjuvant 
chemoradiotherapy (CRT) is nevertheless variable, and even with successful local treatment a 
substantial number of patients develops metastatic disease. Tumor hypoxia is recognized as 
common determinant of resistance to radiotherapy and metastatic disease progression; hence, 
targeting tumor hypoxia in radiation response and metastasis is an appealing strategy to improve 
overall outcome of rectal cancer patients.     
 
              
Figure 2.1 Multimodal treatment in locally advanced rectal cancer. Following diagnostic procedures and staging, 
chemoradiotherapy is given prior to surgery. Treatment response is evaluated and patients are followed for 5 years to 
detect local or distant recurrences. Pictures adapted from www.gastrolab.net, www.danisfoundation.org, Oslo 
University Hospital, and AH Ree; printed with permission. 
Diagnosis and staging Response evaluation and follow-up
Treatment:Neoadjuvant chemoradiotherapy and surgery
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3  Background 
3.1 Rectal cancer 
3.1.1 Epidemiology 
The annual incidence of rectal cancer in the Norwegian population of 5.0 million adds up to 
more than 1,300. The age-adjusted incidence rates per 100 000 persons-years is 17.0 for men and 
11.5 for women, leading to a male:female ratio of 1.5 4*. Most patients have regional disease at 
the time of diagnosis (Table 3.1). The age-specific incidence rates show that rectal cancer is 
mainly a disease of the elderly, with a significant rise in incidence from the age of 60. The 
incidence rates have been stable for more than 30 years but are expected to increase due to an 
aging population 5. Worldwide, CRC incidence rates are highest in the more developed regions 
(Australia, New Zealand, USA and Europe), and Norway has one of the highest incidence rates 
in Europe 1,6.  
 
Five-year relative survival for rectal cancer was 64.8 % for men and 67.9 % for women in 
Norway in 2007-11 and was considerably higher in patients with localized and regional disease 
than in patients with systemic disease (Table 3.1)4. The survival rates (of all stages) of rectal 
cancer have increased over the last 40 years in Norway (Figure 3.1) and are among the highest 
in the world 2,7,8.  
 
 
 
Table 3.1 Age-adjusted incidence rates and 5-year relative survival (%) from rectal cancer according to stage for 
tumors diagnosed 2007-11. Data from the Cancer Registry of Norway.        
                                                 
* Numbers from the Cancer Registry of Norway include tumors of the rectum, rectosigmoid large bowel, and anal 
canal.  
Stage Rate per 100 000 5-year survival (%) Rate per 100 000 5-year survival (%)
Total 17.0 (100%) 65 11.5 (100%) 68
Localized 4.2 (24%) 82 3.3 (29%) 90
Regional 9.0 (53%) 76 5.7 (50%) 74
Distant 3.2 (18%) 16 2.1 (17%) 16
Unknown 0.6 (6%) 56 0 66
Men Women
11 
 
 
            
Figure 3.1 5-year relative survival from rectal cancer by period and gender in 1972-2011. Data from the Cancer 
Registry of Norway.  
 
3.1.2 Diagnosis and staging 
When a rectal tumor is suspected, typically in a patient presenting with rectal bleeding or altered 
stool habits, diagnostic procedures include digital rectal investigation and endoscopy with tumor 
biopsies, to determine the precise site and histopathological characteristics of the tumor. The 
disease site(s) within the pelvic cavity is confirmed by magnetic resonance (MRI) imaging. 
There is no clear anatomical border between the sigmoid colon and the rectum. A rectal tumor is 
by definition located up to 15 cm from the anal verge as determined by rigid endoscopy 
(corresponding to 12 cm when determined by MRI) 9. Rectal cancers are commonly categorized 
into low/mid/high cancers according to their distal edge measured from the anal verge. Most 
rectal cancers are adenocarcinomas, but a small fraction (1-2%) are neuroendocrine tumors with 
different prognosis and treatment 10. A histological subtype of rectal adenocarcinoma (5-15%) is 
the mucinous carcinoma, in which large amounts of mucin are produced. This subtype is 
associated with poorer response to CRT and a poorer prognosis than non-mucinous rectal tumors 
11,12. 
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Prognosis of rectal cancer is highly heterogeneous, and staging of the disease at diagnosis is 
essential to stratify patients into subgroups and accordingly, determine the treatment strategy 
13,14. Among patients with potentially curative disease, some are at high risk of local recurrence 
from surgery alone and will benefit from CRT prior to surgery. If the disease is extensively 
disseminated at diagnosis, symptom palliation and prolonged survival are the aim of treatment; 
in contrast, if metastasis is limited to a single organ, curative treatment is increasingly considered 
possible with multimodal approaches9. Treatment decisions should be made in multi-disciplinary 
teams of specialist surgeons, oncologists, pathologists and radiologists, and be based on patient 
history and examination, and diagnostic and staging procedures 9, 15,16. 
 
Tumor Node Metastasis (TNM) staging 
The TNM system of classification of malignant tumors is also the standard staging system for 
rectal cancer.  It categorizes cancers based on the anatomic extent of disease; size and extent of 
the primary tumor (T-stage), involvement of regional lymph nodes (N-stage) and presence or 
absence of distant metastasis (M-stage)13 (Table 3.2). The prefix “c” denotes clinical staging, 
while histopathologic staging is designated “p”. Clinical or histopathologic staging after 
neoadjuvant therapy is designated by the prefix “yc” or “yp”. 
 
 
Table 3.2 TNM staging of rectal cancer, from the American Joint Committee on Cancer’s Cancer Staging Manual 
7th Edition. Subclassification of T4 was introduced in the 6th Edition, and the order changed in the 7th Edition. 
 
 
TNM stage at diagnosis is determined by imaging (cTNM). MR imaging is the recommended 
modality for the evaluation of tumor extent in the pelvic cavity (extramural T3-4 tumors), while 
endoscopic rectal ultrasound is commonly more accurate for assessing tumor growth into the 
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into the mesorectum
T4
Tumor grows through the mesorectal fascia and invades or is adherent to 
a) the visceral peritoneum 
b) other organs or structures
N0 No regional lymph node metastasis
N1 Metastasis in 1-3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
M0 No distant metastasis
M1 Distant metastasis
T
N
M
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bowel wall (T1-2 tumors)9. Both modalities allow detection of regional lymph node metastases, 
while CT (computed tomography) is used to examine thoracic and abdominal organs for any 
distant metastases17. The most common sites for rectal cancer metastases are the liver, 
peritoneum, and lungs, or more infrequently, the skeleton or the brain.  
 
Mesorectal fascia (MRF) involvement 
The rectum is surrounded by the mesorectum, a fatty layer containing lymph nodes and vessels 
delineated by the mesorectal fascia. The standard surgical technique in rectal cancer, total 
mesorectal excision (TME), involves removal of the rectum and the entire mesorectum to the 
MRF, keeping the tumor and all locally draining lymph nodes intact (Figure 3.2). The surgeon 
dissects in the plane of the MRF, establishing the lateral or circumferential resection margin 
(CRM). The goal of curative surgery is to obtain resection margins with no tumor cells, as 
involvement of resection margins, in particular the CRM, is associated with disease recurrence 
and poor survival 18-21.     
    
           
Figure 3.2 Total mesorectal excision: Sagittal picture of a male pelvis depicting the boundaries for mesorectal 
excision of a rectal adenocarcinoma. Adapted from Bleday R, Shibata D. Surgical oncologic principles for resection of 
primary rectal adenocarcinoma. UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2013. Copyright © 2013. 
Printed with permission. 
 
 
Preoperative MR evaluation can predict if it is possible to achieve a free CRM after surgery 22,23 
If the MRF is involved or positive, defined as proximity (≤1 mm) 24  or actual infiltration by 
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tumor, pathologic lymph nodes or infiltrated vessels into the MRF (Figure 3.3), the risk of an 
involved CRM after surgery is high 9,19. In T4 rectal tumors, the MRF is infiltrated per definition; 
while in T3 tumors the MRF is not infiltrated, but may be classified as positive if the tumor is 
closer than 1 mm.  
 
 
 
 
Figure 3.3 Positive mesorectal fascia (MRF). The MRF is positive if the distance to the MRF from the primary T3 
tumor (T), lymph node metastasis (N) or vessel infiltration is shorter than 1 mm. Adapted from Knut Håkon Hole, Oslo 
University Hospital, printed with permission.  
 
 
 
Currently, TNM stage and predicted distance to MRF are the parameters evaluated in staging at 
diagnosis of rectal cancer in Norway17. Other prognostic factors suggested for inclusion in 
diagnostic staging are tumor location (low tumors spread more easily via venous and lymphatic 
vessels), extent of extramural spread of T3-tumors (> 5mm extramural spread indicates poor 
prognosis), extramural venous invasion and pelvic sidewall lymph node involvement 14,25,26.  
 
3.1.3 Radiotherapy in locally advanced rectal cancer 
While surgery is the principal treatment in rectal cancer, additional cancer therapy is 
administered to patients with locally advanced rectal cancer (LARC) to improve outcome 27.  
The classic definition of LARC is a rectal tumor that grows beyond the rectal wall or has lymph 
node spread to an extent that precludes complete removal by surgery alone, warranting additional 
treatment 3. The definition of LARC has changed with increasing knowledge of risk factors and 
Mesorectal fascia
Rectum
Mesorectum
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with improved staging. In this thesis, the term LARC comprises rectal cancer patients for whom 
neoadjuvant radiotherapy with curative intent is recommended in the Norwegian guidelines: T4 
tumors, T3 tumors within 3 mm from the MRF and tumors of any T stage with pathological 
lymph nodes or vessel infiltration within 3 mm from to the MRF, as assessed by diagnostic MRI 
17 (Figure 3.4). In the national guidelines, the 3 mm margin was recently changed to less than 
2mm.  
 
                   
 
Figure 3.4 Sagittal (A) and transversal (B) magnetic resonance images of middle/low anterior T3 rectal cancer with 
tumor extension within 1 mm from the left seminal vesicle, indicated by arrow. The red line indicates the mesorectal 
fascia. Images provided by Knut Håkon Hole, Oslo University Hospital, printed with permission.  
 
 
 
In LARC, neoadjuvant CRT, consisting of fractionated radiotherapy in combination with 
chemotherapy, is the standard treatment. While LARC traditionally has been associated with 
high risk of local recurrence and poor patient survival, the introduction of the TME surgical 
technique along with neoadjuvant CRT has reduced the rate of local recurrences from up to 40 % 
to about 5% 28-30.  
 
Radiotherapy 
Radiotherapy is given prior to surgery in LARC patients to achieve macroscopic tumor 
downsizing and control of subclinical tumor extension within the pelvic cavity, to enable 
complete tumor removal with sufficient microscopic margins by surgical resection. Preoperative 
radiotherapy as part of LARC treatment was introduced in randomized trials in European 
16 
 
 
countries in the 1980-90’s 31,32. In 2001 a large randomized trial reported reduced risk of local 
recurrence in patients receiving preoperative radiotherapy and surgery compared to surgery alone 
32. Compared to adjuvant treatment, advantages of preoperative radiotherapy include potential 
downsizing of the tumor, less toxicity and higher compliance 33,34. While adjuvant radiotherapy 
was the standard for years in e.g. the USA, the current international standard treatment is 
preoperative radiotherapy combined with chemotherapy.  
 
One of two preoperative radiotherapy regimens are generally applied in rectal cancer; the 
conventional long-course regimen (2 Gy × 25 or 1.8 Gy × 28) with concomitant 5-fluorouracil 
(FU)/capecitabine or a short-course regimen (5 Gy × 5, in one week) 9. Downsizing and 
downstaging effects are more pronounced with the first approach 35,36, and this is the standard 
treatment regimen in LARC in most countries. In Norway the standard neoadjuvant therapy is 
the long-course regimen combined with capecitabine: 23 daily fractions of 2 Gy to macroscopic 
tumor volume and area of risk, followed by 2 daily boost fractions of 2 Gy to macroscopic tumor 
volume, as determined by CT-based planning. Surgery is usually scheduled 6-8 weeks after the 
last radiation dose to allow tumor shrinkage.  
 
 
Neoadjuvant chemoradiotherapy 
Not long after the introduction of preoperative radiotherapy, chemotherapeutic agents that 
sensitize tumor cells to ionizing radiation (i.e. radiosensitizing agents) were integrated into the 
combined modality treatment to improve the efficacy of the radiotherapy 37,38. Three randomized 
phase III studies established preoperative 5FU-based CRT as standard therapy in LARC33,39,40. 
The trials showed a significant reduction in local recurrence rates by preoperative 5-FU-based 
CRT compared to postoperative 5-FU based CRT33 and compared to preoperative radiotherapy 
alone 39,40. The oral fluoropyrimidine capecitabine is a more convenient alternative, and early 
results from trials comparing the two regimens indicate that capecitabine is equivalent to 5-FU 
41,42. 
 
Adding fluoropyrimidine-based chemotherapy to preoperative radiotherapy may increase acute 
and late toxicity in some degree 39,43,44, but the main contributor to the toxicity seen after CRT is 
17 
 
 
the radiotherapy. The standard CRT regimen in rectal cancer is reported to confer considerable 
postoperative morbidity and toxicity in clinical studies 33, 45. Radiotherapy for rectal cancer is 
associated with considerable long-term adverse effects on bowel and anorectal function, 
especially in terms of bowel frequency, urgency and fecal incontinence 43,46. 
 
3.1.4 Response evaluation  
Re-staging of rectal tumors after neoadjuvant therapy is performed to evaluate tumor response 
and potentially modify the subsequent therapy. Parameters of tumor response are often used as 
early surrogate end points for outcome in clinical trials.  
 
Histopathologic tumor response is regarded as the primary outcome of preoperative treatment in 
rectal cancer. The surgical resection margins are evaluated for residual disease, and especially 
the positive CRM status (i.e., residual tumor in the resection margin) is correlated to poor 
prognosis 47 (R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic 
residual tumor)13. Histopathologic TN stage (‘pTN’ or ‘ypTN’ if neoadjuvant therapy is 
administered) is determined by examination of the surgical specimen. Pathological complete 
response (pCR), defined as absence of viable tumor cells in the primary tumor (ypT0), is 
associated with a favorable long-term outcome. The validity of pCR as a prognostic marker have 
been debated, but a recent pooled analysis of more than 3.000 patients found that patients with 
pCR after standard CRT has better long-term outcome than those without pCR 48. While the 
TNM system considers viable tumor cells and not the degree of tumor tissue regression, an 
alternative method to evaluate histopathologic response is tumor regression grade (TRG) 49,50. 
Based on the presence of residual tumor cells and the extent of fibrosis as proposed tumor 
regression in surgically excised rectal tumors can be graded on a scale from 1-5 51 , or more 
simplified, a scale of TRG 1-3. 
 
MR-based radiological methods to evaluate tumor response are currently under investigation52. 
Conventional MR can be used to determine anatomical tumor regression 53 (yTN stage54, TRG 55, 
tumor volume 56-58), while functional MR may determine biological parameters as markers of 
treatment response 59.  
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The ultimate evaluation of response to treatment in clinical trials is 5-year overall survival 
(OS)51, while other survival endpoints, e.g., disease-free survival (DFS) or metastases-free 
survival (MFS), may also be used depending on the setting60. 
 
3.1.5  Strategies to improve rectal cancer treatment 
Although the local control with standard CRT treatment is good for the majority of LARC 
patients, some patients experience poor response to the treatment. These patients could benefit 
from further improvement of the neoadjuvant treatment. Intensification of treatment by 
integration of combination chemotherapy into the standard single-agent (fluoropyrimidine-based) 
CRT has been investigated in clinical trials. Addition of oxaliplatin (OXA) is being investigated 
in clinical phase III trials. Results of the early endpoints (i.e. pCR and toxicity) are 
disappointing, although results of long-term endpoints are awaited 42,61-65. Integration of 
molecularly targeted agents as radiosensitizers in LARC is currently being investigated in early 
clinical trials.  
 
The potentially improved local control of intensified treatment must be balanced with the 
increased risk of toxicity. While acute toxicities may cause interruption in the CRT delivery and 
delay definitive surgical treatment, surgical complications and long-term sequelae may strongly 
impede patients’ quality of life 2,28.  
 
Despite reduced rates of local recurrence, distant recurrences remain a significant problem in 
rectal cancer. Local control seems insufficient to reduce the rate of distant recurrences. 20-40% 
of radically treated rectal cancer patients develop metastases 66. Distant metastases are now the 
predominant reason for reduced life expectancy in rectal cancer, and new strategies must include 
focus on distant control. The introduction of systemic chemotherapy in rectal cancer treatment 
has been suggested to target micrometastatic disease. Adjuvant chemotherapy is administered to 
LARC patients in the USA and at many European centers 9. The evidence for a survival benefit 
from adjuvant chemotherapy is debated, and in Norway it is currently not recommended 17,67-69 
70.. Systemic neoadjuvant chemotherapy (NACT) as a supplement to CRT in LARC is under 
investigation in clinical trials 71-75.  
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3.2  Tumor hypoxia  
Hypoxia, oxygenation deficiency, is a hallmark of solid tumors associated with an aggressive 
tumor phenotype, resistance to cytotoxic treatment, and metastatic behavior 76. Tumor hypoxia is 
a result of imbalance between supply and consumption of oxygen 77. As the tumor vasculature 
cannot meet the demands of the cancer cells, solid tumors are invariably less well oxygenated 
compared to the normal tissue of origin 78. In an attempt to improve oxygenation, tumors induce 
the expression of proangiogenic factors activating angiogenesis, the formation of new blood 
vessels. However, tumor vasculature formed by angiogenesis is dysfunctional and unable to 
supply sufficient oxygen to the tumor tissue 79,80 (Figure 3.5). The resulting tumor hypoxia 
stimulates further angiogenesis; establishing a viscous circle of hypoxia and angiogenesis 81.  
 
               
     
Figure 3.5 The vascular network of normal tissue versus tumor tissue. The tumor vessels are malformed and in 
a state of continuous reconfiguration. The vessels are tortuous with blind ends and arterio-venous (AV) shunts. The 
blood flow is poor and erratic, due to the malformations and unpredictable dilatation and constriction of the vessels 
79,80. Adapted from Brown and Wilson 2004, printed with permission.  
 
Tumor hypoxia is a combination of ‘chronic’ (diffusion-limited) and ‘acute’ (perfusion-limited) 
hypoxia. Chronic hypoxia is a result of tumor angiogenesis lagging behind tumor growth and is 
found distal to blood vessels, beyond the diffusion distance of oxygen. Acute hypoxia is located 
in the proximity of poorly functioning tumor vasculature that is temporarily occluded 77,82. 
Hypoxic areas are heterogeneously distributed within tumor volumes, but the tumor-to-tumor 
variability of oxygenation is greater than intra-tumor variability 77. 
Break in 
vessel walls
Hypoxia
Red blood 
cellsAV shunt
Temporary 
occlusion
Blind 
ends
Normal Tumor 
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There is no exact threshold discriminating hypoxia from normoxia, and the term can refer to 
different cell populations in different contexts. Genomic and proteomic responses to hypoxia 
occur at different levels of the hypoxic scale 76,83. Methods to measure hypoxia in human tumors 
are based on three different principles. Firstly, the physical amount of oxygen may be measured 
in tumors accessible for electrode measurement. Secondly, presence of hypoxic metabolic active 
cells can be detected by their ability to reduce specific compounds, i.e. exogenous markers (e.g. 
pimonidazole, Figure 3.6). Lastly, products of biological processes activated by hypoxia can be 
studied as a measure of hypoxia, i.e. endogenous markers (e.g. the hypoxia-inducible factor 
(HIF) type 1α, carbonic anhydrase-IX (CA9), vascular endothelial factor (VEGF)) 76,84. 
Suggested imaging techniques to assess hypoxia are PET (positron emission tomography) 
scanning and functional MRI techniques 85,86. 
 
 
 
 
 
3.2.1 Cellular adaptive responses to hypoxia   
Severe or prolonged hypoxia is detrimental to the cell, but tumor cells undergo a variety of 
adaptive changes enabling them to survive in a hypoxic environment. The adaptive hypoxic 
cellular processes involve alterations in gene expression, collectively contributing to a more 
clinically aggressive phenotype 77,84,87. By exerting a selective pressure on tumor cells, hypoxia 
results in the emergence of tumor cells that favor tumor progression 88,89.  
 
Figure 3.6 A section of a colorectal xenograft that is 
immunohistochemically stained with the exogenous hypoxia 
marker pimonidazole (brown; pimonidazole).   
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The HIF-1α-pathway is the core cellular hypoxic response pathway. The stability and functional 
activity of the transcription factor HIF-1α is oxygen-regulated. In normoxic conditions, HIF-1α 
is inactivated by posttranslational modifications and subsequent proteosomal degradation. In 
contrast, under hypoxia, it is stabilized and interacts with the constitutively expressed HIF β 
subunit to form the heterodimeric HIF complex which binds to the hypoxia response element of 
a number of target genes to regulate their transcription 83,90 (Figure 3.7).  Activation of the HIF-
1α-pathway affects numerous target genes. This has implications for a range of cellular processes 
e.g. angiogenesis, glucose metabolism, pH regulation, oxygen transport, DNA repair, apoptosis, 
cell proliferation and cell migration 77,82.  Angiogenesis is stimulated under hypoxia by the HIF-
1α-directed upregulation of VEGF and several other angiogenic factors88.  
 
              
 
Figure 3.7 In hypoxic conditions, HIF-1α interacts with HIF-1β, binds to the HRE (hypoxia response element) and 
regulates genes involved in many cellular processes.  
 
 
3.2.3  Hypoxia and radiation response 
The ‘oxygen effect’, the phenomenon that molecular oxygen influences the biological effect of 
ionizing radiation (IR), was first recognized at the beginning of the 19th century when it was 
observed that skin reactions decreased if the radiation source was pressed tightly to the skin, 
indicating that blood flow could modify radiation response91. In the 1950s, Gray et al 92,93  
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 presented the ‘oxygen fixation hypothesis’ stating that oxygen molecules react with free radicals 
produced by IR to yield stable changes in the chemical composition of DNA (oxygen “fixates” 
the DNA damage) 27,94-96. 
 
Tumor hypoxia also influences cellular radiation response through HIF-1α-induced alterations in 
gene expression. HIF-1α may increase radioresistance of solid tumors, independently of the 
tumor oxygenation status 97,98. HIF-1α-regulated cellular processes that may influence tumor 
radiosensitivity are e.g. DNA repair, apoptosis, metabolism, proliferation and angiogenesis 
96,99,100. The ratio of doses administered under hypoxic versus normoxic conditions, needed to 
achieve the same biological effect, is called the ‘oxygen enhancement ratio’ and is 
characteristically in the order of 2.7-3.0 76.  
 
3.2.2  Hypoxia and metastasis 
While hypoxia has been recognized as a main mechanism involved in tumor resistance to 
radiotherapy for many years, more recent research supports the hypothesis that tumor hypoxia is 
one of the major driving forces of the metastatic process. Experimental and clinical studies have 
shown that hypoxic tumors have increased propensity to develop metastatic disease. Hypoxic 
tumor signaling can affect nearly every step of the metastatic process 81,88. For example, hypoxia 
promotes the processes of endothelial mesenchymal transition (EMT) and intravasation. HIF1α-
signaling in tumor cells may render the tumor vasculature leaky by affecting the cell layers 
tumor cells must cross to reach the circulation 88 (Figure 3.8). The endothelial cells of functional 
vessels are supported by a pericyte coating promoting stability and permeability control. During 
hypoxia-mediated angiogenesis the pericytes detach101. Although the role of pericytes in 
metastasis is still unclear, experimental and clinical studies suggest that poor pericyte coverage is 
associated with development of metastasis 102,103.            
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Figure 3.8 Tumor hypoxia and intravasation. Hypoxia stimulates the development of abnormal tumor vessels, 
characterized by loosely connected endothelial cells, a disrupted basement membrane and detached pericytes 
facilitating intravasation. Tumor-associated macrophages (TAM) stimulate growth of abnormal vessels in hypoxic 
tumors. Hypoxia promotes the biological process termed endothelial mesenchymal transition (EMT). Adapted from 
De Bock et al 2011, printed with permission.  
 
3.2.3 Strategies to target tumor hypoxia 
A number of strategies have been explored to target tumor hypoxia in radiation response. The 
first strategies aimed to overcome the hypoxic radioresistance by improving tumor oxygenation 
during radiotherapy, e.g. hyperbaric oxygenation, carbogen breathing (95% O2), red blood cell 
transfusions and erythropoietin injections 85. Oxygen-mimicking drugs that specifically 
radiosensitize hypoxic cells (e.g. nitroimidazole derivates)76 , hypoxia-activated prodrugs (e.g. 
tirapazamine)104 have been evaluated in clinical trials. With the discovery of HIF-1α, a molecular 
target of the hypoxic response was identified. The approach of targeting hypoxic radioresistance 
by suppression of the radioresistant phenotype of hypoxic tumor cells, is being investigated in 
clinical trials 104,105. This strategy includes targeting HIF-1α itself 106 and targeting proteins in 
HIF-1α-mediated cellular processes influencing radiosensitization (i.e. targeting VEGF 88,97 in 
angiogenesis and CA9 96 in  glycolysis). Several therapeutic agents not originally intended to 
target HIF-1α, are shown to exert effects on this factor 107.  
 
Strategies to target tumor hypoxia in metastatic disease progression has not been widely explored 
yet, although some experimental studies have reported encouraging results by inhibitors of HIF-
1α 108 and of the HIF-1α-regulated CA9 109 and VEGF 88. 
Hypoxia Normoxia
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3.3 The metastatic process 
The main cause of cancer deaths is metastatic disease; the spread of cancer from one organ to 
another non-adjacent organ. The formation of a metastasis is a multistep process involving 
dissemination of cancer cells to distant organ sites and subsequent adaption to the 
microenvironment 110. The cascade includes establishment of a vascular network in the primary 
tumor, invasion of the host stroma, intravasation, survival in the circulation and arrest in a new 
organ where the reverse processes of extravasastion and invasion take place 111 (Figure 3.9). 
 
        
        
      
Figure 3.9 The main steps in the metastasis development. Adapted from Fidler 2003, printed with permission.   
 
 
Primary tumor proliferation and angiogenesis 
When tumors grow beyond a few millimeters in diameter, new blood vessels must be formed to 
support further tumor growth. Hypoxia and nutrient deprivation triggers an ‘angiogenic switch’; 
a change in the balance between angiogenic activators and inhibitors promoting angiogenesis, 
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the formation of new blood vessels 112. The pro-angiogenic factor VEGF which binds to its 
receptors on endothelial cell membranes, is the main regulator of angiogenesis113.  In contrast to 
vasculogenesis, the creation of tumor vessels seen during embryogenesis, angiogenesis involves 
sprouting of new vessels from existing vessels 113.  
 
Capillary vessels are supported by perivascular cells, pericytes 114, that wrap around the 
endothelial tubing to provide stability and permeability control (Figure 3.10). During the process 
of angiogenesis, the pericytes detach from mature blood vessels to permit remodeling of the 
vessels and establishment of a tumor capillary network 112. PDGF, which signals through the 
PDGFRB (PDGF receptor type β) on pericytes, stimulates recruitment of pericytes along the 
advancing endothelial sprout, pericyte attachment and proliferation 115. The pericyte layer of 
tumor vessels is often non-functional, and the neovasculature is commonly prone to leakiness 
and in a state of continuous reconfiguration, facilitating tumor cell intravasation 101,102. 
  
 
 
Local invasion and intravasation 
To reach the circulation, tumor cells must invade the surrounding extracellular matrix (ECM) 
and stromal cell layers and intravasate into the lumina of lymph or blood vessels. To invade the 
ECM, cellular adhesion molecules and ECM components must be degraded through proteolytic 
Pericytes
Figure 3.10 Tumor angiogenesis 
During angiogenesis, stimulatory signals 
within the microenvironment induce 
pericyte detachment from mature blood 
vessels to allow sprouting of new vessels.   
 
ECM: extracellular matrix; EPC: endothelial 
progenitor cell; MMP: matrix 
metalloproteinases 
 
Adapted from Weis & Cheresh 2011, 
printed with permission.  
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activity, e.g. by matrix metallopreoteases. Cellular migration through the ECM also requires 
tumor cell motility. Altered adhesive properties of tumor cells are necessary to both to promote 
detachment of cells from the primary tumor, and to allow adhesion to ECM proteins and 
endothelial cells. Various cell adhesion molecules, e.g. integrins and cadherins regulate the 
process of adhesion116. During the process of EMT, tumor cells within epithelial sheets lose their 
adherent properties and dissociate into individual motile cells110. To reach the systemic 
circulation after moving through the ECM, cancer cells must cross the layers of pericytes and 
endothelial cells 110, 117.   
 
Survival in the circulation and arrest at a distant organ 
After entering the blood or lymphatic vessels, tumor cells can disseminate widely through the 
systemic circulation. Single tumor cells or small cell clusters may be detected in the blood (i.e. 
circulating tumor cells) and bone marrow (i.e. disseminating tumor cells) as they enter 
circulation. The bone marrow seems to be a common homing organ for blood-borne 
disseminated cells from various epithelial tumors 118. Individual carcinoma types form 
metastases in a limited subset of target organs. According to the hypothesis of Stephan Paget, 
certain tumor cells (the ‘seeds’) have specific affinity for the microenvironment of certain organs 
(the ‘soil’) 111,119. Consistent with this hypothesis, the formation of overt metastasis may reflect 
the adaptability of tumor cells to a particular foreign microenvironment 110.  
 
Extravasation and metastatic colonization 
To enter the tissue parenchyma of a new tissue, cancer cells must adhere to and penetrate the 
vessel wall 110. The establishment of a metastatic foci involve the same processes as in the 
primary tumor (i.e. adhesion, proteolysis and migration). The extravasated carcinoma cells must 
survive in the foreign microenvironment to form micrometastasis. To become overt metastases, 
the tumor cells must proliferate and form macroscopic metastases; the process of metastatic 
colonization 111. 
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3.4  Cancer treatment 
The three traditional modalities of cancer treatment, surgery, radiotherapy and chemotherapy, are 
increasingly combined, as focus on individualized cancer therapy has shifted treatment strategies 
towards multimodal treatment. The aim of combined modality treatment is to tailor each of the 
modalities so their antitumor effect is maximized with minimal toxicity to normal tissues 120. 
Rectal cancer was probably the first cancer form to exploit the multidisciplinary approach 
systematically, combining all treatment modalities. 
 
3.4.1  Surgery 
Surgery is the oldest cancer treatment modality and the primary treatment strategy of most solid 
malignancies. For some cancer forms, the extent of the surgical procedure has been reduced in 
the modern era, while it has been extended in the case of rectal cancer. The current standard 
surgical technique in rectal cancer, TME, was developed in the 1980s 121 and was established as 
a standard technique in most European countries in the 1990s30.  
 
While surgery is effective as curative treatment in locally resectable tumors, combination with 
radiotherapy or chemotherapy is often warranted in patients with locally advanced cancers at 
high risk of local recurrences following surgery alone 27. Radiotherapy and/or chemotherapy may 
be administered before or after surgery, as neoadjuvant or adjuvant therapy, respectively 122.  
 
3.4.2 Radiotherapy 
The use of IR for the treatment of cancer dates back to the late 19th century after the discovery of 
x-rays by Wilhelm Röntgen in 1895 and radium by Marie and Pierre Curie in 1898 91,123. Today 
around 50% of cancer patients will receive radiotherapy during the course of their illnesses, 
either as part of curative or palliative therapy 124. Radiotherapy has a place in local treatment of 
most types of cancers, either as an alternative to surgery in early-stage cancers, or more often as 
an element of multimodal treatment 125. With recent technological advances, it is expected that 
the role and use of radiotherapy will increase. Curative radiotherapy can be classified as radical, 
given as a definitive treatment; or adjuvant, given before or after definitive management of the 
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primary tumor, usually surgery. Administered prior to surgery, the main aim of radiotherapy is to 
decrease the tumor size and render the tumor resectable, while the aim of postoperative 
radiotherapy is to eradicate any residual, microscopic disease 124.  
 
The rationale of radiotherapy is to produce DNA damage that will induce tumor cell death. 
Radiotherapy exploits high-energy IR, to induce DNA damage, particularly DNA double-strand-
breaks 27. The DNA damage is created either directly through the ionization within the DNA 
molecule or indirectly through formation of free radicals; highly reactive molecules which 
initiate a chain of events that result in DNA damage. Upon DNA damage, the cell activates DNA 
damage response mechanisms. A variety of cellular responses are initiated in order to repair the 
DNA damage or alternatively kill the cells if the DNA cannot be repaired. Compared to normal 
cells, rapidly proliferating tumor cells have reduced capacity to repair radiation-induced DNA 
damage and are therefore more sensitive to IR than normal cells 126-127.  
 
Fractionation, the delivery of several fractions of IR, with each fraction consisting of a relatively 
small dose, typically 2 Gy, is an important principle in radiotherapy. The ‘5Rs of radiobiology’ is 
a model that explains how fractionated radiation exploits differences between tumor cells and 
normal cells to target tumor cells 127-129. Normal tissues proliferate relatively slowly and have 
time to repair damage before replication, while in rapidly proliferating tumor tissue unrepaired 
damage can be lethal. The rate of repopulation between fractions is lower in the tumor than in 
the normal tissue, allowing the normal tissue to tolerate a larger fractionated dose. After a dose 
of radiation, most surviving cells will be in the radioresistant cell cycle S phase. In contrast to 
normal tissues, tumor cells are allowed to redistribute throughout the cell cycle before the next 
dose of IR into more radiosensitive phases. The process of reoxygenation limits the negative 
effect of hypoxic cells in fractionated therapy 87. Immediately after a dose of radiation the 
proportion of hypoxic cells in a tumor will be increased, but due to reoxygenation the proportion 
of hypoxic cells is reduced if sufficient time is allowed 94. Cellular radiosensitivity, may differ 
in tumor and normal cells as it is influenced by intrinsic factors, e.g. genetic aberrations, as well 
as extrinsic factors, e.g. oxygenation.  
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Fractionation aims to protect the normal tissue as radiotherapy exerts normal tissue toxicity. 
Early (acute) side effects in rapidly proliferating tissues are usually transient, while late (chronic) 
side effects in tissues with a slower turnover are often irreversible and progressive46,130.  
 
3.4.3  Systemic therapeutics  
Chemotherapy 
Surgery and radiotherapy dominated the field of cancer therapy into the 1960s, when 
chemotherapy was increasingly incorporated into cancer treatment 120. Traditional 
chemotherapeutic agents target tumor cells, mainly by initiating massive DNA damage in rapidly 
diving cells inducing cell death. The aim of chemotherapy applied in systemic doses is to target 
tumor cells in the primary tumor as well as disseminated tumor cells. Like radiotherapy, 
chemotherapy may be applied as curative therapy, alone or as supplement to the definitive 
treatment; or as palliative treatment. Applied as neoadjuvant therapy, micrometastatic disease 
can be targeted early 122.  
 
Concomitant chemoradiation refers to the administration of chemotherapeutic agents in 
combination with radiotherapy. Combined with radiotherapy, chemotherapeutic agents may be 
applied to increase tumor control and to eradicate distant micrometastases outside the radiation 
field 131, 132. Some chemotherapeutic agents exhibit radiosensitizing effects and may be 
administered concomitantly with radiotherapy to enhance the local treatment effect of radiation  
(i.e .radiosensitizers) 97 37,38. Strictly speaking, radiosensitizing agents need not necessarily have 
inherent cytotoxic activity; however most radiosensitizers do and may thereby contribute to 
normal tissues toxicity. Radiosensitizers are generally administered in lower doses than when the 
drug is given as monotherapy to protect the normal tissues, limiting the systemic effects. 
Concurrent use of multiple radiosensitizing agents is challenging, for example, the added toxicity 
may necessitate dose reductions and interruptions in treatment 133,134. 
 
Preoperative fluoropyrimidine-based CRT is well-established as standard treatment regimen in 
rectal cancer. The potential role of OXA as radiosensitizer in rectal cancer and the administration 
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of OXA-based chemotherapy as systemic therapy, is currently being investigated in clinical 
trials.  
 
5-FU 
The pyrimidine analogue 5-FU exerts its cytotoxic effect by inhibiting the thymidylate synthase 
enzyme, leading to reduced production of the nucleotide base thymidine and impaired DNA 
synthesis. Leucovorin/folinic acid may be given together with 5-FU to enhance its the cytotoxic 
activity 34. Administered in sublethal concentrations in combination with radiotherapy, 5-FU 
exerts radiosensitizing effects, due to altered DNA repair and cell cycle regulation 34,37,135.  
 
5-FU based chemotherapy is applied as adjuvant treatment in colon cancer and in metastatic 
CRC 9. 5-FU is used concurrently with radiotherapy in several cancer forms including rectal 
cancer 132. The most frequent mode of 5-FU administration in combination with radiotherapy is 
continuous intravenous infusion, which compared to bolus infusions confers better effects , 34, 136. 
The oral fluoropyrimidine capecitabine is a more convenient alternative. Capecitabine is a 
prodrug of 5-FU with the convenience of oral administration. Capecitabine-based regimens are 
compared to 5-FU based regimens in phase III trials in rectal cancer, and early results indicate 
that capecitabine is equivalent to 5-FU in CRT regimens 41,42.  
 
OXA 
The platinum analog OXA exerts cytotoxic effects by induction of DNA lesions and inhibition of 
DNA synthesis 137. Clinical trials have established OXA in combination with fluoropyrimidines 
as adjuvant treatment in curative treatment of colon cancer 138 and as treatment of metastatic 
CRC 139. Further, in CRC patients with resectable liver metastases, perioperative chemotherapy, 
i.e. before and after surgery, with 5FU/leucovorin and OXA is recommended 140. After the 
success of OXA in treatment of metastatic CRC and in the adjuvant setting in colon cancer, 
expectations were high for OXA as additional component of CRT in LARC, although there was 
a scarcity of preclinical evidence regarding radiosensitizing effects of OXA in CRC 141,142. 
 
 OXA as part of the preoperative CRT regimen in rectal cancer is being investigated in five 
ongoing phase III trials. In three of the trials addition of OXA to 5-FU-based CRT did not 
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improve pCR rates, while toxicity was increased compared to 5-FU alone 42,61-63. In contrast, in a 
fourth trial 64, pCR rates were improved; although the increase was small, without increased 
toxicity. A fifth study has recently been completed 65.  Although final data on local control and 
long-term survival are awaited, the available data indicate increased toxicity without added 
benefit from OXA, and do not support the use of OXA in standard neoadjuvant CRT regiments 
in LARC. The role of OXA in rectal cancer is not clear, e.g. OXA-based NACT is under 
investigation in early clinical trials 143, both in combination with CRT 71-75 and as an alternative 
to CRT in patients with intermediate risk. 
 
 
Molecularly targeted therapeutics  
Ideally molecularly targeted therapeutics would be agents designed specifically against well-
defined targets critical for tumor survival not compromising for normal tissues. The target should 
be measurable in the clinic, and levels should correlate with clinical outcome when the targeted 
drug is administered 144,145 . 
 
Most targeted therapeutics interfere with aberrant cell signaling pathways that drive malignant 
transformation in tumors. Activation of cell signaling pathways are typically initiated by the 
binding of a ligand to the extracellular domain of a transmembrane receptor, thereby activating 
its tyrosine kinase intracellular domain, initiating a cascade of intracellular reactions 146. The 
main therapeutic strategies to target cell signaling are monoclonal antibodies and small-molecule 
tyrosine kinase inhibitors. The antibodies may be directed against the ligand or against the 
extracellular part of the receptor, while tyrosine kinase inhibitors diffuse into cells to reach their 
target at the intracellular part of the receptor or in downstream pathways 147. 
 
There is growing interest in the potential value of combining targeted drugs with radiotherapy132. 
A number of currently available targeted agents may be expected to modulate one or more of the 
phenomena described by ‘the 5Rs’ of classic radiobiology and thereby have the potential to 
enhance tumor radiosensitivity. As targeted agents confer other types of toxicity than 
conventional chemotherapy, overlapping toxicity with radiotherapy may be less pronounced 
148,149 . In rectal cancer several drugs targeting cell proliferation and angiogenesis have shown 
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promising results evaluated in combination with standard CRT in preclinical and clinical trials. 
Recently, a new class of targeted agents, histone deacetylase inhibitors, has been implemented as 
radiosensitizers in preclinical and early clinical trials in rectal cancer. 
 
Inhibitors of the EGFR pathway 
The transmembrane EGFR regulates signaling pathways of cell proliferation and survival, and is 
overexpressed in many tumor types 150. Cetuximab and panitumumab are monoclonal antibodies 
that bind to EGFR with high specificity and prevent downstream EGFR-mediated signaling. In 
metastatic CRC, the antibodies have shown to improve survival in patients with wild-type KRAS 
tumors 150,151. The potential role of cetuximab as a radiosensitizer was assessed in a landmark 
randomized phase III study in patients with locally advanced head and neck cancer, which 
showed that cetuximab in combination with radiotherapy significantly improved OS compared to 
radiation alone 152. Cetuximab and panitumumab have been evaluated as part of preoperative 
CRT in rectal cancer in several phase I/II trials. Longer follow-up and finally randomized trials 
are needed, but early surrogate endpoints (pCR, TRG) have not showed significantly improved 
response to treatment, while toxicity is relatively frequent 28,151,153. Nevertheless, it remains 
possible that a subset of patients will benefit from cetuximab- or panitumumab-based CRT in 
rectal cancer 154. 
 
The small-molecule tyrosine kinase inhibitors gefitinib and erlotinib specifically target the kinase 
activity of the EGFR. They are implemented in the treatment of lung cancer patients with EGFR-
mutations, and have shown promising results as a radiosensitizer in preclinical 155 and in early 
clinical trials in rectal cancers 156. High-grade toxicity have necessitated dose-reductions in the 
clinical trials and further studies are ongoing to evaluate tolerability and efficacy 151. 
 
Angiogenesis inhibitors 
As angiogenesis is important for tumor growth and malignant progression, it is an attractive 
target for anticancer treatment. Most antiangiogenic strategies target the VEGF pathway by 
inhibiting the functions of the key proangiogenic growth factor VEGF or its corresponding 
receptors 97,157. These agents probably exhibit their antiangiogenic effects by paradoxically 
normalizing tumor vessels, transiently reducing tumor hypoxia. Vessel normalization confers a 
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more efficient delivery of drugs and oxygen to the cancer cells, with the potential of enhancing 
efficacy of chemotherapeutic drugs and radiotherapy 151,158. This hypothesis of mechanism 
behind the effects of antiangiogenic agents could explain why angiogenesis inhibitors have 
showed limited success as single agents in clinical trials, but seem to be more effective in 
combination with chemotherapy or radiation 38,97,158. 
 
Bevacizumab is a monoclonal antibody directed against the VEGF ligand preventing it from 
binding to its receptor on endothelial cells. For metastatic CRC, bevacizumab improves survival 
when combined with chemotherapy 159,160, while in the adjuvant setting in colon cancer addition 
of bevacizumab have failed to improve survival in phase III trials 161,162. Bevacizumab have 
shown radiosensitizing effects in experimental models 163 and have been evaluated in phase I-II 
trials in combination with CRT in rectal cancer. The pCR rates are not impressive in most trials, 
and increased toxicity and postoperative complications are worrying 151,164,165 .  
 
Histone deacetylase (HDAC) inhibitors 
HDAC inhibitors were originally designed as epigenetic therapeutics. While cancer traditionally 
has been considered to originate from genetic defects166, growing evidence suggests that 
epigenetic modulation also plays a crucial role in cancer development167. Epigenetic changes 
refer to regulation of gene expression via posttranslational modification of protein complexes 
associated with DNA, without alterations in the DNA sequence 168. Unlike genetic alterations, 
epigenetic alterations are reversible, and therefore an intriguing potential target for therapy 169.  
 
The DNA strand is wound around cores of histone proteins, composing nucleosome units that 
comprise the chromatin. Altered chromatin structure by posttranslational modifications of 
histone tails regulate gene expression 169 . Acetylation of lysine residues on histone tails is 
regulated by two enzymes; while acetylation is mediated by histone acetyl transferase, it is 
prevented by HDAC 170. HDAC also affect acetylation status of numerous non-histone proteins 
171 and it has been suggested that HDAC should be redefined as lysine deacetylases, to reflect 
that its substrate is acetylated lysyl residues, not exclusive for histones 107. 
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HDAC inhibition as a potential form of epigenetic therapy has been suggested for a range of 
diseases, including cancer 167 as aberrant HDAC activity is a common feature of malignant cells 
170,172. HDAC inhibitors promote acetylation of histones; a process generally associated with 
activated gene transcription173. The regulation of transcription by histone acetylation is probably 
more complex174 and HDAC inhibitors may also result in downregulation of genes172. Further, 
HDAC inhibitors induce acetylation of a large number of non-histone proteins, thereby 
influencing their function; e.g. transcription factors and multiple proteins involved in cellular 
processes 172(Figure 3.11). Hence, gene expression is affected by HDAC inhibitors by direct 
transcriptional effects by acetylation of histones and indirectly by acetylation of e.g. transcription 
factors. It is presumed that 5-10% of genes are influenced by HDAC inhibitors 171. Acetylation 
of histone and non-histone proteins by HDAC inhibitors affects a variety of cellular processes 
closely connected with tumor progression. 
 
 
   
         
Figure 3.11 HDAC inhibitors induce acetylation of histone and non-histone proteins with resultant changes in key 
cellular functions.  
 
 
The molecular effects of the HDAC inhibitors are not fully revealed. HDAC inhibition may 
affect the DNA damage response by downregulation of DNA repair genes and altered activity of 
DNA repair proteins171. Cell motility and proliferation are also inhibited, while apoptosis and 
cell cycle arrest are induced173. Several types of HDAC inhibitors are found to repress 
Histone acetylation Non-histone protein acetylation
Transcription factor 
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angiogenesis, and accumulating evidence supports that this repression is mediated by disrupting 
the functions of HIF-1α, the master regulator of the cellular hypoxic response171. Recently some 
HDAC inhibitors have been shown to repress HIF-1α function, and it has gradually been realized 
that the tumor growth inhibiting effects of HDAC inhibitors are partially mediated by this 
mechanism 107,175. The precise biochemical mechanisms for the HDAC inhibitor-initiated 
repression of HIF1α-functions remain unclear 107,176.  
 
After identification of the first HDAC in 1996, more than twenty HDAC inhibitors have been 
investigated in clinical trials as single agents or in combination therapies 177. In 2006, the first 
HDAC inhibitor, also the first agent to target the epigenome, vorinostat, was approved as single-
agent treatment in refractory cutaneous T-cell lymphoma (CTCL) 178. Clinical trials on HDAC 
inhibitors as single-agent therapy for various solid malignancies have reported tolerable, 
reversible side effects (fatigue, nausea, diarrhea, hematological effects). Despite promising result 
in CTCL, clinical benefit of HDAC inhibitors as single agent for various cancer forms has been 
variable 171. Early clinical trials evaluating HDAC inhibitors in combination with cytotoxic 
therapies, i.e. conventional chemotherapeutic agents179-181 and IR182 are more encouraging. In 
preclinical studies, HDAC inhibitors have shown radiosensitizing effects in several tumor types 
169 170. HDAC inhibitor-induced suppression of DNA damage repair is shown in experimental 
studies 170,173,183. A number of ongoing clinical trials are examining the combination of HDAC 
inhibitors and radiotherapy for various malignancies 169.  
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3.5  Biomarkers  
A biological marker or biomarker can be defined as a characteristic that is objectively measured 
as an indicator of normal biological processes, pathological processes, or a response to a 
therapeutic intervention 184,185. Biomarkers may be used as diagnostic tools, as tools for staging 
of disease or to predict and monitor clinical treatment response 184 and as early surrogate 
endpoints in clinical trials. Prognostic biomarkers give information on expected patient outcome 
independent of treatment or after standard treatment 186. Predictive biomarkers aim to determine 
response to a specific therapy187. Pharmacodynamic biomarkers measure treatment effects in the 
target tissue 146.  
 
The clinicopathological TNM staging system is the gold standard for evaluating prognosis in 
rectal cancer, but there are numerous other prognostic markers. One of the first biomarkers 
introduced in CRC was serum carcinoembryonic antigen (CEA), a normal cell product that is 
overexpressed in many adenocarcinomas and in a variety of inflammatory diseases 188,189. In 
CRC, elevated serum CEA level at diagnosis (≥ 5 ng/mL) have been shown to have an adverse 
impact on prognosis, independent of tumor stage 47. CEA-levels are followed in CRC patients as 
an indicator of disease progression, although 30 % of recurrences do not produce CEA 26. A 
more recently proposed biomarker in CRC is the presence of tumor cells in blood or bone 
marrow (i.e. circulating tumor cells (CTC) or disseminated tumor cells (DTC), respectively) 190-
192. When entering the circulation as part of the metastatic process, single tumor cells or small 
cell clusters can be detected in the blood or in the bone marrow, hence detection of CRC or DTC 
may be a useful marker of early systemic dissemination.  
 
Increasing numbers of predictive biomarkers have been implemented into clinical routine to 
guide treatment decisions with the introduction of molecularly targeted agents. Presence of gene 
aberrations in the patient’s tumor 193  has been the main method to identify subpopulations of 
patients that may benefit from specific agents 194 (Table 3.3). However, as many targeted agents 
inhibit kinases at the hub of cell signaling cascades, the activity of several downstream kinases is 
influenced and aberrations of several genes affect response to therapy. For example, the 
mutational status of several other proteins downstream to the EGFR has been shown to predict 
outcome of anti-EGFR therapies in metastatic CRC, but currently KRAS, BRAF, and NRAS 
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mutational status is the only predictive biomarkers incorporated into clinical practice. Mutations 
in different codons of a gene may influence the response to treatment, exemplified by the 
individual mutations within the KRAS gene 193. Pathway signaling activity conducted by the 
drug target may reflect mutation status of several genes and can potentially be used as a 
biomarker of drug response 195. For many targeted drugs, e.g. antiangiogenic agents, there are 
currently no validated predictive biomarkers 151,196,197.  
 
  
 
Table 3.3 Targeted therapeutics with established predictive biomarkers. 
CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; CML, chronic myelogenous leukemia; ALL, acute 
lymphatic leukemia, GIST, gastrointestinal stromal tumor; ALL, acute lymphatic lymphoma. 
 
 
The concept of integrating tumor biological parameters in treatment decisions by the use of 
predictive biomarkers may also be applied for multimodal treatment combining radiotherapy and 
chemotherapy. There are several potential predictive biomarkers of radiation response e.g. 
markers of tumor hypoxia, but these are currently not sufficiently validated to be integrated in 
the clinical decision process 187 . In rectal cancer predictive biomarkers of response to the 
standard CRT have been proposed 198-200.   
 
In drug development, the identification of biomarkers is necessary to measure drug delivery and 
activity as well as to assess which patients that are likely to benefit from the therapy 201. While 
predictive biomarker are useful to aim to the patient response, pharmacodynamic biomarkers 
Drug Tumor Target(s) Biomarker
Cetuximab CRC EGFR KRAS/BRAF/NRAS  wildtype
Panitumumab CRC EGFR KRAS/BRAF/NRAS  wildtype
Gefitinib NSCLC EGFR EGFR  mutations
Erlotinib NSCLC EGFR EGFR  mutations
Crizotinib NSCLC ALK, MET ALK  rearrangement, MET  amplification
Trastuzumab Breast cancer (gastric cancer) HER-2 HER-2 expression, ERBB2  amplification
Lapatinib Breast cancer (gastric cancer) HER-2 HER-2 expression, ERBB2  amplification
Imatinib CML, ALL, GIST KIT, BCR/ABL, PDGFR KIT  mutations (exon 9 and 11), PDGFRA 
mutations, BCR/ABL  translocation
Dasatinib CML, ALL BCR/ABL, SRC BCR/ABL  translocation
Nilotinib CML BCR/ABL BCR/ABL  translocation
Vemurafenib Melanoma RAF BRAF  mutation (V600)
Everolimus Renal cell carcinoma mTOR TSC1 or TSC2 mutation/deletion
Temsirolimus Renal cell carcinoma mTOR TSC1 or TSC2 mutation/deletion
Sunitinib Renal cell carcinoma, GIST PDGFR, VEGFR, KIT KIT mutations (exon 9)
Ruxolitinib Myelofibrosis JAK2 JAK2 mutations
Vandetanib Medullary thyroid cancer RET RET mutations
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measure drug effect on its target, i.e. biological activity 146. The biological activity of a drug is 
not necessarily the mechanism of drug action and may not be linked to tumor response. For 
example, in clinical trials combining HDAC inhibitors and radiotherapy, tumor histone 
acetylation has been proposed as a pharmacodynacmic biomarker. While useful as a marker for 
HDAC inhibition at the target, tumor histone hyperacetylation does not appear to reflect tumor 
response 202,203.   
 
With the introduction of targeted agents, pharmacodynamic biomarkers may be used to 
determine the optimum dose of a new drug. Traditionally phase I trials have been used to 
determine the maximum tolerated dose (MTD), by escalating the treatment dose until predefined 
dose-limiting toxicity (DLT) is reached 204. For molecularly targeted agents, the dose that results 
in clinically relevant levels of target modulation may differ from MTD, and the optimum dose 
may be the dose as the dose that is associated with a pharmacodynamic biomarker reflecting the 
mechanism of drug action in the tumor 149,205,206. 
Recently, search for new biomarkers have focused on imaging and molecular biomarkers 9. With 
the development of the microarray technique during, molecular profiling as a novel approach to 
the discovery of biomarkers has emerged. Gene and protein expression profiling is among the 
most widely recognized and extensively studied methods to identify molecular biomarkers. 
Another promising strategy to identify new biomarkers is the utilization of emerging imaging 
technologies 207. 
A biomarker test should be simple to perform, easy and fast to evaluate, accurate (high 
sensitivity and specificity), cost-effective and reproducible 186,208. Most biomarkers described to 
date have been identified in retrospective studies, to be used in the clinic biomarkers should be 
validated in prospective, randomized clinical trials 207.  
39 
 
 
4 Aims 
 
Rectal cancer is a heterogeneous disease in terms of response to treatment, frequently 
multimodal, and the ability to metastasize. Recognizing that tumor hypoxia is a common 
determinant of resistance to cytotoxic therapies and metastatic behavior, the principal aim of the 
present work was to characterize this particular phenotype by applying a number of translational 
approaches in experimental and clinical cancer research, with the ultimate goal of improving 
radiation response and inhibiting metastasis in rectal cancer. 
 
This ambition was endeavored through the following study objectives: 
1 The characterization of hypoxic tumor kinase activities associated with early systemic 
disease dissemination in LARC patients scheduled to receive neoadjuvant CRT. 
2 The evaluation of radiosensitizing effects of the HDAC inhibitor vorinostat under 
hypoxia and in combination with capecitabine in experimental CRC models. 
3 The identification of biomarkers of HDAC inhibitor activity within the context of a phase 
I study undertaken in patients receiving pelvic radiotherapy in combination with 
vorinostat. 
4 The examination of chemotherapy effects on tumor radiation sensitivity in the clinical 
setting of neoadjuvant treatment of LARC and in experimental CRC models. 
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5 Summary of papers 
 
Paper I: Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and 
early systemic dissemination  
 
Even with successful local treatment, a substantial number of patients with LARC develop 
metastatic disease as a result of systemic dissemination of non-eradicated tumor cells. Tumor 
hypoxia initiates adaptive cellular responses which involve activation of a range of kinase 
signaling pathways that contribute in driving the metastatic process. The prospective phase II 
CRT trial, the LARC-RRP study: Locally Advanced Rectal Cancer – Radiation Response 
Prediction (ClinicalTrials NCT00278694) enrolled 113 patients from October 2005 to March 
2010. Patients received NACT and CRT followed by surgery and no further treatment. The aim 
of the Paper I study was to assess how kinase activities of the primary tumor from the LARC-
RRP study patients may be associated with early systemic disease dissemination, defined as the 
presence of DTC in bone marrow. A high-throughput peptide microarray technology 209,210 was 
used to study the effect on ex vivo tyrosine kinase activity of the kinase-inhibitor sunitinib, an 
anti-angiogenic agent, in baseline tumor biopsies of 55 patients. The absence or presence of DTC 
in patient bone marrow sampled at the time of diagnosis was determined by immunomagnetic 
selection, and association between tumor kinase activity profiles and DTC status was studied.  
 
Sixty percent of cases were DTC-positive and these patients had a significantly poorer 
metastasis-free survival than patients without DTC in the bone marrow. Sunitinib inhibition of 
overall tyrosine kinase activity was stronger in the DTC-negative patients. Phosphorylation of 31 
of 102 array kinase substrates was significantly more strongly inhibited by sunitinib in tumor 
samples from the DTC-negative patients compared to the tumor samples from patients with 
positive DTC status. Among kinase substrates that were differentially inhibited, a significant 
portion was involved in angiogenesis-related pathways, mainly peptides representing receptors 
of PDGF, VEGF, and erythropoietin.  
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In summary, hypoxic tumor kinome signaling was different in rectal cancer patients with and 
without early systemic dissemination. Low signaling mediated by PDGFR in patients with DTC 
in the bone marrow may represent a poorly functioning pericyte layer, enabling metastatic 
progression.  
 
 
Paper II: Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia 
and with capecitabine in experimental colorectal carcinoma 
 
Responses to established neoadjuvant CRT in LARC may vary considerably. Strategies to 
improve radiation response, i.e., by novel radiosensitizing agents, are warranted. The HDAC 
inhibitor vorinostat has been shown to sensitize experimental tumor models to radiation. In this 
study we wanted to expand the preclinical investigation 203 of vorinostat as a radiosensitizing 
agent in rectal cancer.  
 
Since solid tumor, including rectal carcinomas, often contain a substantial fraction of hypoxic 
radioresistant cells, novel radiosensitizers should be evaluated both under normoxic and hypoxic 
conditions in preclinical models. Furthermore, before introduction in clinical trials, potential 
interactions between a new drug and the established treatment regimen should be investigated in 
experimental models. We therefore aimed to study radiosensitizing effects of vorinostat under 
hypoxia and in combination with fluroropyrimidine-based chemotherapy that is currently used in 
LARC treatment.  
 
In four CRC cell lines and one CRC xenograft model, radiosensitizing effects of vorinostat under 
hypoxic conditions were evaluated by measuring in vitro clonogenic cell survival and in vivo 
tumor growth delay, respectively. In two CRC xenograft models, radiosensitizing effect of 
vorinostat when combined with capecitabine was evaluated by tumor growth delay assessment.  
 
Vorinostat caused radiosensitization under hypoxic conditions both in vitro, in terms of 
significantly lowering clonogenicity of irradiated cells, and in vivo by enhancing radiation-
42 
 
 
induced tumor growth delay. In addition, vorinostat synergized with the sensitizing effect of 
capecitabine in radiation-induced tumor growth delay.  
 
Taken together, our results from the expanded preclinical investigation of vorinostat as 
radiosensitizer in CRC models support the introduction of vorinostat as an additional component 
of CRT in LARC trials. 
 
 
Paper III: The identification of potential biomarkers of histone deacetylase inhibitor 
activity in a phase I combined-modality study with radiotherapy 
 
Following promising result of the histone deacetylase inhibitor vorinostat as radiosensitizer in 
experimental CRC models, the PRAVO trial was conducted 182,211. This phase I trial was 
designed to evaluate both clinical and novel biomarker endpoints in patients with advanced 
gastrointestinal malignancies receiving pelvic palliative radiotherapy combined with vorinostat.  
 
Potential pharmacodynamic biomarkers of vorinostat activity reflecting timing of vorinostat 
administration relative to the fractionated radiotherapy were explored by gene expression 
profiling of peripheral blood mononuclear cells (PBMC) sampled from 14 study patients at 
baseline (T0) and two and 24 hours (T2 and T24) after the patients had received vorinostat. Gene 
expression was compared for T2 versus T0, for T24 versus T2, and for T24 versus T0.  
 
Functional annotation analyses of the approximately 2100 differentially expressed genes for the 
comparisons T2 versus T0 and T24 versus T2 identified several enriched biological processes, 
with the Gene Ontology (GO) term transcription (GO:0006350) as the most significant in both 
comparisons. The top-three biological pathways were common for both comparisons and 
included signaling factors of the cell cycle. 1602 transcripts revealed a biphasic pattern of 
regulation from T0 through T2 and T24, as they were found to be differentially expressed both at 
two hours of vorinostat exposure (T2 versus T0) and on the T24 versus T2 comparison, while no 
differential expression was observed comparing the T24 and T0 groups. With a stricter p-value 
cutoff and by introducing a log2-fold change cutoff of 1.0, the list of differentially expressed 
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probes with biphasic pattern was reduced to 38 genes. Five of these genes were recognized both 
as players in the DNA damage response and targets for regulation by HDAC inhibitors and were 
therefore selected for verification by Realtime-quantitative polymerase chain reaction (RT-
qPCR) which confirmed significant time-dependent changes for all genes. The expression of the 
same five genes was assessed further by RT-qPCR analysis of two colorectal xenografts after 
exposure of vorinostat, revealing significant and transient MYC repression.  
 
The confirmation of MYC as the only one of the selected genes with rapid and transient change 
in expression in all tested conditions may point to a particular importance of myc in the 
therapeutic setting of vorinostat in combination with fractionated radiation.  
 
 
Paper IV:  Is oxaliplatin-containing neoadjuvant chemotherapy an alternative to radiation 
in T3 rectal cancer?  
 
In LARC, neoadjuvant therapy is generally given as long-term CRT or short-term radiotherapy, 
which may cause significant toxicity. Recent data from randomized studies indicate no additional 
benefit from OXA in CRT 42,61-64,212. Still, OXA is well established in adjuvant and palliative 
regimens in CRC and in NACT in liver metastasis surgery, which suggests potential neoadjuvant 
benefit also in LARC.  
 
In a non-randomized study of LARC patients (LARC-RRP ClinicalTrials NCT00278694 212), 
two NACT cycles with the Nordic FLOX regimen were administered prior to long-term CRT. 
Tumor volumes were calculated from MRI examinations at baseline, after NACT and after 
NACT + CRT for 72 patients. Additionally, the impact of previous OXA exposure on 
experimental radiosensitivity was examined in CRC cell lines.  
 
All tumors except one responded to NACT, and in all but three patients, additional tumor volume 
reduction resulted from the subsequent CRT (median volume reduction of 63% and 68%, 
respectively). The NACT volume responses were significantly larger in T3 than in T4 cases 
(70.5% and 47.9%, respectively; p <0.001). Only 11% of patients required FLOX dose 
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adjustment because of toxicity. OXA-resistant CRC cells were significantly more radiosensitive 
than the OXA-sensitive counterparts. 
 
In LARC, OXA-containing NACT led to substantial tumor volume reduction, as assessed by 
MRI volumetry, with particularly good responses in T3 cases.  Additional tumor volume 
reduction was observed after subsequent CRT in almost all cases, suggesting that pretreatment 
with OXA-containing NACT did not impede tumor response to CRT. Experimental results 
rather suggested enhanced radiosensitivity of OXA-resistant CRC cells. Individualization of 
neoadjuvant therapy, omitting CRT for more favorable toxicity profiles in LARC T3 cases, is 
worth investigating. 
 
 
 
.  
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6 Methodological considerations 
 
 
Table 6.1 Model system and main assays. RT-qPCR, real-time qualitative polymerase chain reaction; MR: magnetic 
resonance. 
 
6.1  Experimental CRC models 
6.1.1 Cell cultures 
Tumor cells grown in culture are valuable as models of cancer, as continuous growth permits 
performance of standardized experiments. One of the main limitations of this model is the lack of 
a tumor microenvironment, and cells grown in vitro lack the architectural and cellular 
complexity of in vivo tumors 213. Unwanted selection pressure during prolonged culture may 
modify the genotype and phenotype of the cells, and as a result the cell line may not be 
representative of the original tumor in situ 214. Furthermore, there is a risk of cross contamination 
between different cell lines used in the laboratory. To ensure that the cells are not modified or 
contaminated, cell line identity should be verified prior to experiments. Identities of the cell lines 
used in this thesis were validated by short tandem repeat profiling (genetic fingerprinting) 215 216.  
 
Cell line Derived from  Patient (gender/age)  Origin Reference 
HCT116 Primary colon carcinoma Male /- ATCC  217 
SW620 Lymph-node metastasis from colon cancer Male /51 ATCC  218 
HT29 Primary colon carcinoma Female/44 ATCC  219 
KM20L2 Primary colon carcinoma - NCI  220 
 
Table 6.2 Characterization of colorectal carcinoma cell lines used in this thesis. ATCC, American Type Culture 
Collection; NCI, National Cancer Institute (of the United States of America).  
Model system Methods
Clinical trial LARC-RRP Immunomagnetic selection of disseminated tumor cells
Tumor kinase activity profiling
Cell cultures Clonogenic survival  (under normoxia and hypoxia)
Xenografts Tumor growth delay (under normoxia and hypoxia)
Clinical trial PRAVO Gene expression profiling, RT-qPCR
Xenografts RT-qPCR
Clinical trial LARC-RRP Tumor MR volumetry
Cell cultures Clonogenic survival 
Paper I
Paper II
Paper III
Paper IV
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6.1.2 Xenografts  
In the animal experiments described in this thesis, ectopic xenografts were established by 
subcutaneous injections of cells in culture on athymic nude mice (T-cell deficient).  Xenografts 
are created by transplanting human tumor cells into mice or rats; either by injection of cells in 
suspension or by implantation of human tumor tissue (from the original tumor or from a 
xenograft established from cells in suspension) 221. The xenografts may be established 
subcutaneously (ectopic xenografts) or in the organ system of the original tumor (orthotopic 
xenografts)214.  The microenvironment of orthotopic xenografts is more similar to the in situ 
tumor. However, disadvantages of the orthotopic model include difficult establishment, 
commonly the need for imaging to monitor tumor response, and possibility that the tumor or the 
treatment may disrupt vital organ functions 131.  Ectopic models are usually preferred to study 
radiation response as radiation can be delivered without exposing critical organs 214. To avoid 
rejection of the human tumor cells, immunocompromised mice are commonly used. Although 
mice share 99% of their genes with humans 222, the predictive value of xenograft models for 
performance in clinical trials have been questioned and there are several limitations to this 
model. For xenografts established from cell lines grown in vitro, selection pressure might have 
altered the cells 221. The microenvironment is different from an in situ tumor; and radiation 
response may be influenced by abnormal immune responses and presence of mouse rather than 
human stroma 131,214. 
 
6.1.3  Experimental treatments 
Systemic therapeutics 
For in vitro experiments involving the HDAC inhibitor vorinostat, the drug was diluted in culture 
medium from frozen stock solutions immediately before addition to cell cultures. Vorinostat (1or 
2μM) was added to the cell cultures for an incubation period of 18 hours. In animal experiments, 
vorinostat (100 mg/kg) was diluted in dimethyl sulfoxide (DMSO) and given by intraperitoneal 
injections three hours before IR; capecitabine (359 mg/kg) was suspended in Arabic gum and 
given orally to mice by gavage.  
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Radiation 
IR was delivered to cell lines in culture by an x-ray unit (dose rate of 1.0 Gy/min) 24 hours after 
cell seeding. Control cells were simultaneously placed in room temperature. To irradiate tumor 
xenograft, a linear accelerator was used (dose rate of 2.6 Gy/min). Control mice were also 
anaesthetized, by subcutaneous injections of the zoletil mixture (tiletamine, zolazepam, xylazine 
and butorphanol), and brought to the radiation room. The xenografts were irradiated with a 
schedule of four or five fractions of 2 Gy with 24 hours between each fraction.  
 
Hypoxic radiation  
Hypoxia chamber 
An unequivocal in vitro model of a cellular hypoxic environment has not been established 223. 
Chambers, in which a desired oxygenation level is established by flushing with 5% CO2 and N2, 
are often used to establish hypoxia 223-225. Mimicking hypoxia by pharmacological means is not 
recommended. Although HIF1-α may be activated pharmacologically, other consequences of 
hypoxia will not be reproduced 224,226.   
 
A hypoxia chamber was used to establish hypoxic conditions (1% O2) of cell cultures in order to 
study radiation response under hypoxia in vitro. While the oxygen tension in the chamber is 
controlled, the actual oxygenation level at the cellular level might be different 224, 227. The 
oxygenation level at the time of radiation is critical for induction of DNA damage; hence the 
cells must be kept hypoxic during IR to study hypoxic radiation response. The cells were kept in 
sealable plastic flasks and transferred to the x-ray unit for immediate IR after removal from the 
hypoxia chamber 228. Alternatively, transportable preincubated chambers could have been used 
to keep cells hypoxic during IR 225,229. 
 
The technique of western blot immunostaining 230  was used to evaluate the HIF1α-level, to 
assess if cells responded to hypoxia upon treatment in the chamber. Proteins were separated by 
gel electrophoresis and transferred to a membrane for detection by antibodies specific to the 
target protein, and presence of immunoreactive proteins were detected by chemiluminescence. 
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Radiobiologically, hypoxia is often defined as oxygen concentrations below those causing 
maximum resistance to radiation, by the oxygen effect; about 0.02 per cent. Radioresistance may 
already occur at oxygen levels of 4-5% and from a clinical standpoint it has been proposed that 
intermediate hypoxic cells are the most important for prognosis, as they are resistant to therapy 
and still have the ability to proliferate 83,231. The fact that we observed increased HIF1α-levels in 
cells treated with hypoxia and increased radioresistance of cells irradiated under hypoxia, 
indicate that the cells did experience hypoxia.  
 
 
                       
 
Clamping 
The technique of clamping was used to study radiation response under hypoxia in vivo, 232-235. 
Xenografts were established distally on the thigh of the mice to allow a clamp to be placed over 
the proximal thigh of anesthetized mice during IR (Figure 6.2). Unilateral xenografts were used 
in the treatment-experiments as only one leg can be clamped at the time and differential 
treatment of tumors on the same mouse is not recommended. To confirm that tumor blood supply 
to clamped xenografts was minimal, radioactive iodine was injected intravenously to the mice; 
and radioactivity in excised xenografts were compared for clamped and unclamped tumors of the 
same mice, revealing significantly reduced radioactivity in clamped tumors (3% of radioactivity 
in unclamped tumors). Blood pressure and tumor blood flow may be influenced by e.g. 
Figure 6.1 Hypoxia chamber 
A Ruskinn INVIVO2 200 Hypoxic Workstation was 
used to establish oxygen level of 1%. 
 
Cells were incubated for 18 hours and 
simultaneously exposed to vorinostat or control 
before sealing the flasks and transferring them to a 
nearby x-ray unit for immediate irradiation. 
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anesthesia and stress 236, underlining the importance of keeping non-treatment related conditions 
as similar as possible across treatment groups. An alternative method described to establish 
hypoxia in vivo involves exposing mice to cycles of oxygen-reduced air 237, but this method 
would not allow IR under hypoxic conditions. 
 
  
 
Figure 6.2 The clamping procedure. Before clamping, the mice were anesthetized and vaseline was applied to 
protect the skin. The clamp (with a step to protect the femoral bone), were placed over the proximal thigh of the mice. 
After 3.5 minutes of clamping, the tumors were irradiated. The mice were clamped for a total period of 5 minutes.  
 
Immunohistochemical stains of the exogenous hypoxia marker pimonidazole were made from 
seven mice with bilateral xenografts (data not included in paper). The same fraction of 
pimonidazole stained cells was detected in unclamped and clamped xenografts (31%). 
Pimonidazole needs a hypoxic period of 30 min to form complexes and its expression is mostly 
seen at a certain distance from the blood vessels, hence this marker is thought to identify mainly 
chronically hypoxic cells 238. As the tumors were exposed to hypoxia for only five minutes in our 
experiments, a clamping-induced increased fraction of pimonidazole-stained cells could not be 
expected.  
 
Establishment of OXA-resistant cell lines 
The human colorectal carcinoma cell lines HT29 and KM20L2 were repeatedly exposed to 
increasing concentrations of OXA for 7 and 9 months, respectively, using two exposure 
regimens. To establish the 4OXA variants, the cells were exposed to OXA for 4 h, starting at an 
initial OXA concentration of 2 μM; increasing by 2-μM increments (terminating at 46 μM and 
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28 μM for HT29 and KM20L2, respectively). The 72OXA variants were generated by exposure 
to OXA for 72 h, with an initial OXA concentration of 0.2 μM, increasing by 0.2-μM increments 
(terminating at 4.0 μM and 3.0 μM for HT29 and KM20L2, respectively).  Resistance was 
maintained by exposing the cells to the final concentrations every 4-6 weeks.  
 
OXA resistance of the variant cell lines was confirmed by the MTS cell proliferation assay. The 
MTS assay is based on the fact that living cells can reduce the MTS compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) into a 
colored product that can be measured spectrophotometrically 239.  By measuring the cellular 
metabolic activity, the fraction of proliferating cells is determined and can be used to study short-
term (usually 72 hours) cell culture drug resistance. 
  
6.1.4 Experimental radiosensitivity 
Clonogenic cell survival assay   
The clonogenic cell survival assay is the in vitro gold standard for the measurement of cell kill 
following IR exposure. The assay measures the proliferative or clonogenic capacity of individual 
cells 214,226,240. Cell death after IR is primarily caused by mitotic catastrophe, which may require 
several cell divisions, reflected in this long term assay. Radiation induces transient growth arrest, 
which can be misinterpreted as cytotoxicity in short term assays based on cell number 214. In the 
most common form of the clonogenic assay, single cell suspensions are seeded into tissue culture 
plates or flasks, and after attachment of the cells to the plates (>6 hours) the cells are treated 240. 
In our experiments, cells were irradiated 24 hours after seeding, before replication. Colonies (> 
50 cells) were counted after 7-14 days depending on the specific cell line, and surviving fractions 
relative to the relevant control were calculated.  
 
Tumor growth delay (TGD) assay   
In the TGD assay, the most common assay to assess in vivo radioresponse, xenografts are 
allowed to grow to a certain size or volume, then the mice are randomized and experimental 
therapy is given. The smallest and largest tumor diameter are measured typically 2-3 times a 
week to calculate the tumor volume 241 relative to the tumor volume at the start of treatment. 
51 
 
 
Commonly, time to doubling or five-doubling (T2x and T5x) of tumor volume is calculated for 
all tumors and TGD is calculated as the difference between T2x/T5x for each tumor compared to 
the average of the control tumors. The average TGD for the control group and each treatment 
group is reported  214. 
    
6.2 Clinical trials  
6.2.1 Phase I and II study design  
Careful design of study protocols and rigorous control of study conduct are necessary to enable 
evaluation of relevant clinical and biomarker endpoints in clinical trials 242. 
 
The main aim of a phase I study is to determine safety and tolerability, typically in terms of 
establishing MTD and DLT, of a novel therapeutic agent 205. The 3 + 3 expansion cohort design 
is traditionally used; the occurrence of an acute DLT in one of three patients on the same dose 
level triggers recruitment of further three patients to the same dose level. The dose escalation 
continues until at least two patients in a cohort of three to six patients experience a DLT 206.  
Phase I studies evaluating the combination of systemic drugs with presumed radiosensitizing 
activity and radiation or standard chemoradiation, confer additional challenges compared to 
conventional studies of systemic cytotoxic chemotherapy 131.  For example, it may be difficult to 
decide whether a toxic event is greater than could be expected from radiotherapy alone.  
 
The aim of a phase II trial is to assess activity, safety and feasibility of a new treatment. 
Traditionally phase II trials have been designed as single-arm studies with no control group, but 
randomized phase II designs are increasingly chosen to allow direct comparison of a new 
treatment to standard treatment 204. Predictive biomarker are increasingly incorporated into study 
design to select eligible patients based on treatment tolerability and response 243. 
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6.2.1  The LARC-RRP trial 
In the non-randomized phase II trial LARC-RRP (Locally Advanced Rectal Cancer – Radiation 
Response Prediction; ClinicalTrial NCT00278694 212), OXA-based NACT and CRT were given 
to patients with LARC scheduled for CRT and subsequent surgery. The study was approved by 
the Regional Committee for Medical and Health Research Ethics South-East Norway and was 
performed in accordance with the Declaration of Helsinki. Written informed consent was 
required for participation. The primary inclusion criterion was histologically confirmed rectal 
adenocarcinoma from LARC tumors as defined by the Norwegian guidelines at the time of the 
conduct of the study: T4 tumors, T3 tumors within 3 mm from the MRF and tumors of any T 
stage with pathological lymph nodes within 3 mm from the MRF, as assessed by diagnostic MRI 
17. A total of 113 patients were enrolled between October 2005 and March 2010. Patients with 
systemic disease at diagnosis were included if the metastases were potentially resectable and 
curative treatment was planned (n = 10). Diagnostic investigations included clinical assessment, 
rigid rectoscopy, pelvic MRI and CT of the chest and abdomen. The rectoscopy was performed 
under heavy sedation, and in this setting the primary tumor was biopsied and for a subgroup of 
patients, bone marrow was collected from the anterior iliac crests, As described in paper I, the 
presence of DTC in bone marrow and kinase activity profiling in study-specific tumor biopsies 
were evaluated for a subgroup of patients (n = 55) (Figure 6.3).  
 
The treatment protocol included two 2-weekly cycles of NACT, the Nordic FLOX regimen: 
OXA 85 mg/m2 on day 1, 5-FU 500 mg/m2 and folinic acid 60 mg/m2 daily on days 1 and 2. 
Following NACT, CRT was delivered over five weeks. Radiotherapy was given according to the 
Norwegian guidelines (25 x 2 Gy to target volumes as detailed previously). During the 
radiotherapy course, concomitant chemotherapy was given as OXA 50 mg/m2 once weekly and 
capecitabine 825 mg/m2 twice daily on days of radiotherapy. Surgery was planned 6-8 weeks 
after completion of the preoperative treatment. The resected primary tumor specimens were 
subjected to routine histological evaluation according to standard criteria (ypTN stage and CRM) 
and TRG, using the five-point scale proposed by Bouzourene et al 50.  Further, radiological 
response to neoadjuvant chemotherapy and CRT was evaluated by MRI (ycTN stage). As 
described in paper IV, a study-specific MRI was performed after the administration of NACT 
and the first three radiotherapy fractions in a subgroup of patients (n = 72).  
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Seventy-two LARC-RRP patients had MRI examinations both at baseline, after NACT and after 
completed CRT. To calculate tumor volumes, the tumors were manually contoured in the tumor-
containing axial MR images by the study radiologist, and whole-tumor volumes were obtained 
by multiplying the cross-sectional tumor area in individual slices by the sum of the slice 
thickness and slice gap. Recent advances in MRI technology has improved the accuracy in tumor 
size measurement, and MR volumetry after preoperative CRT has been investigated as a 
parameter of treatment response in rectal cancer and is reported to correlate well with 
downstaging, TRG and disease-free survival DFS 53,56,244. Tumor volume changes after NACT, 
after CRT and after the total preoperative treatment were calculated (Figure 6.3).  
 
 
 
Figure 6.3 LARC-RRP Timeline  
 
Patients were scheduled for follow-up consultations for five years postoperatively, at three- and 
six-month intervals for the first and second year, respectively, and every twelve months 
thereafter. Review procedures included clinical examination, blood tests, and CT scanning of the 
chest, abdomen, and pelvis. Locally recurrent or metastatic disease and death of any cause were 
recorded. Valid observations of the presence or absence of distant metastases or local recurrence 
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required designated radiological examination and/or bioptic verification.  A flow chart describing 
the two subgroups evaluated in paper I and IV is given in Figure 6.4. 
 
 
Figure 6.4 Patient cohorts analyzed in papers I and IV. LARC-RRP, locally advanced rectal cancer – radiation 
response prediction; NACT, neoadjuvant chemotherapy; IMS, immunomagnetic selection, MR, magnetic resonance; 
CRT, chemoradiotherapy.  
 
 
6.2.2  The PRAVO trial 
In the Pelvic Radiation and Vorinostat (PRAVO) phase I study (ClinicalTrials NCT0045351)212 
the HDAC inhibitor vorinostat was administered in combination with fractionated radiation to 
pelvic target volumes in patients with advanced gastrointestinal carcinoma. The study was 
approved by the Regional Committee for Medical and Health Research Ethics South-East 
Norway and was performed in accordance with the Declaration of Helsinki. Written informed 
consent was required for participation. The principal eligibility criterion was histologically 
confirmed carcinoma scheduled to receive pelvic palliative radiation. The primary objective of 
the PRAVO trial was to determine tolerability of vorinostat when administered concomitantly 
with palliative radiation to pelvic target volumes 182. The trial was the first clinical trial to report 
on the combination of a HDAC inhibitor and radiotherapy when published in 2010, and showed 
that vorinostat could be safely combined with short-term   pelvic radiotherapy. This study further 
aimed to assess the biological activity of vorinostat, in terms of tumor histone acetylation 182, and 
LARC-RRP patients
n = 113 
n = 71 Bone marrow aspiration Scheduled to MR after NACT
n = 55 n = 72
- Ineligible after registration (n = 5)
- Withdrew consent (n = 1)
- Died during NACT (n = 1)
- Did not receive NACT (n = 7)
- MR not performed (n = 11)
- Ineligible after registration (n = 3)
- Withdrew consent (n = 1)
- Died during NACT (n = 1)
- No kinase activity analysis (n = 4)
- IMS not possible (n = 6)
Paper IV
MR at baseline, after NACT, after CRTIMS and kinase activity profiling
Paper I
n = 65
n = 99
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to identify possible biomarkers reflecting timing of HDAC inhibitor administration with regard 
to radiotherapy.  
 
Seventeen patients were enrolled between Feb 2007 and May 2009. One patient withdrew 
consent after the first treatment day. Ten patients had rectal cancer, whereas the rest had primary 
tumors in the colon (n=6) or stomach (n=1). Radiotherapy was delivered to target volumes in 3 
Gy-fractions to a total dose of 30 Gy over two consecutive weeks. Vorinostat was administered 
orally once daily, 3 hours before each radiotherapy fraction. The study adopted the standard 3+3 
design 206, where patients were enrolled onto four sequential dose levels of vorinostat, starting at 
100 mg daily with dose escalation (in 100 mg increments) for every third evaluable patient, 
provided no dose-limiting toxicity had been observed at the preceding dose. Tumor biopsies 
were sampled at baseline and on the third treatment day to assess histone deacetylation. 
Peripheral blood for was drawn from patients at baseline (before commencement of study 
treatment; termed T0) and on the third treatment day (two and 24 hours after the patients had 
received the daily dose of vorinostat; termed T2 and T24 respectively) (Figure 6.5).  
 
 
Figure 6.5 PRAVO study timeline. PBMC, peripheral blood mononuclear cells. Figure adapted from Ree et al 2014 
(paper III)  
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6.3 Functional assays 
6.3.1 Detection of disseminated tumor cells  
An immunocytological technique of immunomagnetic selection (IMS) was used to detect DTC 
in bone marrow from 71 patients (Figure 6.5) 245,246. Mononuclear cells were isolated from the 
bone marrow aspirate and incubated with magnetic beads coated with the MOC31 antibody 
which recognizes the Ep-CAM antigen, a membrane protein that is highly expressed in CRC 
cells but not in normal bone marrow cells 247. The cells were subsequently exposed to a magnetic 
field to separate bead-rosetting cells from unbound cells. A patient sample was classified as 
positive for DTC if a minimum of two rosetted cells were identified by microscopy. The 
immunomagnetic method has demonstrated high sensitivity for detection of DTC in CRC 
patients and allows a rapid enrichment of tumor cells from a high number of mononuclear cells 
245. Limitations are related to antibody specificity and sensitivity. Other methods for detection of 
DTC in bone marrow are immunocytochemistry and RT-qPCR 248. 
 
.       
 
Figure 6.5 Immunomagnetic selection of tumor cells from bone mallow sample. Picture from the Department of 
Tumor Biology, the Radium hospital, Oslo University Hospital. Printed with permission. 
 
                                                                                                                                               
6.3.2 Tumor tyrosine kinase activity profiling 
The cell phenotype is determined not only by gene and protein expression levels, but also by 
posttranslational modifications of proteins, e.g. phosphorylation catalyzed by protein kinases249. 
The protein kinase component of the human genome, the kinome, was identified by Manning and 
colleagues in 2002 250. Of 518 protein kinases, 90 are tyrosine kinases i.e. protein kinases that 
catalyze phosphorylation of protein tyrosine residues 210. Tyrosine kinases are involved in cell 
signaling as part of transmembrane receptors and as enzymes located inside the cell 251. Protein 
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kinase activity may be assessed by protein phosphorylation levels representing end products of 
kinase activity rather than the enzymatic activity resulting in it, e.g. by mass spectrometry. 
Kinase activity assays measure the actual enzymatic activity leading to a specific signal 
transduction 249,252. In paper I, a high-throughput kinase substrate microarray technology 
(Tyrosine Kinase PamChip® Arrays) was used to determine tyrosine kinase activity in tumor 
samples from LARC patients. A chip containing peptide substrates with sites for phosphorylation 
generates an individual phophosubstate signature from each sample lysate, allowing functional 
comparison of active signaling pathways in different biological samples. 
 
Baseline tumor biopsies (snap-frozen in liquid nitrogen and stored at -80C) were sectioned by a 
cryostat microtome. Hematoxylin-eosin stained slides were evaluated for tumor content and 
normal tissue present was roughly removed by dissection guided by the stains. ~ 5 mm3 tumor 
tissue was cut in 10 μm sections by the microtome (the required number of sections was 
calculated after measuring the samples’ width and length). As kinase activity is sensitive to small 
variations, all samples were lysed simultaneously. The Pam Chip 96-well array were used: 144 
peptides representing 100 different proteins are spotted to a porous membrane. Each peptide 
represents a sequence corresponding to a specific tyrosine kinase substrate. The sample lysates 
are pumped through interconnected pores to allow enzymatic reaction with the peptide 
substrates. Adenosine triphosphate (ATP) is added to initiate phosphorylation reaction. Upon 
addition of a fluorescent-labeled antiphosphotyrosine antibody, phosphorylation levels are 
determined by recording spot fluorescent signal intensities 253 (Figure 6.6).  
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Figure 6.6 Peptide microarrays for profiling of kinase activity. Adapted from Hilhorst et al, printed with permission. 
The chips on the picture is a 4-well chip, while we used 96-well plates. ATP, adenosine triphosphate; ADP, adenosine 
diphosphate.  
 
 
 
In addition to four technical replicates from each patient tumor, three replicates were incubated 
with the tyrosine kinase inhibitor sunitinib, to diminish the problem of inter-unit variation 
between array plates; as peptide phosphorylation levels in presence of sunitinib could be 
normalized against the corresponding baseline levels, measured on the same unit (Figure 6.7).  
 
                            
 
Figure 6.7 Tyrosine kinase activity array – the principle of analysis. The level of individual array peptide 
substrate phosphorylation (P) generated by the patient’s tumor sample was measured in the absence and presence 
of the specific tyrosine kinase inhibitor (TKI; e.g., sunitinib). The inhibition ratio (signal intensities with/without tyrosine 
kinase inhibitor) was calculated. Five (of the total number of 144) array peptides (A-E) are drawn for simplicity. TKI; 
tyrosine kinase inhibitor.   
A B C D
EA B C D
E
P
P
P
P
P
P
Kinase activity 
Tumor sample in absence of TKI 
Kinase activity
Tumor sample in presence of TKI  
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Signal intensities for each spot, i.e. for each kinase peptide substrate per array were calculated by 
using the software BioNavigator (PamGene International B.V.) and subsequently log2-
transformed. For each peptide, the sunitinib-induced log2-fold change was calculated by 
subtracting the log2-transformed signal in the absence of sunitinib from that in the presence of 
sunitinib. Peptides with sample-averaged signal less than 210 in the control condition were 
excluded, leaving 102 of the 144 array peptides for further analysis.  
 
Levels of sunitinib inhibition in DTC-positive and DTC-negative patients were compared by a 
two-sample t-test. Principal component analysis was performed using the 55 samples as 
observations and the 102 peptide substrates as variables. The sunitinib inhibition profiles were 
determined by sorting the data according to the value of the first principal component (peptides) 
and the value of the scores on the first principal component (samples). Distribution of value of 
the score on the first principal component was compared to clinical parameters using correlation 
coeffecients for continuous variables and one-way ANOVA tests for categorical data. Data 
processing was performed in Matlab R2010A.  
 
Kinase activity profiling by the PamGene Platform has been used in functional characterization 
of cancer biology, particularly for therapy prediction 198,252,254-256. Advantages of kinase peptide 
substrate arrays include quick, parallel readout of many peptides requiring small quantities of 
protein (5-15 μg) 210. A detailed annotation of potential upstream kinases of specific peptide 
substrates is essential for this analysis and has gained reliability over the last years 252. Peptide 
sensitivity to kinases will however not necessarily be the same ex vivo as in vivo, as the tertiary 
structure and spatiotemporal regulatory mechanisms which normally control enzyme specificity 
are largely lost, hence the upstream kinases for a given peptide substrate could be different in the 
ex vivo setting 249,252. The technology is relatively new and computational tools for data 
analysis/methods for analyzing results from kinase activity microarrays and data validation are 
not standardized. A potential method to validate results is to assess levels of phosphorylated 
array peptide substrates or downstream proteins by western immunoblot, but in our study 
scarcity of patient material did not enable it. To account for intra-tumor heterogeneity, several 
tumor biopsies from each tumor should ideally be analyzed 257 but will also be hampered by 
limited availability and quantity of relevant tissue in a clinical study setting. 
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6.3.4 Gene expression profiling    
As described in paper III, gene expression profiling of PBMC was performed to identify possible 
pharmacodynamic biomarkers of vorinostat activity when combined with fractionated 
radiotherapy. To identify biomarkers that reflect mechanisms of action of a systemic agent with 
proposed radiosensitizing effects, tumor biopsies sampled after the patient has started radiation 
treatment cannot be analyzed as any regulatory activity would reflect the combined treatment of 
radiation and the systemic drug, and the accumulated radiation dose would probably be the main 
contributor149. Tumor biopsy sampling is too invasive to consistently use tumor tissue for 
determining drug activity in the clinical setting 205. Non-irradiated PBMC is an easy accessible 
surrogate tissue, which allows performance of analysis at several time points. Several studies 
have demonstrated biological activity of HDAC inhibitor in PBMCs in terms of histone 
acetylation 181,258. 
 
By microarray technology, transcriptional activity in term of messenger RNA, i.e. gene 
expression, of thousands of genes can be assessed simultaneously. The subsequent data analysis 
is called gene expression profiling. In paper III a standard DNA microarray analysis was 
performed by the Norwegian Microarray Consortium on RNA from PBMC samples of the 14 
study patients for whom a full set of three PBMC samples was obtained. Following RNA 
isolation, the purified RNA was copied into labeled complementary RNA (cRNA). The cRNA 
was amplified and then hybridized against the Illumina Human WG-6 v3 BeadChip DNA 
microarray platform, consisting of 48 000 probes. Spot intensities from all probes, reflecting 
bound cRNA, were recorded 259. 
 
Statistical and functional annotation analysis 
Array data from all PRAVO patient samples at each time point were pooled, irrespective of the 
vorinostat dose administered to the patients, to increase the statistical power of analysis of 
differential gene expression between the time points. Following quality control and 
preprocessing, the data was log2-transformed to stabilize the variance and normalize distribution 
of signals 260. Differential gene expression between the sample groups T0, T2, and T24 was 
determined by first applying a Benjamin and Hochberg false discovery rate-adjusted p-value 
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cutoff of 0.05, and secondly a p-value of 0.01 and a log2-fold change cutoff of 1.0 was used. The 
false discovery rate is a statistical method of controlling for multiple testing 261. Analysis was  
performed using Bioconductor version Release 2.11.1 and the Bioconductor packages lumi 
1.14.0, linear models for microarray data (limma) 3.4.4, and illuminaHumanv3BeadID.db 1.6.0 
(www.bioconductor.org).  
 
The probes that were identified as differentially expressed among sample groups T0, T2 and T24 
were analyzed using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID v6.7), which is a bioinformatic resource that can extract biological meaning associated 
with large gene lists 262.  Annotation analysis can map genes by their biological processes (e.g., 
gene ontology terms) or biological pathways, and statistically highlight the most overrepresented 
(enriched) biological annotation. In our study enriched biological processes and pathways were 
identified using the GOTERM_BP_FAT and KEGG_PATHWAY algorithm, applying a p-value 
cutoff of 0.01. 
 
Data validation 
RT-qPCR is often used to validate microarray results (RNA levels) for the most interesting genes 
261, furthermore changes in gene expression can be validated at the protein level 261. In our study, 
38 genes with a biphasic pattern of regulation from T0, through T2 and T24 were identified by 
the stricter criteria used (log2-fold change cutoff 1.0, p < 0.01). Five genes were selected for 
validation by RT-qPCR. 
 
Similarly to DNA microarrays, RT-qPCR exploits the binding of complementary nucleic acid 
sequences 263. After reverse transcription of RNA to cDNA, the double-stranded DNA is 
denaturated at 95 C. Specific primers are used to bind to their complementary sequence on the 
two strands of cDNA, and the strands then are extended by a DNA polymerase. One copy of the 
DNA strand is made after each cycle, hence the number of copies will accumulate exponentially, 
and there will be a quantitative relationship between the amount of starting target sequence and 
the amount of PCR product accumulated at any particular cycle 264. Fluorescent probes were 
used to detect the number of amplicons 265. A fluorescence detection threshold is reached after a 
specific cycle depending on the initial concentration of the target DNA sequence, and relative 
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expression levels are calculated. The expression of house-keeping genes, constitutively 
expressed internal control genes, is used to normalize mRNA fraction.  cDNA from a reference 
cell line was included on all plates to be able to pool the patients and compare baseline 
expression levels between patients. The data were analyzed using the GeneExpression Analysis 
for iCycler iQ® Real-Time PCR Detection System Software (BioRad) and expressed as gene 
expression relative to the level in the reference cell line. The data were subsequently log2-
transformed and fold-change for T2 versus T0 and T24 versus T2 was calculated. 
 
6.4 Statistical analyses  
Except from the microarray/molecular profiling analyses, statistical analysis was performed 
using Predictive Analytics SoftWare Statistics version 19.0 and SigmaPlot software version 12. 
Two-sample Student’s t-test was used for comparisons of normally distributed continuous 
variables between groups. The non-parametric Mann-Whitney rank-sum was used when the 
distribution of data did not resemble the normal distribution, determined by Q-Q plots or the 
Shapiro-Wilk normality test. Categorical variables were analyzed using Pearson’s chi-square or 
Fisher exact tests. All statistical tests were 2-sided, and p<0.05 was considered statistically 
significant. Metastasis-free, disease-free and overall survival was estimated by the Kaplan-Meier 
method. The log-rank test was used to determine survival differences between groups of patients.   
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7 Discussion  
7.1  Towards a more personalized rectal cancer treatment? 
Cancer is a biologically heterogeneous disease resulting from accumulation of genetic and 
epigenetic alterations, and the clinical outcome varies among patients 257,266.  An overarching aim 
in cancer therapy is to customize treatment to provide the optimum result for the individual 
patient: personalized cancer therapy. The term ‘personalized cancer therapy’ is often used to 
describe the administration of targeted agents based on molecular characteristics of individual 
tumors 207, while a broader definition refers to tailoring of cancer treatment on the basis of 
individual patient characteristics. Based on tumor or patient characteristics, individuals may be 
classified into subpopulations with different predicted outcome and response to treatment.  
The clinical management of rectal cancer is an excellent example of how multimodal treatment 
regimens may be individualized, i.e. tailored to subgroups of patients 208. Clinicopathological 
factors, such as TNM staging, tumor histology and tumor resection margin (MRF)  are utilized to 
divide rectal cancer patients into risk groups, stratified to receive different treatment 267. Patients 
with LARC are treated with neoadjuvant fluoropyrimidine-based CRT, a treatment regimen that 
has proven to improve local control. Although most LARC tumors respond well to this 
treatment, some experience minimal or no treatment effect and may benefit from intensified 
treatment. As with any cancer therapy, the goal in rectal cancer treatment is to optimize outcome 
while minimizing treatment toxicity, and an increased treatment efficacy must be balanced 
towards potentially increased normal tissue effects. The standard preoperative treatment confers 
considerable early and late toxicity and some LARC patients may benefit from a less intensive 
preoperative treatment. To optimize survival and minimize treatment toxicity, rectal cancer 
treatment should be increasingly individualized.  
 
To allow improved staging and stratification of rectal cancer patients for more differentiated 
treatment, biomarkers that predict the response of an individual patient’s tumor to multimodal 
treatment and indicate treatment-associated toxicities prior to treatment are needed208.  The 
biology of tumor heterogeneity is only partially depicted by the existing diagnostic staging 
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approaches in rectal cancer, and additional biological biomarkers are warranted to allow more 
advanced stratification of patients. Over the past years, tumor heterogeneity at the molecular 
level has been increasingly explored and our understanding of the molecular biology of cancer 
has increased enormously. New technologies that characterize cancers on the molecular level 
have emerged, e.g. genome, transcriptome, proteome and kinome profiling 268. In addition to the 
identification of potential biomarkers, these technologies withhold potential to explore the tumor 
biology and identify novel molecular targets of therapy 208. High-throughput microarray-based 
molecular profiling has been utilized both to identify prognostic and predictive signatures as well 
as to explore the molecular aspects of rectal cancer 267.  
 
Tumor heterogeneity is also depicted by differences in the tumor microenvironment 269. Tumor 
hypoxia is an important element of the microenvironment known to be a mediator of resistance 
to cytotoxic therapy (radiation and chemotherapy) and metastatic disease progression.  While the 
problem of hypoxia has been addressed for many years, increased knowledge of the adaptive 
responses to hypoxia on a molecular level, together with and focus on personalized therapy, 
has reemphasized the importance of tumor hypoxia in cancer therapy.  
 
7.2 Hypoxic signaling and metastatic development 
Tumor hypoxia is one of the major forces driving the metastatic process 88. On the molecular 
level, adaptive cellular responses to hypoxia involve activation of a range of signaling pathways 
that interfere with regulatory mechanisms, collectively contributing to a malignant phenotype.  
Hypoxic signaling interferes with almost every step of the metastatic processes. Molecular 
profiling is a potential strategy to explore the biological complexity in hypoxic tumors. Tyrosine 
kinases are key mediators in signaling cascades activated by hypoxia and regulating central 
biological processes of malignancy, such as proliferation and angiogenesis. Studying the 
functional tumor kinome in early metastatic progression of rectal cancer could improve our 
understanding of the hypoxic response in metastasis, and potentially enable identification of 
actionable targets in hypoxic metastatic signaling.  
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The recently completed prospective phase II trial, the LARC-RRP study, offers a unique 
opportunity to explore the concept of tumor hypoxia as a determinant of metastatic behavior in a 
defined clinical context. Tyrosine kinase activity profiling of biopsies from primary tumors from 
which tumor cells had disseminated to the patients’ red bone marrow compartment at the time of 
diagnosis, interpreted as a biomarker of early systemic dissemination, allowed us to study 
molecular profiles of tumors with high metastatic recurrence risk. In paper I, we compared 
tumor kinase activity in LARC-patients with and without DTC in the bone marrow. Using 
peptide arrays with tyrosine kinase substrates, several kinases involved in angiogenic signaling 
were found to be differentially inhibited by the kinase-inhibitor sunitinib in tumor samples from 
patients with and without early tumor dissemination, implying different levels of tumor kinase 
activity in these patients. Interestingly, the ex vivo sunitinib inhibition of phosphorylation of 
PDGFRB array substrates by tumor samples from patients with DTC was significantly lower 
than for patients without DTC. Low sunitinib inhibition of PDGFRB phosphorylation may 
reflect a low level of PDGF-mediated signaling in these tumors. PDGF binds to its receptor 
expressed on pericytes, stimulating their proliferation and attachment to the endothelial layer 115. 
Pericytes within the primary tumor microenvironment probably serve as gatekeepers in tumor 
cell metastasis. Pericyte depletion, or a poor pericyte coverage of the tumor endothelium, may 
result from tumor hypoxia 88 and therefore be associated with poor patient prognosis. The role of 
pericytes in the process of tumor metastasis and the relationship to tumor hypoxia should be 
further explored.  
 
7.3 Hypoxic tumor radiosensitization by histone deacetylase inhibitors 
New insight into molecular radiobiology has provided an opportunity for the rational integration 
of molecularly targeted therapeutics in radiotherapy for biological optimization of radiation 
effect. An array of novel actionable molecular targets, which may be exploited to enhance tumor 
response to radiotherapy, have been uncovered; including targets in pathways involved in tumor 
proliferation, angiogenesis and hypoxia 38. Tumor hypoxia is recognized as a main contributor to 
clinical radiation resistance. Since the first description of the phenomena of hypoxic 
radioresistance more than 100 years ago, not long after the discovery of ionizing radiation, 
targeting of tumor hypoxia as a strategy to improve radiation response has been explored. With 
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the recent developments in molecular oncology, new strategies have emerged. An appealing 
strategy for improving radiation efficacy may be to counteract hypoxia-induced tumor signaling 
activity.  
 
The HDAC inhibitors were originally designed as epigenetic therapeutics for modification of the 
chromatin structure, but have been found to modify several non-histone proteins. HDAC 
inhibition influences several processes involved in cellular radiation response e.g. angiogenesis, 
DNA damage signaling, cell cycle progression and apoptosis, and are shown to exert 
radiosensitizing effect in experimental and clinical studies. Recently, results from experimental 
models have indicated that HDAC inhibitors suppress hypoxic signaling by repressing the HIF-
1α transcription factor, and this could be the mechanistic rationale for the observed 
radiosenstitizing properties of HDAC inhibitors 270. 
 
Preclinical evaluation of vorinostat 
Vorinostat, one of the most studied HDAC inhibitors and the first to be approved for clinical use, 
has been evaluated by our group in the preclinical and early clinical setting. Initially, tumor cell 
radiosensitization and associated cell cycle responses in human CRC cell lines incubated with 
HDAC inhibitors were assessed 203,271. In human CRC xenograft models, significant delay of 
tumor growth was observed following fractionated radiation combined with daily injections of 
the mice with vorinostat, compared to radiation treatment alone 203.  
 
In paper II the preclinical investigation of vorinostat was expanded by studying radiosensitizing 
effects by vorinostat under hypoxic conditions and in combination with capecitabine in vitro and 
in vivo.  It has been suggested that all radiosensitizers should be evaluated under hypoxia in 
preclinical models, at least in vitro, as the oxygenation level is highly relevant for the 
radioresponse 131. Vorinostat enhanced radiosensitivity of cell lines exposed to hypoxia during 
radiation, counterbalancing hypoxia-induced radioresistance. The tumor growth delay (relative to 
untreated tumors) of irradiated hypoxic xenografts in mice given vorinostat was similar to the 
growth delay of xenograft irradiated under normoxic conditions, suggesting that the drug 
contributed to abolish the radioresistant hypoxic phenotype.  
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Potential antagonistic effects of the combination of a new drug with an established standard 
treatment should be evaluated in the preclinical setting. Hence, in rectal cancer, potential 
radiosensitizers should be evaluated in combination with the standard 5-FU-based regimen. In 
our experiments, the combination of capecitabine and vorinostat increased radiosensitivity in 
terms of reduced clonogenic survival of cell cultures and delayed tumor growth of xenografts.  
 
Biomarkers of vorinostat activity in a clinical setting 
Following the initial preclinical evaluation of vorinostat, a phase I clinical trial, the PRAVO 
study was conducted. This trial, undertaken in patients treated with vorinostat combined with 
pelvic fractionated radiotherapy in advanced gastrointestinal malignancies, was the first to report 
on the use of an HDAC inhibitor in clinical radiotherapy, and demonstrated that vorinostat was 
well tolerated in combination with pelvic radiotherapy 182. In addition to evaluation of treatment 
tolerability and response, the trial was designed to identify potential pharmacodynamic 
biomarker or indicators of vorinostat action in clinical radiotherapy.  
 
In the setting of fractionated radiotherapy, a novel drug should elicit a radiosensitizing molecular 
event at each radiation fraction; hence a pharmacodynamic biomarker should reflect the timing 
of drug administration with regard to radiation exposure in a transient and periodic manner 149.  
Tumor histone hyperacetylation has been suggested as a pharmacodynamic biomarker of HDAC 
inhibitor activity. However, there are several limitations of tumor histone acetylation as a 
biomarker of vorinostat activity in combination with fractionated radiation. With the exception 
of the verification that vorinostat has reached its target, tumor acetylation does not seem to be a 
permissive requirement for radiosensitization by vorinostat 203. Additionally, biomarkers 
established for single-agent therapy will require reevaluation in clinical trials combining the 
agent with radiotherapy. The most direct method to study pharmacodynamic markers is by 
assessing tumor tissue, but the non-irradiated peripheral lymphocytes are suggested as a 
surrogate tissue in radiation trials if the objective is to determine mechanisms of a presumed 
radiosensitizing drug, as the radiation itself confers molecular perturbations in the tumor tissue. 
However, this method does not account for inherent tumor resistance mechanisms, such as drug 
efflux pumps or the inability of the drug to reach hypoxic tumors 169.  
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In paper III, we aimed to identify biomarkers of vorinostat activity, reflecting the appropriate 
timing of drug administration in fractionated radiotherapy applying gene expression array 
analysis of PRAVO study patients’ PBMC sampled at baseline (T0), and on-treatment two and 
24 hours (T2 and T24) after the patient had received vorinostat. 1600 array probes exhibited 
increased or decreased expression at T2, but returned to baseline level at T24, and were therefore 
identified as potential biomarkers reflecting timing of vorinostat administration in the 
fractionated radiotherapy protocol. Applying more stringent statistical criteria, the list of 
potential biomarkers was reduced to 38 candidates. Of these, we selected five genes for 
validation based on both the relevance in the DNA damage response, which is recognized as a 
mechanism contributing to radiosensitivity, and previous indication of regulation by HDAC 
inhibitors. The biphasic pattern of gene expression was confirmed for these genes by RT-qPCR. 
For the same five genes, expression levels in two CRC xenograft models 3 and 12 hours after 
vorinostat administration were assessed, but only the MYC regulation was validated in the 
xenograft models.  
 
It has been suggested that the myc protein acts synergistically with the transcription factor HIF1α 
under hypoxic conditions thereby increasing radiation resistance 272 273. As recent evidence 
indicates that HDAC inhibitors suppress HIF-1α activity, the radiosensitizing effect of HDAC 
inhibitors may potentially be mediated through suppression of the myc/HIF-1α synergy in 
hypoxic tumors.  
 
 
7.4 Neoadjuvant chemotherapy and tumor radiation response  
Most rectal cancer deaths are from systemic disease, and the administration of a 
chemotherapeutic agent in systemic doses to target micrometastatic disease is a potential strategy 
to reduce development of metastases. Adjuvant treatment has not been shown to improve 
survival 70; possibly because the systemic chemotherapy is administered too late to kill early 
disseminated cells before metastasis are established. Also, a substantial number of patients are 
not fit to receive chemotherapy postoperatively 40. Neoadjuvant chemotherapy prior to CRT 
(induction therapy) is an alternative strategy to deliver systemic chemotherapy. Other 
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neoadjuvant strategies are chemotherapy after CRT (consolidation therapy) or chemotherapy 
alone without CRT 143. Applied in a neoadjuvant setting, a chemotherapeutic agent will target the 
primary tumor in addition to micrometastases. In this setting, the chemotherapeutic agent can be 
given at full systemic doses, but still with potentially acceptable toxicity. Reports from non-
randomized and randomized phase II trials evaluating the addition of NACT to CRT in LARC 
are encouraging, with high local control rates and promising long-term outcomes 71-75.  A phase 
III trial is recruiting patients to be randomized to receive CRT alone or NACT followed by CRT 
(ClinicalTrials NCT01804790) 14,212,274.   
 
Administered as NACT prior to CRT, a chemotherapeutic agent could potentially kill non-
hypoxic cells, and by selecting for radioresistant hypoxic tumor cells reduce the efficacy of 
subsequent CRT. In the clinical setting, NACT might impact CRT efficacy if the added toxicity 
would necessitate dose reductions and interruptions in CRT treatment275 as well as increase the 
risk of surgical complications. Tumor radiation response following exposure to a potential 
neoadjuvant chemotherapeutic agent should therefore be evaluated in experimental and clinical 
settings. In Paper IV we evaluated tumor response to NACT and CRT by MR volumetry in the 
phase II LARC-RRP study of patients receiving OXA-based NACT prior to CRT. A substantial 
downsizing of the primary tumor was observed after NACT (median tumor volume reduction 
63%). An additional volume reduction of similar magnitude was observed after CRT (median 
tumor volume reduction 68%) and was not influenced by the response to NACT. The additional 
tumor volume reduction seemed to be larger in the group with poor NACT response (69 versus 
60%), but the difference was not significant.  
 
To study the influence of OXA-treatment prior to radiation in a preclinical setting, we assessed 
radiosensitivity by the in vitro clonogenic assay in OXA-resistant variants of two CRC cell lines. 
Interestingly, the experimental radiosensitivity of OXA-resistant cell lines was increased, rather 
than decreased, compared to the parental cell line. A possible mechanism for the (OXA-induced) 
enhanced radiosensitivity, is specific targeting of radioresistant hypoxic cells by OXA.  
 
Only 11% of the LARC-RRP patients required NACT dose adjustment because of acute 
toxicity.  Radiation-induced acute toxicities may cause interruption in treatment delivery and 
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delay definitive surgical treatment, whereas surgical complications and long-term functional 
impairment may strongly impede patients’ quality of life 43,46. As responses to OXA-based 
NACT in terms of tumor volume reduction was unexpectedly large in most patients in our 
study, the administration of NACT might be an alternative to CRT for selected patients, with 
the benefit of less normal tissue toxicity. Preliminary results from ongoing phase II trials 
evaluating NACT without CRT in moderate risk LARC patients, indicate encouraging efficacy 
276, 277. If applied as induction therapy, early evaluation of response to NACT would allow 
stratification of patients into prognostic groups scheduled to receive different treatment, i.e. 
intensified CRT or no CRT. A planned phase III study (PROSPECT) will evaluate the impact 
of selective use of radiation. In this study intermediate-risk patients will be randomized to 
receive NACT and responders will proceed directly to rectal cancer surgery 278.  
 
An alternative approach to the standard CRT is NACT and short-course radiation before delayed 
surgery, assessed in the RAPIDO phase II trial 279. Outcome and toxicity rates for the two 
preoperative radiotherapy regimens are similar 280,281. In less advanced rectal tumors where 
downsizing is not necessary, the convenient short-course radiotherapy is equivalent to CRT 9. 
Studies indicate that downsizing after short-course radiotherapy can be achieved if surgery is 
delayed  282, 283. 
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8 Conclusions  
 
In this work, recognizing that rectal cancer is a heterogeneous disease in terms of response to 
treatment and the ability to metastasize, we have shown that: 
 
1. Angiogenesis-related tumor signaling, particularly kinase activity mediated by PDGFR, 
was inhibited by sunitinib in LARC patients without detectable tumor cells in bone 
marrow at the time of diagnosis. 
 
If intact tumor angiogenic signaling of pericytes reflects a low likelihood of early 
systemic disease dissemination, deregulated PDGFR signaling may correspondingly 
manifest dysfunctional tumor vasculature and increased risk of tumor cell dissemination. 
Even with the complexity of recent study data on the use of anti-angiogenic therapeutics 
in CRC, the concept of tumor vasculature normalization withholds the potential to 
prevent development of metastasis and also to improve responses to radiation and 
chemotherapy 284,285. 
 
2. The HDAC inhibitor vorinostat exhibited radiosensitizing effects under hypoxic 
conditions and in combination with capecitabine in experimental CRC models.  
 
These results support the hypothesis that vorinostat targets hypoxic radioresistant cells 
and encourage the introduction of vorinostat in CRT trials in high-risk LARC. 
Intensification of CRT in rectal cancer by the addition of vorinostat may improve 
treatment responses in a subgroup of poor-responding patients with treatment failure 
ascribed to tumor hypoxia.  
 
3. Several potential biomarkers of HDAC inhibitor activity, e.g. transient MYC repression, 
were identified by PBMC gene expression profiling of patients in a phase I study 
receiving vorinostat and fractionated pelvic radiotherapy.  
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The strategy of gene expression array analysis of non-irradiated surrogate tissue 
identified genes with transient induction or repression following vorinostat 
administration, fulfilling the requirement of being pharmacodynamic biomarkers for 
HDAC inhibitor activity in fractionated radiotherapy. In studying systemic agents with 
presumed radiosensitizing activity, trial design to allow identification of biomarker 
endpoints both of drug action and of treatment tolerability and response needs particular 
attention, and we believe the present study design may function as a template set-up for 
future LARC trials. 
 
4. In a phase II study of LARC patients, OXA-containing NACT led to substantial tumor 
volume reduction with particularly good responses in T3 cases, without compromising 
subsequent CRT response. Experimental CRC models that were made OXA-resistant 
showed enhanced radiosensitivity compared to the respective OXA-sensitive 
counterparts. 
 
These results suggest that OXA-containing NACT might be an alternative to CRT in low-
risk T3 rectal cancer, offering a more favorable toxicity profile, and that OXA-containing 
chemotherapy might even contribute to enhancement of tumor radiation sensitivity.  
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9 Perspectives 
 
As a common determinant of resistance to radiotherapy and development of metastasis, tumor 
hypoxia is recognized as a central aspect of tumor heterogeneity in rectal cancer. To improve 
treatment strategies for hypoxic tumors, further exploration of the complex network of the 
hypoxic cellular response is necessary, to elucidate mechanisms on how hypoxia drives the 
metastatic process and to characterize regulatory mechanisms of hypoxic radiation resistance.  
 
The identification of reliable biomarkers of tumor hypoxia is warranted for use in clinical trials 
and ultimately in clinical practice. In this respect, functional MRI represents a promising 
technology for non-invasive assessment of the degree of tumor hypoxia. The combination of 
functional imaging with molecular tumor profiling may represent a novel approach to the 
detection of biomarkers as well as actionable targets of hypoxia. The ongoing OxyTarget clinical 
study at Akershus University Hospital (ClinicalTrials NCT01816607) is evaluating this approach 
in rectal cancer patients. 
 
High-risk rectal cancer patients, identified by predictive or prognostic markers (e.g. markers of 
tumor hypoxia), could benefit from an intensified CRT with targeted radiosensitizers. A potential 
strategy to target tumor hypoxia in radiation response is to combine radiotherapy with HDAC 
inhibitors. There are currently a number of clinical trials investigating the combination of HDAC 
inhibitors and radiotherapy in various cancer forms. Our group has demonstrated encouraging 
results of the HDAC inhibitor vorinostat as radiosensitizer in experimental CRC models and with 
acceptable safety in the clinical phase I setting, and the next step should be a phase I/II trial 
evaluating vorinostat as additional component of preoperative CRT in LARC. 
 
The potential role of NACT in rectal cancer is currently being explored in clinical trials. 
Metastatic disease is the main cause of treatment failure in rectal cancer, and administration of a 
systemic therapeutic agent may reduce the risk of metastatic development. While high-risk rectal 
cancer patients may benefit of NACT in addition to CRT, the concept of replacing CRT with 
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NACT in patients at low risk of local recurrences might spare patients from radiotherapy-related 
toxicity. 
 
Taken together, treatment of rectal cancer in the near future will certainly apply increasingly 
personalized approaches by tailoring multimodal treatment to the specific requirements of each 
patient.  
 
75 
 
 
10 References 
1. Ferlay, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 
2012. Eur J Cancer 49, 1374-1403 (2012). 
2. Valentini, V., et al. Evidence and research in rectal cancer. Radiother Oncol 87, 449-474 (2008). 
3. Weber, G.F., Rosenberg, R., Murphy, J.E., Meyer zum Buschenfelde, C. & Friess, H. Multimodal 
treatment strategies for locally advanced rectal cancer. Expert Rev Anticancer Ther 12, 481-494 
(2012). 
4. Cancer-Registry-of-Norway. Cancer in Norway 2011 - Cancer incidence, mortality, survival and 
prevalence in Norway.  (Oslo, 2013). 
5. Bray, F., Wibe, A., Dorum, L.M. & Moller, B. [Epidemiology of colorectal cancer in Norway]. 
Tidsskr Nor Laegeforen 127, 2682-2687 (2007). 
6. Ferlay, J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J 
Cancer 127, 2893-2917 (2010). 
7. Verdecchia, A., et al. Recent cancer survival in Europe: a 2000-02 period analysis of 
EUROCARE-4 data. Lancet Oncol 8, 784-796 (2007). 
8. Coleman, M.P., et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the 
UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-
based cancer registry data. Lancet 377, 127-138 (2011). 
9. Schmoll, H.J., et al. ESMO Consensus Guidelines for management of patients with colon and 
rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23, 2479-2516 
(2012). 
10. Wang, A.Y. & Ahmad, N.A. Rectal carcinoids. Curr Opin Gastroenterol 22, 529-535 (2006). 
11. Shin, U.S., et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and 
prognosis. Ann Surg Oncol 18, 2232-2239 (2011). 
12. Oberholzer, K., et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging 
indicates poor response to neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 82, 842-848 
(2012). 
13. American-Joint-Comittee-on-Cancer (ed.) Cancer staging handbook, (American-Joint-
Committee-on-Cancer, 2010). 
14. Dewdney, A., Cunningham, D. & Chau, I. Selecting patients with locally advanced rectal cancer 
for neoadjuvant treatment strategies. Oncologist 18, 833-842 (2013). 
15. Pahlman, L. & Torkzad, M.R. Rectal cancer staging: is there an optimal method? Future Oncol 7, 
93-100 (2011). 
16. Yeung, J.M., Ferris, N.J., Lynch, A.C. & Heriot, A.G. Preoperative staging of rectal cancer. 
Future Oncol 5, 1295-1306 (2009). 
17. Norwegian-Gastrointestinal-Cancer-Group. National Programme for preoperative radiotherapy in 
rectal cancer. (2012). 
18. Nagtegaal, I.D. & Quirke, P. What is the role for the circumferential margin in the modern 
treatment of rectal cancer? J Clin Oncol 26, 303-312 (2008). 
19. Glimelius, B., et al. Mesorectal fascia instead of circumferential resection margin in preoperative 
staging of rectal cancer. J Clin Oncol 29, 2142-2143 (2011). 
20. Wibe, A., et al. Prognostic significance of the circumferential resection margin following total 
mesorectal excision for rectal cancer. Br J Surg 89, 327-334 (2002). 
21. Quirke, P., Durdey, P., Dixon, M.F. & Williams, N.S. Local recurrence of rectal adenocarcinoma 
due to inadequate surgical resection. Histopathological study of lateral tumour spread and 
surgical excision. Lancet 2, 996-999 (1986). 
22. Smith, N. & Brown, G. Preoperative staging of rectal cancer. Acta Oncol 47, 20-31 (2008). 
23. MERCURY-Study-Group. Extramural depth of tumor invasion at thin-section MR in patients 
with rectal cancer: results of the MERCURY study. Radiology 243, 132-139 (2007). 
76 
 
 
24. Taylor, F.G., et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction 
of surgical margin status in rectal cancer. Br J Surg 98, 872-879 (2011). 
25. Shihab, O.C., et al. Relevance of magnetic resonance imaging-detected pelvic sidewall lymph 
node involvement in rectal cancer. Br J Surg 98, 1798-1804 (2011). 
26. van de Velde, C.J., et al. EURECCA colorectal: Multidisciplinary management: European 
consensus conference colon & rectum. Eur J Cancer (2013). 
27. Steel, G. (ed.) Basic Clinical Radiobiology, (Arnold, 2002). 
28. Rodel, C., Hofheinz, R. & Liersch, T. Rectal cancer: state of the art in 2012. Curr Opin Oncol 24, 
441-447 (2012). 
29. Aklilu, M. & Eng, C. The current landscape of locally advanced rectal cancer. Nat Rev Clin 
Oncol 8, 649-659. 
30. Wibe, A., et al. A national strategic change in treatment policy for rectal cancer--implementation 
of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 
45, 857-866 (2002). 
31. Swedish-rectal-cancer-trial. Improved survival with preoperative radiotherapy in resectable rectal 
cancer. Swedish Rectal Cancer Trial. N Engl J Med 336, 980-987 (1997). 
32. Kapiteijn, E., et al. Preoperative radiotherapy combined with total mesorectal excision for 
resectable rectal cancer. N Engl J Med 345, 638-646 (2001). 
33. Sauer, R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J 
Med 351, 1731-1740 (2004). 
34. Patel, P.A. Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer. 
Anticancer Drugs 22, 311-316 (2011). 
35. Marijnen, C.A., et al. No downstaging after short-term preoperative radiotherapy in rectal cancer 
patients. J Clin Oncol 19, 1976-1984 (2001). 
36. Rodel, C., Trojan, J., Bechstein, W.O. & Woeste, G. Neoadjuvant short- or long-term 
radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis 30 Suppl 2, 102-
108 (2012). 
37. Bischoff, P., Altmeyer, A. & Dumont, F. Radiosensitising agents for the radiotherapy of cancer: 
advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat 19, 643-662 
(2009). 
38. Dumont, F., Altmeyer, A. & Bischoff, P. Radiosensitising agents for the radiotherapy of cancer: 
novel molecularly targeted approaches. Expert Opin Ther Pat 19, 775-799 (2009). 
39. Gerard, J.P., et al. Preoperative radiotherapy with or without concurrent fluorouracil and 
leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24, 4620-4625 (2006). 
40. Bosset, J.F., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 
355, 1114-1123 (2006). 
41. Hofheinz, R.D., et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally 
advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13, 
579-588 (2012). 
42. Roh, M.S., Yothers G. A., O'Connell M. J. The impact of capecitabine and oxaliplatin in the 
preoperative multilmodality treatment in patients with carcinoma of the rectum: NSABP R-04. 
Journal of Clinical Oncology 29(2011). 
43. Braendengen, M., et al. Late patient-reported toxicity after preoperative radiotherapy or 
chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. Int 
J Radiat Oncol Biol Phys 81, 1017-1024 (2011). 
44. Glimelius, B., Holm, T. & Blomqvist, L. Chemotherapy in addition to preoperative radiotherapy 
in locally advanced rectal cancer - a systematic overview. Rev Recent Clin Trials 3, 204-211 
(2008). 
45. Wolff, H.A., et al. Gender affects acute organ toxicity during radiochemotherapy for rectal 
cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol 108, 
48-54 (2013). 
77 
 
 
46. Bruheim, K., et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J 
Radiat Oncol Biol Phys 76, 1005-1011 (2010). 
47. Compton, C., Fenoglio-Preiser, C.M., Pettigrew, N. & Fielding, L.P. American Joint Committee 
on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88, 
1739-1757 (2000). 
48. Maas, M., et al. Long-term outcome in patients with a pathological complete response after 
chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11, 
835-844 (2010). 
49. Rodel, C., et al. Prognostic significance of tumor regression after preoperative 
chemoradiotherapy for rectal cancer. J Clin Oncol 23, 8688-8696 (2005). 
50. Bouzourene, H., Bosman, F.T., Seelentag, W., Matter, M. & Coucke, P. Importance of tumor 
regression assessment in predicting the outcome in patients with locally advanced rectal 
carcinoma who are treated with preoperative radiotherapy. Cancer 94, 1121-1130 (2002). 
51. Glynne-Jones, R., Mawdsley, S., Pearce, T. & Buyse, M. Alternative clinical end points in rectal 
cancer--are we getting closer? Ann Oncol 17, 1239-1248 (2006). 
52. Evans, J., Patel, U. & Brown, G. Rectal cancer: primary staging and assessment after 
chemoradiotherapy. Semin Radiat Oncol 21, 169-177 (2011). 
53. Barbaro, B., et al. Locally advanced rectal cancer: MR imaging in prediction of response after 
preoperative chemotherapy and radiation therapy. Radiology 250, 730-739 (2009). 
54. Hole, K.H., Larsen, S.G., Groholt, K.K., Giercksky, K.E. & Ree, A.H. Magnetic resonance-
guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant 
treatment in organ-infiltrating rectal cancer. Radiother Oncol 107, 178-183 (2013). 
55. Patel, U.B., et al. Magnetic resonance imaging-detected tumor response for locally advanced 
rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29, 3753-3760 
(2011). 
56. Yeo, S.G., et al. Tumor volume reduction rate after preoperative chemoradiotherapy as a 
prognostic factor in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 82, e193-199 
(2012). 
57. Yeo, W., et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular 
carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors 
from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J 
Clin Oncol 30, 3361-3367 (2012). 
58. Nougaret, S., et al. MR volumetric measurement of low rectal cancer helps predict tumor 
response and outcome after combined chemotherapy and radiation therapy. Radiology 263, 409-
418 (2012). 
59. Lambrecht, M., et al. Value of diffusion-weighted magnetic resonance imaging for prediction and 
early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary 
results. Int J Radiat Oncol Biol Phys 82, 863-870 (2012). 
60. Mathoulin-Pelissier, S., Gourgou-Bourgade, S., Bonnetain, F. & Kramar, A. Survival end point 
reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 26, 3721-
3726 (2008). 
61. Aschele, C., et al. Primary tumor response to preoperative chemoradiation with or without 
oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized 
phase III trial. J Clin Oncol 29, 2773-2780 (2010). 
62. Gerard, J.P., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally 
advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 
28, 1638-1644 (2010). 
63. Gerard, J.P., et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in 
rectal cancer. J Clin Oncol 30, 4558-4565 (2012). 
78 
 
 
64. Rodel, C., et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 
fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial 
results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13, 679-687 
(2012). 
65. PETACC6-trial-NCT00766155. clinical.trials.gov. 
66. Glynne-Jones, R. & Kronfli, M. Locally advanced rectal cancer: a comparison of management 
strategies. Drugs 71, 1153-1177 (2011). 
67. Glimelius, B., et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised 
trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44, 904-912 
(2005). 
68. Bujko, K., Glynne-Jones, R. & Bujko, M. Adjuvant chemotherapy for rectal cancer. Ann Oncol 
21, 2443 (2010). 
69. Glimelius, B. Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in 
Europe? Nat Clin Pract Oncol 1, 58-59 (2004). 
70. Bosset, J.F., et al. Fluorouracil-based adjuvant chemotherapy after preoperative 
chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. 
Lancet Oncol (2014). 
71. Calvo, F.A., et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced 
rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative 
chemoradiation. Ann Oncol 17, 1103-1110 (2006). 
72. Chua, Y.J., et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total 
mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11, 241-
248 (2010). 
73. Chau, I., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous 
chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk 
rectal cancer. J Clin Oncol 24, 668-674 (2006). 
74. Koeberle, D., et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently 
with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 
98, 1204-1209 (2008). 
75. Gunnlaugsson, A., et al. Multicentre phase II trial of capecitabine and oxaliplatin in combination 
with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. Eur J Cancer 45, 807-
813 (2009). 
76. Overgaard, J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25, 4066-4074 
(2007). 
77. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer 
Metastasis Rev 26, 225-239 (2007). 
78. Chan, D.A. & Giaccia, A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26, 
333-339 (2007). 
79. Ebbesen, P., et al. Taking advantage of tumor cell adaptations to hypoxia for developing new 
tumor markers and treatment strategies. J Enzyme Inhib Med Chem 24 Suppl 1, 1-39 (2009). 
80. Brown, J.M. & Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 
437-447 (2004). 
81. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist 9 Suppl 5, 10-
17 (2004). 
82. Harris, A.L. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47 (2002). 
83. Rademakers, S.E., et al. Molecular aspects of tumour hypoxia. Mol Oncol 2, 41-53 (2008). 
84. Vaupel, P., Mayer, A. & Hockel, M. Tumor hypoxia and malignant progression. Methods 
Enzymol 381, 335-354 (2004). 
85. Harada, H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res 52, 545-556 
(2011). 
79 
 
 
86. Li, S.P., Padhani, A.R. & Makris, A. Dynamic contrast-enhanced magnetic resonance imaging 
and blood oxygenation level-dependent magnetic resonance imaging for the assessment of 
changes in tumor biology with treatment. J Natl Cancer Inst Monogr, 103-107 (2011). 
87. Bristow, R.G. & Hill, R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic 
instability. Nat Rev Cancer 8, 180-192 (2008). 
88. De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: 
risky liaisons, or not? Nat Rev Clin Oncol 8, 393-404 (2011). 
89. Yoo, Y.G., Christensen, J. & Huang, L.E. HIF-1alpha confers aggressive malignant traits on 
human tumor cells independent of its canonical transcriptional function. Cancer Res 71, 1244-
1252 (2011). 
90. Lendahl, U., Lee, K.L., Yang, H. & Poellinger, L. Generating specificity and diversity in the 
transcriptional response to hypoxia. Nat Rev Genet 10, 821-832 (2009). 
91. Bernier, J., Hall, E.J. & Giaccia, A. Radiation oncology: a century of achievements. Nat Rev 
Cancer 4, 737-747 (2004). 
92. Gray, L.H., Conger, A.D., Ebert, M., Hornsey, S. & Scott, O.C. The concentration of oxygen 
dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26, 638-648 
(1953). 
93. Thomlinson, R.H. & Gray, L.H. The histological structure of some human lung cancers and the 
possible implications for radiotherapy. Br J Cancer 9, 539-549 (1955). 
94. Hall, E.G., AJ. Radiobiology for the Radiologist.  (Lippincott Williams & Wilkins, 2006). 
95. Bertout, J.A., Patel, S.A. & Simon, M.C. The impact of O2 availability on human cancer. Nat Rev 
Cancer 8, 967-975 (2008). 
96. Meijer, T.W., Kaanders, J.H., Span, P.N. & Bussink, J. Targeting hypoxia, HIF-1, and tumor 
glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18, 5585-5594 (2012). 
97. Shannon, A.M. & Williams, K.J. Antiangiogenics and radiotherapy. J Pharm Pharmacol 60, 
1029-1036 (2008). 
98. Williams, K.J., et al. Enhanced response to radiotherapy in tumours deficient in the function of 
hypoxia-inducible factor-1. Radiother Oncol 75, 89-98 (2005). 
99. Moeller, B.J. & Dewhirst, M.W. HIF-1 and tumour radiosensitivity. Br J Cancer 95, 1-5 (2006). 
100. Garcia-Barros, M., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. 
Science 300, 1155-1159 (2003). 
101. Raza, A., Franklin, M.J. & Dudek, A.Z. Pericytes and vessel maturation during tumor 
angiogenesis and metastasis. Am J Hematol 85, 593-598 (2010). 
102. Yonenaga, Y., et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels 
correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 
69, 159-166 (2005). 
103. Cooke, V.G., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal 
transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-81 (2012). 
104. Wilson, W.R. & Hay, M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 393-410 
(2011). 
105. Begg, A.C., Stewart, F.A. & Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat 
Rev Cancer 11, 239-253 (2011). 
106. Palayoor, S.T., et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances 
radiosensitivity of prostate carcinoma cells. Int J Cancer 123, 2430-2437 (2008). 
107. Chen, S. & Sang, N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress 
hypoxia-inducible factors. J Biomed Biotechnol 2011, 197946 (2011). 
108. Ali, M.A., et al. SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting 
hypoxia inducible factor-1alpha expression. Int J Oncol 34, 1051-1060 (2009). 
109. Gieling, R.G. & Williams, K.J. Carbonic anhydrase IX as a target for metastatic disease. Bioorg 
Med Chem 21, 1470-1476 (2012). 
80 
 
 
110. Valastyan, S. & Weinberg, R.A. Tumor metastasis: molecular insights and evolving paradigms. 
Cell 147, 275-292 (2011). 
111. Fidler, I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev 
Cancer 3, 453-458 (2003). 
112. Weis, S.M. & Cheresh, D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. 
Nat Med 17, 1359-1370 (2011). 
113. Carmeliet, P. & Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. 
Nature 473, 298-307 (2011). 
114. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 
(2011). 
115. Gerhardt, H. & Semb, H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl) 86, 
135-144 (2008). 
116. Bogenrieder, T. & Herlyn, M. Axis of evil: molecular mechanisms of cancer metastasis. 
Oncogene 22, 6524-6536 (2003). 
117. De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: 
risky liaisons, or not? Nat Rev Clin Oncol 8, 393-404. 
118. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat Rev Clin Oncol 6, 
339-351 (2009). 
119. Paget. The distribution of secondary growths in cancer of the breast. The Lancet 1, 571-573 
(1880). 
120. DeVita, V.T., Jr. & Chu, E. A history of cancer chemotherapy. Cancer Res 68, 8643-8653 (2008). 
121. Heald, R.J., Husband, E.M. & Ryall, R.D. The mesorectum in rectal cancer surgery--the clue to 
pelvic recurrence? Br J Surg 69, 613-616 (1982). 
122. Caley, A.K.A.T.J. Adjuvant therapy. Medicine 40, 1-4 (2011). 
123. Connell, P.P. & Hellman, S. Advances in radiotherapy and implications for the next century: a 
historical perspective. Cancer Res 69, 383-392 (2009). 
124. Skliarenko, J.W.P. Radiotherapy: practical applications and clinical aspects. Medicine 39, 705-
710 (2011). 
125. Vordermark, D. Ten years of progress in radiation oncology. BMC Cancer 11, 503 (2011). 
126. Formenti, S.C. & Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol 10, 718-726 
(2009). 
127. Withers, H.R. Biological basis of radiation therapy for cancer. Lancet 339, 156-159 (1992). 
128. Steel, G.G., McMillan, T.J. & Peacock, J.H. The 5Rs of radiobiology. Int J Radiat Biol 56, 1045-
1048 (1989). 
129. Harrington, K., Jankowska, P. & Hingorani, M. Molecular biology for the radiation oncologist: 
the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol (R Coll Radiol) 19, 561-571 
(2007). 
130. Selzer, E. & Hebar, A. Basic principles of molecular effects of irradiation. Wien Med Wochenschr 
162, 47-54 (2012). 
131. Harrington, K.J., et al. Guidelines for preclinical and early phase clinical assessment of novel 
radiosensitisers. Br J Cancer 105, 628-639 (2011). 
132. Seiwert, T.Y., Salama, J.K. & Vokes, E.E. The concurrent chemoradiation paradigm--general 
principles. Nat Clin Pract Oncol 4, 86-100 (2007). 
133. Mohiuddin, M. & Mohiuddin, M.M. Neoadjuvant chemoradiation in rectal cancer: time to start in 
a new direction. J Clin Oncol 29, e350-351; author reply e352-353 (2011). 
134. Martin, L.K. & Bekaii-Saab, T. Optimizing neoadjuvant therapy for rectal cancer with 
oxaliplatin. J Natl Compr Canc Netw 11, 298-307; quiz 307 (2013). 
135. Shewach, D.S. & Lawrence, T.S. Antimetabolite radiosensitizers. J Clin Oncol 25, 4043-4050 
(2007). 
81 
 
 
136. O'Connell, M.J., et al. Improving adjuvant therapy for rectal cancer by combining protracted-
infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331, 502-507 
(1994). 
137. Stein, A. & Arnold, D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 13, 
125-137 (2012). 
138. Andre, T., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as 
adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27, 3109-
3116 (2009). 
139. de Gramont, A., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line 
treatment in advanced colorectal cancer. J Clin Oncol 18, 2938-2947 (2000). 
140. Nordlinger, B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery 
alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a 
randomised controlled trial. Lancet 371, 1007-1016 (2008). 
141. Hermann, R.M., Rave-Frank, M. & Pradier, O. Combining radiation with oxaliplatin: a review of 
experimental results. Cancer Radiother 12, 61-67 (2008). 
142. Folkvord, S., et al. Inhibitory effects of oxaliplatin in experimental radiation treatment of 
colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? 
Radiother Oncol 86, 428-434 (2008). 
143. Glynne-Jones, R., Anyamene, N., Moran, B. & Harrison, M. Neoadjuvant chemotherapy in MRI-
staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? 
Ann Oncol 23, 2517-2526 (2012). 
144. Zhukov, N.V. & Tjulandin, S.A. Targeted therapy in the treatment of solid tumors: practice 
contradicts theory. Biochemistry (Mosc) 73, 605-618 (2008). 
145. Sledge, G.W., Jr. What is targeted therapy? J Clin Oncol 23, 1614-1615 (2005). 
146. Adjei, A.A. & Hidalgo, M. Intracellular signal transduction pathway proteins as targets for cancer 
therapy. J Clin Oncol 23, 5386-5403 (2005). 
147. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001). 
148. Ma, B., Corry, J., Rischin, D., Leong, T. & Peters, L.J. Combined modality treatment for locally 
advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case 
report and review of the literature. Ann Oncol 12, 1015-1017 (2001). 
149. Ree, A.H. & Hollywood, D. Design and conduct of early-phase radiotherapy trials with targeted 
therapeutics: Lessons from the PRAVO experience. Radiother Oncol 108, 3-16 (2013). 
150. Glynne-Jones, R., Mawdsley, S. & Harrison, M. Antiepidermal growth factor receptor 
radiosensitizers in rectal cancer. Anticancer Drugs 22, 330-340 (2011). 
151. Torino, F., Sarmiento, R. & Gasparini, G. The contribution of targeted therapy to the neoadjuvant 
chemoradiation of rectal cancer. Crit Rev Oncol Hematol 87, 283-305 (2013). 
152. Bonner, J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and 
neck. N Engl J Med 354, 567-578 (2006). 
153. Weiss, C., et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and 
oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int 
J Radiat Oncol Biol Phys 78, 472-478 (2010). 
154. Grimminger, P.P., et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in 
locally advanced rectal cancer. Clin Cancer Res 17, 3469-3477 (2011). 
155. Palumbo, I., et al. Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a 
colorectal cancer cell line. Int J Colorectal Dis (2013). 
156. Valentini, V., et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with 
preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial 
(1839IL/0092). Int J Radiat Oncol Biol Phys 72, 644-649 (2008). 
157. Cao, Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv 
Cancer Res 100, 113-131 (2008). 
82 
 
 
158. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. 
Science 307, 58-62 (2005). 
159. Marquardt, F., Rodel, F., Capalbo, G., Weiss, C. & Rodel, C. Molecular targeted treatment and 
radiation therapy for rectal cancer. Strahlenther Onkol 185, 371-378 (2009). 
160. Hurwitz, H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic 
colorectal cancer. N Engl J Med 350, 2335-2342 (2004). 
161. Allegra, C.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the 
colon: results of NSABP protocol C-08. J Clin Oncol 29, 11-16 (2011). 
162. de Gramont, A., et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment 
for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13, 1225-1233 
(2012). 
163. Willett, C.G., et al. Combined vascular endothelial growth factor-targeted therapy and 
radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33, S35-40 (2006). 
164. Willett, C.G., et al. A safety and survival analysis of neoadjuvant bevacizumab with standard 
chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced 
rectal cancer. Oncologist 15, 845-851 (2010). 
165. Landry, J.C., et al. Phase 2 study of preoperative radiation with concurrent capecitabine, 
oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, 
oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 
3204. Cancer 119, 1521-1527 (2012). 
166. Stratton, M.R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553-
1558 (2011). 
167. Tang, J., Yan, H. & Zhuang, S. Histone deacetylases as targets for treatment of multiple diseases. 
Clin Sci (Lond) 124, 651-662 (2013). 
168. Inche, A.G. & La Thangue, N.B. Chromatin control and cancer-drug discovery: realizing the 
promise. Drug Discov Today 11, 97-109 (2006). 
169. Shabason, J.E., Tofilon, P.J. & Camphausen, K. Grand rounds at the National Institutes of Health: 
HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15, 2735-2744 
(2011). 
170. Camphausen, K. & Tofilon, P.J. Inhibition of histone deacetylation: a strategy for tumor 
radiosensitization. J Clin Oncol 25, 4051-4056 (2007). 
171. Khan, O. & La Thangue, N.B. HDAC inhibitors in cancer biology: emerging mechanisms and 
clinical applications. Immunol Cell Biol 90, 85-94 (2012). 
172. Spiegel, S., Milstien, S. & Grant, S. Endogenous modulators and pharmacological inhibitors of 
histone deacetylases in cancer therapy. Oncogene 31, 537-551 (2012). 
173. Richon, V.M., Garcia-Vargas, J. & Hardwick, J.S. Development of vorinostat: current 
applications and future perspectives for cancer therapy. Cancer Lett 280, 201-210 (2009). 
174. Koprinarova, M., Botev, P. & Russev, G. Histone deacetylase inhibitor sodium butyrate enhances 
cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous 
recombination. DNA Repair (Amst) 10, 970-977 (2011). 
175. Ellis, L., Hammers, H. & Pili, R. Targeting tumor angiogenesis with histone deacetylase 
inhibitors. Cancer Lett 280, 145-153 (2009). 
176. Qian, D.Z., et al. Class II histone deacetylases are associated with VHL-independent regulation of 
hypoxia-inducible factor 1 alpha. Cancer Res 66, 8814-8821 (2006). 
177. Giannini, G., Cabri, W., Fattorusso, C. & Rodriquez, M. Histone deacetylase inhibitors in the 
treatment of cancer: overview and perspectives. Future Med Chem 4, 1439-1460 (2012). 
178. Baylin, S.B. & Jones, P.A. A decade of exploring the cancer epigenome - biological and 
translational implications. Nat Rev Cancer 11, 726-734 (2011). 
179. Ramalingam, S.S., et al. Carboplatin and Paclitaxel in combination with either vorinostat or 
placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28, 56-62 
(2010). 
83 
 
 
180. Fakih, M.G., Groman, A., McMahon, J., Wilding, G. & Muindi, J.R. A randomized phase II 
study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory 
colorectal cancer. Cancer Chemother Pharmacol 69, 743-751 (2010). 
181. Munster, P.N., et al. A phase II study of the histone deacetylase inhibitor vorinostat combined 
with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J 
Cancer 104, 1828-1835 (2011). 
182. Ree, A.H., et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative 
radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 
1 study. Lancet Oncol 11, 459-464 (2010). 
183. Richon, V.M. Targeting histone deacetylases: development of vorinostat for the treatment of 
cancer. Epigenomics 2, 457-465 (2010). 
184. Biomarkers-Definitions-Working-Group. Biomarkers and surrogate endpoints: preferred 
definitions and conceptual framework. Clin Pharmacol Ther 69, 89-95 (2001). 
185. Strimbu, K. & Tavel, J.A. What are biomarkers? Curr Opin HIV AIDS 5, 463-466 (2010). 
186. Krause, M. & Baumann, M. Clinical biomarkers of kinase activity: examples from EGFR 
inhibition trials. Cancer Metastasis Rev 27, 387-402 (2008). 
187. Yaromina, A., Krause, M. & Baumann, M. Individualization of cancer treatment from 
radiotherapy perspective. Mol Oncol 6, 211-221 (2012). 
188. Benchimol, S., et al. Carcinoembryonic antigen, a human tumor marker, functions as an 
intercellular adhesion molecule. Cell 57, 327-334 (1989). 
189. Bolocan, A., Ion, D., Ciocan, D.N. & Paduraru, D.N. Prognostic and predictive factors in 
colorectal cancer. Chirurgia (Bucur) 107, 555-563 (2012). 
190. Flatmark, K., et al. Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br 
J Cancer 104, 1434-1439 (2011). 
191. Rahbari, N.N., et al. Meta-analysis shows that detection of circulating tumor cells indicates poor 
prognosis in patients with colorectal cancer. Gastroenterology 138, 1714-1726 (2010). 
192. Pantel, K. & Alix-Panabieres, C. Circulating tumour cells in cancer patients: challenges and 
perspectives. Trends Mol Med 16, 398-406 (2010). 
193. Martini, M., Vecchione, L., Siena, S., Tejpar, S. & Bardelli, A. Targeted therapies: how personal 
should we go? Nat Rev Clin Oncol 9, 87-97 (2011). 
194. LoRusso, P.M., et al. Translating clinical trials into meaningful outcomes. Clin Cancer Res 16, 
5951-5955 (2010). 
195. Ree, A.H., et al. Tumor phosphatidylinositol-3-kinase signaling and development of metastatic 
disease in locally advanced rectal cancer. PLoS One 7, e50806 (2012). 
196. Jubb, A.M. & Harris, A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. 
Lancet Oncol 11, 1172-1183 (2010). 
197. Willett, C.G., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation 
therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27, 
3020-3026 (2009). 
198. Folkvord, S., et al. Prediction of response to preoperative chemoradiotherapy in rectal cancer by 
multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 78, 555-562 (2010). 
199. Kuremsky, J.G., Tepper, J.E. & McLeod, H.L. Biomarkers for response to neoadjuvant 
chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74, 673-688 (2009). 
200. Ghadimi, B.M., et al. Effectiveness of gene expression profiling for response prediction of rectal 
adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23, 1826-1838 (2005). 
201. Giannini, G., Cabri, W., Fattorusso, C. & Rodriquez, M. Histone deacetylase inhibitors in the 
treatment of cancer: overview and perspectives. Future Med Chem 4, 1439-1460. 
202. Stimson, L. & La Thangue, N.B. Biomarkers for predicting clinical responses to HDAC 
inhibitors. Cancer Lett 280, 177-183 (2009). 
84 
 
 
203. Folkvord, S., Ree, A.H., Furre, T., Halvorsen, T. & Flatmark, K. Radiosensitization by SAHA in 
experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation 
status. Int J Radiat Oncol Biol Phys 74, 546-552 (2009). 
204. Griffiths, G. Clinical trials in oncology. Medicine 40, 20-23 (2011). 
205. LoRusso, P.M., Boerner, S.A. & Seymour, L. An overview of the optimal planning, design, and 
conduct of phase I studies of new therapeutics. Clin Cancer Res 16, 1710-1718 (2010). 
206. Le Tourneau, C., Lee, J.J. & Siu, L.L. Dose escalation methods in phase I cancer clinical trials. J 
Natl Cancer Inst 101, 708-720 (2009). 
207. Wistuba, II, Gelovani, J.G., Jacoby, J.J., Davis, S.E. & Herbst, R.S. Methodological and practical 
challenges for personalized cancer therapies. Nat Rev Clin Oncol 8, 135-141 (2011). 
208. Grade, M., Wolff, H.A., Gaedcke, J. & Ghadimi, B.M. The molecular basis of 
chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch 
Surg 397, 543-555 (2012). 
209. Peppelenbosch, M.P. Kinome profiling. Scientifica (Cairo) 2012, 306798 (2012). 
210. Piersma, S.R., Labots, M., Verheul, H.M. & Jimenez, C.R. Strategies for kinome profiling in 
cancer and potential clinical applications: chemical proteomics and array-based methods. Anal 
Bioanal Chem 397, 3163-3171 (2010). 
211. Bratland, A., Dueland, S., Hollywood, D., Flatmark, K. & Ree, A.H. Gastrointestinal toxicity of 
vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic 
radiotherapy. Radiat Oncol 6, 33 (2011). 
212. Clinicaltrials.gov. A service of the United States National Institutes of Health. 
213. McAllister, S.S. & Weinberg, R.A. Tumor-host interactions: a far-reaching relationship. J Clin 
Oncol 28, 4022-4028 (2010). 
214. Kahn, J., Tofilon, P.J. & Camphausen, K. Preclinical models in radiation oncology. Radiat Oncol 
7, 223 (2012). 
215. Nims, R.W., Sykes, G., Cottrill, K., Ikonomi, P. & Elmore, E. Short tandem repeat profiling: part 
of an overall strategy for reducing the frequency of cell misidentification. In Vitro Cell Dev Biol 
Anim 46, 811-819 (2010). 
216. Lacroix, M. Persistent use of "false" cell lines. Int J Cancer 122, 1-4 (2008). 
217. Brattain, M.G., Fine, W.D., Khaled, F.M., Thompson, J. & Brattain, D.E. Heterogeneity of 
malignant cells from a human colonic carcinoma. Cancer Res 41, 1751-1756 (1981). 
218. Leibovitz, A., et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36, 
4562-4569 (1976). 
219. Chen, T.R., Drabkowski, D., Hay, R.J., Macy, M. & Peterson, W., Jr. WiDr is a derivative of 
another colon adenocarcinoma cell line, HT-29. Cancer Genet Cytogenet 27, 125-134 (1987). 
220. Morikawa, K., Walker, S.M., Jessup, J.M. & Fidler, I.J. In vivo selection of highly metastatic 
cells from surgical specimens of different primary human colon carcinomas implanted into nude 
mice. Cancer Res 48, 1943-1948 (1988). 
221. Morton, C.L. & Houghton, P.J. Establishment of human tumor xenografts in immunodeficient 
mice. Nat Protoc 2, 247-250 (2007). 
222. Rosenthal, N. & Brown, S. The mouse ascending: perspectives for human-disease models. Nat 
Cell Biol 9, 993-999 (2007). 
223. Wouters, A., Pauwels, B., Lardon, F. & Vermorken, J.B. Review: implications of in vitro 
research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 
12, 690-712 (2007). 
224. Esteban, M.A. & Maxwell, P.H. Manipulation of oxygen tensions for in vitro cell culture using a 
hypoxic workstation. Expert Rev Proteomics 2, 307-314 (2005). 
225. Vordermark, D., Katzer, A., Baier, K., Kraft, P. & Flentje, M. Cell type-specific association of 
hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein accumulation and radiobiologic tumor 
hypoxia. Int J Radiat Oncol Biol Phys 58, 1242-1250 (2004). 
85 
 
 
226. Harrington, K.J., et al. Guidelines for preclinical and early phase clinical assessment of novel 
radiosensitisers. Br J Cancer 105, 628-639. 
227. Randers-Eichhorn, L., Bartlett, R.A., Frey, D.D. & Rao, G. Noninvasive oxygen measurements 
and mass transfer considerations in tissue culture flasks. Biotechnol Bioeng 51, 466-478 (1996). 
228. Itani, W., Geara, F., Haykal, J., Haddadin, M. & Gali-Muhtasib, H. Radiosensitization by 2-
benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon 
cancer cells. Radiat Oncol 2, 1 (2007). 
229. Shibamoto, Y., Tachi, Y., Tanabe, K., Hatta, H. & Nishimoto, S. In vitro and in vivo evaluation 
of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation. Int J 
Radiat Oncol Biol Phys 58, 397-402 (2004). 
230. Jensen, E.C. The basics of western blotting. Anat Rec (Hoboken) 295, 369-371 (2012). 
231. Wouters, B.G. & Brown, J.M. Cells at intermediate oxygen levels can be more important than the 
"hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147, 
541-550 (1997). 
232. Yaromina, A., et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major 
determinants of local tumour control after fractionated irradiation. Radiother Oncol 83, 304-310 
(2007). 
233. Patterson, L.H., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by 
AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82, 1984-1990 (2000). 
234. Marini, P., et al. Combined treatment with lexatumumab and irradiation leads to strongly 
increased long term tumour control under normoxic and hypoxic conditions. Radiat Oncol 4, 49 
(2009). 
235. Rofstad, E.K. & Maseide, K. Radiobiological and immunohistochemical assessment of hypoxia 
in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int J Radiat 
Biol 75, 1377-1393 (1999). 
236. Beck-Bornholdt, H.P. Should tumors be clamped in radiobiological fractionation experiments? 
Int J Radiat Oncol Biol Phys 21, 675-682 (1991). 
237. Rofstad, E.K., Gaustad, J.V., Egeland, T.A., Mathiesen, B. & Galappathi, K. Tumors exposed to 
acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. 
Int J Cancer 127, 1535-1546 (2010). 
238. Goethals, L., et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic 
and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 65, 246-254 (2006). 
239. Hatok, J., et al. In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 
9, 1-7 (2009). 
240. Franken, N.A., Rodermond, H.M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells 
in vitro. Nat Protoc 1, 2315-2319 (2006). 
241. Tomayko, M.M. & Reynolds, C.P. Determination of subcutaneous tumor size in athymic (nude) 
mice. Cancer Chemother Pharmacol 24, 148-154 (1989). 
242. Lieu, C.H., Tan, A.C., Leong, S., Diamond, J.R. & Eckhardt, S.G. From bench to bedside: 
lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst 
105, 1441-1456 (2013). 
243. Mandrekar, S.J., An, M.W. & Sargent, D.J. A review of phase II trial designs for initial marker 
validation. Contemp Clin Trials 36, 597-604 (2013). 
244. Yeo, S.G., et al. Tumor volume reduction rate measured by magnetic resonance volumetry 
correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer. 
Int J Radiat Oncol Biol Phys 78, 164-171 (2010). 
245. Flatmark, K., et al. Immunomagnetic detection of micrometastatic cells in bone marrow of 
colorectal cancer patients. Clin Cancer Res 8, 444-449 (2002). 
246. Forus, A., Hoifodt, H.K., Overli, G.E., Myklebost, O. & Fodstad, O. Sensitive fluorescent in situ 
hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates. Mol 
Pathol 52, 68-74 (1999). 
86 
 
 
247. Went, P., et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in 
colon, stomach, prostate and lung cancers. Br J Cancer 94, 128-135 (2006). 
248. Alix-Panabieres, C., Riethdorf, S. & Pantel, K. Circulating tumor cells and bone marrow 
micrometastasis. Clin Cancer Res 14, 5013-5021 (2008). 
249. Sikkema, A.H., den Dunnen, W.F., Diks, S.H., Peppelenbosch, M.P. & de Bont, E.S. Optimizing 
targeted cancer therapy: towards clinical application of systems biology approaches. Crit Rev 
Oncol Hematol 82, 171-186 (2011). 
250. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase 
complement of the human genome. Science 298, 1912-1934 (2002). 
251. Krause, D.S. & Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 
353, 172-187 (2005). 
252. Sikkema, A.H., et al. Kinome profiling in pediatric brain tumors as a new approach for target 
discovery. Cancer Res 69, 5987-5995 (2009). 
253. Parikh, K. & Peppelenbosch, M.P. Kinome profiling of clinical cancer specimens. Cancer Res 70, 
2575-2578 (2010). 
254. Bratland, A., et al. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate 
carcinoma cells characterized by multiplex kinase activity profiling. Clin Exp Metastasis 26, 485-
496 (2009). 
255. Roe, K., et al. Hypoxic tumor kinase signaling mediated by STAT5A in development of 
castration-resistant prostate cancer. PLoS One 8, e63723 (2013). 
256. Schrage, Y.M., et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and 
dasatinib as option for treatment. Cancer Res 69, 6216-6222 (2009). 
257. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? 
Nat Rev Cancer 12, 323-334 (2012). 
258. Sandor, V., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 
630176), in patients with refractory neoplasms. Clin Cancer Res 8, 718-728 (2002). 
259. Bucca, G., et al. Gene expression profiling of human cancers. Ann N Y Acad Sci 1028, 28-37 
(2004). 
260. Raspe, E., Decraene, C. & Berx, G. Gene expression profiling to dissect the complexity of cancer 
biology: pitfalls and promise. Semin Cancer Biol 22, 250-260 (2012). 
261. White, C.A. & Salamonsen, L.A. A guide to issues in microarray analysis: application to 
endometrial biology. Reproduction 130, 1-13 (2005). 
262. Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57 (2009). 
263. Kendall, L.V. & Riley, L.K. Reverse transcriptase polymerase chain reaction (RT-PCR). 
Contemp Top Lab Anim Sci 39, 42 (2000). 
264. Arya, M., et al. Basic principles of real-time quantitative PCR. Expert Rev Mol Diagn 5, 209-219 
(2005). 
265. Kendall, L.V., Besselsen, D.G. & Riley, L.K. Fluorogenic 5' nuclease PCR (real time PCR). 
Contemp Top Lab Anim Sci 39, 41 (2000). 
266. Cusnir, M. & Cavalcante, L. Inter-tumor heterogeneity. Hum Vaccin Immunother 8, 1143-1145 
(2012). 
267. Van Schaeybroeck, S., Allen, W.L., Turkington, R.C. & Johnston, P.G. Implementing prognostic 
and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 8, 222-232 (2011). 
268. Stricker, T., Catenacci, D.V. & Seiwert, T.Y. Molecular profiling of cancer--the future of 
personalized cancer medicine: a primer on cancer biology and the tools necessary to bring 
molecular testing to the clinic. Semin Oncol 38, 173-185 (2011). 
269. Cusnir, M. & Cavalcante, L. Inter-tumor heterogeneity. Hum Vaccin Immunother 8, 1143-1145. 
270. Yu, J., Mi, J., Wang, Y., Wang, A. & Tian, X. Regulation of radiosensitivity by HDAC inhibitor 
trichostatin A in the human cervical carcinoma cell line Hela. Eur J Gynaecol Oncol 33, 285-290 
(2012). 
87 
 
 
271. Flatmark, K., et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase 
inhibition. Radiat Oncol 1, 25 (2006). 
272. Podar, K. & Anderson, K.C. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling 
pathways. Cell Cycle 9, 1722-1728 (2010). 
273. Huang, L.E. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ 
15, 672-677 (2008). 
274. Dewdney, A., et al. Multicenter randomized phase II clinical trial comparing neoadjuvant 
oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by 
total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30, 
1620-1627 (2012). 
275. Glynne-Jones, R., Grainger, J., Harrison, M., Ostler, P. & Makris, A. Neoadjuvant chemotherapy 
prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? 
Br J Cancer 94, 363-371 (2006). 
276. Schrag, D., et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal 
cancer. Journal of Clinical Oncology 28, Abstract 3511 (2010). 
277. Fernandez-Martos, C., Estevan, E., Salud, A., Pericay, C. & Gallen, M. Neoadjuvant 
capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) 
patients defined by magnetic resonance (MR): GEMCAD 0801 trial. . Journal of Clinical 
Oncology 30, Abstract 3586 (2012). 
278. Schrag, D. Evolving role of neoadjuvant therapy in rectal cancer. Curr Treat Options Oncol 14, 
350-364 (2013). 
279. Nilsson, P.J., et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally 
advanced rectal cancer--the RAPIDO trial. BMC Cancer 13, 279 (2013). 
280. Bujko, K., et al. Long-term results of a randomized trial comparing preoperative short-course 
radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J 
Surg 93, 1215-1223 (2006). 
281. Ngan, S.Y., et al. Randomized trial of short-course radiotherapy versus long-course 
chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-
Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30, 3827-3833 (2012). 
282. Pettersson, D., et al. Preoperative short-course radiotherapy with delayed surgery in primary 
rectal cancer. Br J Surg 99, 577-583 (2011). 
283. Pettersson, D., et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy 
regimens for rectal cancer. Br J Surg 97, 580-587 (2010). 
284. Fokas, E., McKenna, W.G. & Muschel, R.J. The impact of tumor microenvironment on cancer 
treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev 
31, 823-842 (2012). 
285. Fokas, E., et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by 
normalizing tumor vasculature. Cancer Res 72, 239-248 (2011). 
 
 
  
88 
 
 
11 Paper I-IV 
I

ORIGINAL PAPER
Tumor kinase activity in locally advanced rectal cancer:
angiogenic signaling and early systemic dissemination
Marie Grøn Saelen • Kjersti Flatmark •
Sigurd Folkvord • Rik de Wijn • Heidi Rasmussen •
Øystein Fodstad • Anne Hansen Ree
Received: 11 May 2011 / Accepted: 30 July 2011 / Published online: 11 August 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Tumor hypoxia is a common determinant of
resistance to cytotoxic therapies and metastatic behavior.
In rectal cancer patients receiving preoperative chemo-
radiotherapy, tyrosine kinase activities in tumors with
poor and good treatment responses were found to differ.
Given that tyrosine kinase signaling mediates hypoxic
tissue adaptation, the present study examined whether
tumor kinase activity might also correlate with systemic
dissemination of rectal cancer. Immunomagnetic selec-
tion of disseminated tumor cells (DTC) from bone
marrow aspirates was undertaken in 55 patients with
locally advanced rectal cancer. Using peptide arrays with
144 tyrosine kinase substrates, phosphopeptide signatures
were generated from patients’ baseline tumor biopsies, to
study association between DTC and tumor tyrosine
kinase activity regulated ex vivo by sunitinib. Dissemi-
nated tumor cells were detected in 60% of cases, and
these patients had signiﬁcantly poorer metastasis-free
survival than patients without DTC. Phosphorylation of
31 array tyrosine kinase substrates by tumor samples was
signiﬁcantly more strongly inhibited by sunitinib in the
DTC-negative patients, with a number of phosphosub-
strates representing angiogenic factors. In this cohort of
rectal cancer patients, tumor phenotypes deﬁned by a
subset of tyrosine kinase activities correlating with weak
ex vivo inhibition by sunitinib, was associated with early
systemic dissemination.
Keywords Rectal cancer  Tyrosine kinase signaling 
Angiogenesis  Disseminated tumor cells  Metastasis
Introduction
In order to cure rectal cancer, two therapeutic challenges
must be met, namely eradication of tumor within the pelvic
cavity and secondly, the prevention of systemic tumor
dissemination. The natural disease course of rectal cancer
makes it an ideal model system to explore the possible role
of tumor hypoxia in therapy resistance and development of
metastasis. Tissue hypoxia is deﬁned by reduced oxygen
levels, typically 2% oxygen or less, and occurs in a wide
range of pathological conditions [1, 2]. Within classical
radiobiology, hypoxia is recognized as a main mechanism
involved in tumor resistance to radiation [3, 4]. Moreover,
recent research supports the hypothesis that tumor hypoxia
is one of the major driving forces of the metastatic process
[5]. Adaptive cellular responses to hypoxia allow for pro-
cesses such as proliferation, migration, and in particular
angiogenesis, and involve activation of a range of kinase
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signaling pathways, among them signaling initiated by the
receptor tyrosine kinases PDGFR, VEGFR, and EPOR [1,
5, 6].
Locally advanced rectal cancer (LARC) comprises pri-
mary tumors that grow beyond the rectal wall to an extent
that precludes primary surgical removal with adequate
microscopic margins. Hence, treatment of LARC is mul-
timodal, involving preoperative chemoradiotherapy aimed
at macroscopic downsizing and control of subclinical
tumor extension within the pelvic cavity, to enable com-
plete tumor removal by subsequent surgery. However, even
with successful local treatment, a substantial number of
patients will develop metastatic disease as result of early
undetected systemic dissemination of tumor cells [7]. The
phase II trial Locally Advanced Rectal Cancer—Radiation
Response Prediction (LARC-RRP), registered with Clini-
calTrials.gov number NCT00278694, was launched pri-
marily to identify predictive biomarkers of tumor radiation
sensitivity, and we have recently reported that this was
feasible by kinase activity proﬁling of baseline tumor
biopsies [8]. Using peptide arrays with tyrosine kinase
substrates, we found that phosphopeptide levels generated
by tumors with poor response to the preoperative chemo-
radiotherapy were signiﬁcantly higher than substrate
phosphorylation resulting from tumors with good treatment
response. The elevated kinase activity in poor-responding
tumors was suppressed by ex vivo addition of the tyrosine
kinase inhibitor sunitinib, and represented signaling
implicated in experimental radiation resistance.
Given that tyrosine kinase signaling is involved in
adaptive responses to tumor hypoxia, the present study
aimed to determine how tumor kinase activity might relate
to systemic disease dissemination. Hence, in the investi-
gation of the LARC-RPP study patients reported here, we
endeavored to correlate the individual patient’s tumor
tyrosine kinase activity to negative or positive status for
disseminated tumor cells (DTC) to bone marrow as the
clinical endpoint, using the presence of DTC as biomarker
of metastatic recurrence risk [9]. Immunomagnetic selec-
tion of DTC was performed at the time of diagnosis, and by
applying previously acquired ex vivo sunitinib inhibition
proﬁles from the baseline primary tumor biopsies [8], the
association between the tumor kinome and early systemic
dissemination in terms of DTC status was studied.
Patients and methods
Patients and procedures
The patient population reported here was enrolled between
October 2005 and December 2007. Patient eligibility cri-
teria and evaluation procedures have been described
previously [8]. Three patients with synchronous resectable
liver metastases were also included in this study. The
experimental treatment protocol, intended to intensify
preoperative therapy for LARC, consisted of two cycles of
neoadjuvant chemotherapy (the Nordic FLOX regimen:
oxaliplatin 85 mg/m2 on day 1 and daily bolus ﬂuorouracil
500 mg/m2 and folinic acid 100 mg on days 1 and 2 every
second week) followed by chemoradiotherapy. Radiation
was delivered in daily 2-Gy fractions 5 days per week over
a ﬁve-week period; the initial 23 fractions to the macro-
scopic tumor volume and area at risk, and the two ﬁnal
fractions restricted to the macroscopic tumor, as deter-
mined by computed tomography-based planning. During
the radiotherapy course, concomitant chemotherapy was
given as oxaliplatin 50 mg/m2 once weekly and capecita-
bine 825 mg/m2 twice daily on days of radiotherapy. Sur-
gery was planned 6–8 weeks after completion of the
preoperative treatment. In accordance with national
guidelines, the patients did not receive postoperative
therapy.
The resected primary tumor specimens were histologi-
cally evaluated for response to the preoperative treatment
according to standard criteria (ypTN) and histomorpho-
logic tumor regression grade (TRG), as previously detailed
[8]. Brieﬂy, tumor response was graded within one of ﬁve
TRG categories, spanning from the absence of residual
tumor cells in the resected specimen (pathologic complete
response; TRG 1) to the lack of morphologic signs of tissue
response to treatment (TRG 5) [10]. The review procedures
of patient follow-up included clinical examination, blood
tests, and computed tomography scanning of the chest,
abdomen, and pelvis, at three- and six-month intervals for
the ﬁrst and second year, respectively, and twelve months
thereafter. Locally recurrent or metastatic disease and
death of any cause were recorded. Thus, the study end-
points were histomorphologic tumor response to neoadju-
vant therapy, disease-free survival, and overall survival.
Follow-up data was obtained from the clinical database and
censored on April 6th, 2011. Valid observations of the
presence or absence of distant metastases or local recur-
rence required designated radiological examination and/or
bioptic veriﬁcation. The three patients with resectable liver
metastases at the time of diagnosis were excluded from
analysis of metastasis-free survival.
Study-speciﬁc procedures
At the time of diagnosis, baseline study-speciﬁc primary
tumor biopsies (snap-frozen in liquid nitrogen and stored at
-80C) and bone marrow (15–40 ml drawn from the
anterior iliac crests) were obtained from 71 patients under
heavy sedation. Of these, 16 patients were excluded from
the present study, as six patients had bone marrow samples
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that contained too few mononuclear cells for immuno-
magnetic selection, and ten patients had tumor biopsy
specimens in which kinase activity proﬁling had not been
performed because the patients were either ineligible after
study registration (n = 3), had withdrawn consent (n = 1),
had unexpectedly died during the preoperative treatment
(n = 1), had developed metastatic disease progression
during preoperative treatment that precluded deﬁnitive
surgery (n = 1), had tumor cell content less than 20%
within the biopsy specimen (n = 2), or had a biopsy
specimen in which kinase activity analysis was missing of
unknown reasons (n = 2). Thus, tumor kinase activity
signatures based on previous array phosphosubstrate data
were successfully identiﬁed for 55 patients with known
DTC status, and this study population is present within the
current analyses.
The tumor biopsies were sectioned using a cryostat
microtome, and hematoxylin-eosin stained slides were
evaluated for tumor content. The average tumor cell content
in the biopsy specimens was 44%, and no difference was
found between patients positive and negative for DTC
(P[ 0.66; two-sample t-test). Each biopsy specimen was
aliquoted by cryostat sectioning into 10-lm slices, and total
tissue volume was calculated by multiplying the surface
area of the section with the number of sample sections.
Protein lysates were prepared by adding 36 ll lysis buffer
(M-PER Mammalian Extraction Reagent containing Halt
Phosphatase Inhibitor Cocktail and EDTA-free Halt Prote-
ase Inhibitor Cocktail; Pierce Biotechnology, Inc., Rock-
ford, IL) per mm3 tissue, and following vortexing and
centrifugation, 5 ll of the supernatant was added to the
reaction mixture, which was composed of Abl Reaction
Buffer (50 mmol/l Tris–HCl pH 7.5, 10 mmol/l MgCl2,
1 mmol/l EGTA, 2 mmol/l dithiothreitol, 0.01% Brij 35;
New England BioLabs, Inc., Ipswich, MA), 1 mg/ml bovine
serum albumin, 100 lmol/l ATP, and 12.5 lg/ml of the
monoclonal, FITC-conjugated anti-phosphotyrosine anti-
body (Exalpha Biologicals, Inc., Maynard, MA) to a total
volume of 40 ll in each array. No signiﬁcant variation was
observed in protein concentration in the sample lysates.
Four technical replicates were analyzed from each patient
sample to generate basal phosphosubstrate data. On the
same array plate, using three technical replicates for each
condition, each sample was also incubated in the presence
of 2.5 lmol/l sunitinib (Axxora, Lausen, Switzerland).
For determination of DTC status, superparamagnetic
sheep-antimouse IgG particles (Dynabeads M450; Invit-
rogen–Life Technologies, Oslo, Norway) were conjugated
with the monoclonal antibody MOC-31 (IQ Products,
Groningen, The Netherlands), and for each study patient,
immunomagnetic selection of tumor cells in bone marrow
was undertaken as previously described [11]. Brieﬂy,
mononuclear cells were isolated from the bone marrow
aspirate and incubated with magnetic immunobeads with
conjugated antibody, or without antibody for negative
control, and subsequently exposed to a magnet ﬁeld to
separate bead-rosetting cells from unbound cells. A patient
sample was classiﬁed as positive for DTC if a minimum of
two cells rosetted at least ﬁve beads with the MOC-31
antibody and no rosetted cells were detected in the negative
control.
Data adaptation and statistical analyses
The array data is available in the ArrayExpress database
[12] by accession number E-TABM-913. The curated
sunitinib inhibition data set that had been calculated from
the signal intensity from each array peptide after back-
ground subtraction and used previously [8] was applied as
input for the current statistical analysis. The data was log-
transformed after handling a small number of negative data
points by subtracting the 1% percentile of the data and
subsequently setting all remaining data points with value
less than 1 to the value 1. For each peptide, the sunitinib-
induced log-fold change was calculated by subtracting the
log-transformed signal in the absence of sunitinib (control)
from that in the presence of this tyrosine kinase inhibitor.
Peptides with sample-averaged signal less than 210 in the
control condition were excluded, leaving 102 peptides
above this threshold. A two-sample t-test was performed to
test for different level of sunitinib inhibition in DTC-
positive and DTC-negative patients (Supplementary
Table 1). The sunitinib inhibition proﬁles were visualized
as data color maps, in which clustering of peptides and
samples was imposed by sorting the data according to the
value of the ﬁrst principal component (peptides) and the
value of the scores on the ﬁrst principal component (sam-
ples) of a principal component analysis, using samples as
observations and spots as variables. Distribution of value of
the score on the ﬁrst principal component was compared to
clinical parameters using correlation coefﬁcients for con-
tinuous variables and one-way ANOVA tests for categor-
ical data. Data processing and visualizations were
performed in Matlab R2010A including the statistics
toolbox (Mathworks, Natick, MA).
Disease-free and overall survival was estimated by the
Kaplan–Meier method. The log-rank test was used to
determine survival differences in DTC-positive and DTC-
negative patients. Survival was measured from the date of
bone marrow sampling to the date of recurrent disease
detection or death. Distribution of parameters between
different groups was compared using Pearson’s Chi-square
exact two-sided test for categorical data and two-sample t-
test for continuous variables. The data analysis was per-
formed using SPSS version 16.0 (SPSS Inc., Chicago, IL).
P values less than 0.05 were considered statistically
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signiﬁcant. Pathway connectivity of peptides was deter-
mined using UniProtKB/SwissProt database [13] and lit-
erature search.
Results
Patients
Table 1 describes characteristics of the 55 patients, in
whom immunomagnetic selection of tumor cells in bone
marrow aspirates as well as tyrosine kinase activity
proﬁling of tumor biopsies at the time of study enrolment
were performed. In 60% of patients, a median tumor cell
count of 6 (range 2–150) was detected in the bone marrow
samples (DTC-positive patients). No differences were
found between DTC-positive and DTC-negative patients
regarding gender, age, radiological TNM stage at diagno-
sis, serum carcinoembryonic antigen levels or hemoglobin
count at the time of diagnosis, or histological ypTN stage
or histomorphologic TRG score of the surgical specimens.
Median follow-up was 42 months (range 7–65). Three
patients (one DTC-negative and two DTC-positive indi-
viduals) were noted to have locally recurrent disease.
Table 1 Patient characteristics
TNM tumor–node–metastasis,
yp histopathologic staging
following chemoradiotherapy,
TRG histomorphologic tumor
regression grade following
chemoradiotherapy, CEA
carcinoembryonic antigen
a Censored at a median period
of 42 months (range 7–65)
All patients (n = 55) DTC-negative
patients (n = 22)
DTC-positive
patients (n = 33)
TNM stage at diagnosis
T2 3 (5.5%) 2 (9.1%) 1 (3.0%)
T3 33 (60.0%) 14 (63.6%) 19 (57.6%)
T4 19 (34.5%) 6 (27.3%) 13 (39.4%)
N0 6 (10.9%) 2 (9.1%) 4 (12.1%)
N1 8 (14.5%) 3 (13.6%) 5 (15.2%)
N2 41 (74.5%) 17 (77.3%) 24 (72.3%)
M0 52 (94.5%) 21 (95.5%) 31 (93.9%)
M1 3 (5.5%) 1 (4.5%) 2 (6.1%)
TN stage after chemoradiotherapy
ypT0 12 (21.8%) 5 (22.7%) 7 (21.2%)
ypT1 8 (14.5%) 4 (18.2%) 4 (12.1%)
ypT2 13 (23.6%) 6 (27.3%) 7 (21.2%)
ypT3 14 (25.5%) 4 (18.2%) 10 (30.3%)
ypT4 8 (14.5%) 3 (13.6%) 5 (15.2%)
ypN0 43 (78.2%) 19 (86.4%) 24 (72.7%)
ypN1 9 (16.4%) 3 (13.6%) 6 (18.2%)
ypN2 3 (5.5%) 0 (0%) 3 (9.1%)
TRG
1–2, good responders 40 (72.7%) 16 (72.7%) 24 (72.7%)
3, intermediate responders 9 (16.4%) 5 (22.7%) 4 (12.1%)
4, poor responders 6 (10.9%) 1 (4.5%) 5 (15.2%)
CEA
\5 lg/l 33 (60.0%) 14 (63.6%) 19 (57.6%)
C5 lg/l 22 (40.0%) 8 (36.4%) 14 (42.4%)
Median hemoglobin count, g/dl (range) 13.9 (10.0–16.3) 14.0 (10.0–16.3) 13.9 (10.8–15.4)
Gender
Male 31 (56.4%) 13 (59.1%) 18 (54.5%)
Female 24 (43.6%) 9 (40.9%) 15 (45.5%)
Median age, years (range) 61 (31–73) 61 (38–73) 59 (31–73)
Follow-up resultsa
Locally recurrent disease 3 (5.5%) 1 (4.5%) 2 (6.1%)
Metastatic disease 16 (29.1%) 2 (9.1%) 14 (42.4%)
Death 8 (14.5%) 2 (9.1%) 6 (18.2%)
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Metastasis-free survival was assessed for 52 patients, as the
three patients with synchronous liver metastases at the time
of diagnosis were omitted from this analysis, with the
DTC-positive group demonstrating signiﬁcantly poorer
metastasis-free survival (61%) than the DTC-negative
group (95%; P = 0.007; Fig. 1). At the time of follow-up
data censoring, eight patients were reported as deceased;
the number of cases was not statistically different between
the two groups of patients with negative and positive DTC
status.
Tumor tyrosine kinase activities
Ex vivo sunitinib inhibition proﬁles were derived from 102
(of 144 on the array) peptide kinase substrates that had
signal intensities above the deﬁned threshold. In Fig. 2,
patients (horizontal axis) and peptides (vertical axis) were
sorted according to principal component analysis. No
correlation was observed between tumor kinase activity
inhibition and gender, age, diagnostic TNM stage, ypTN
stage, or serum carcinoembryonic antigen levels or
hemoglobin count. A borderline signiﬁcant association was
found between inhibition of the phosphosubstrates and
tumor response to preoperative treatment in terms of TRG
status (P = 0.049), with the poor responders exhibiting
strongest inhibition (Supplementary Fig. 1).
Based on the scores of the principal component analysis,
ex vivo sunitinib inhibition of tumor kinase activity in
DTC-negative patients was stronger than in patients with
positive DTC status (P = 0.042; Supplementary Fig. 2).
Of the 102 peptides constituting the tyrosine kinase
inhibition proﬁle, phosphorylation of 31 kinase substrates
was signiﬁcantly more strongly inhibited in the DTC-
negative patients than in the DTC-positive individuals
(Table 2). The 31 discriminating phosphopeptides repre-
sented proteins derived from signaling pathways impli-
cated in various cellular processes, such as proliferation,
angiogenesis, and invasion. Of these, 13 peptides, mainly
representing PDGFR, VEGFR, and EPOR, were proteins
involved in angiogenesis-related pathways. Within the
entire 102-peptide panel, 23 angiogenesis-related sub-
strates were identiﬁed (Fig. 3), and sunitinib inhibition of
these phosphosubstrates was stronger in patients with
negative DTC status than in DTC-positive patients
(P = 0.019; Supplementary Fig. 3). Additionally, a sig-
niﬁcantly larger portion of angiogenesis-related substrates
(13 peptides) appeared among the 31 phosphopeptides
discriminating DTC status than within the remaining group
of substrates (ten angiogenesis-related among a total of 71;
P = 0.002).
Discussion
In this cohort of 55 LARC patients, tumor kinase activity
signatures associated with early systemic dissemination
were identiﬁed. For 31 peptides on the tyrosine kinase
substrate array, ex vivo sunitinib inhibition of phos-
phorylation generated by tumor biopsy specimens was
signiﬁcantly stronger for DTC-negative patients than for
patients with tumor cells identiﬁed in bone marrow, as
assessed by immunomagnetic selection at the time of
diagnosis. Many of the discriminating peptide substrates
represented signaling pathways that are activated by
tissue hypoxia, such as signaling mediated by PDGFR,
VEGFR, and EPOR [1, 6]. Accordingly, tumor-generated
Fig. 1 Metastasis-free survival of 52 study patients with locally
advanced rectal cancer as function of negative or positive status for
disseminated tumor cells (DTC) to bone marrow at the time of
diagnosis
Fig. 2 Ex vivo sunitinib inhibition proﬁles from 102 kinase sub-
strates. Patient tumor samples along horizontal axis, annotated by
negative (-) or positive (?) status for disseminated tumor cells to
bone marrow, and phosphosubstrates along vertical axis. Red
corresponds to stronger and blue to weaker inhibition of substrate
phosphorylation. (Color ﬁgure online)
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phosphorylation of 23 angiogenesis-related peptides was
weakly inhibited in DTC-positive patients, who had
signiﬁcantly poorer metastasis-free survival than patients
without evidence of early systemic tumor dissemination.
Various reports have demonstrated that the presence of
tumor cells in bone marrow is a prognostic biomarker
associated with metastatic recurrence [14], including in
colorectal cancer [9]. In this study, hypothesizing that
hypoxic tumor signaling mediates both radiation resistance
and metastatic progression in rectal cancer, and using
previously acquired data [8], we endeavored to correlate
the individual patient’s tumor tyrosine kinase activity to the
DTC status. In two previous works applying the array
technology with tyrosine kinase substrates, we were able to
calculate basal kinase activity data and correlate with the
biological parameters of interest [8, 15]. In the present
study, however, after normalization of basal phosphosub-
strate level read-outs, no difference was found among the
study patients when comparing those with and without
DTC (data not shown). Since a reasonable explanation
Table 2 Array phosphopeptides (generated by tumors from patients with and without disseminated tumor cells to bone marrow) with different
levels of ex vivo sunitinib inhibition (P\ 0.05), listed according to signaling pathway connectivity
Peptide substratea Position of peptide sequenceb Phosphorylationb Common namea
Angiogenesis
PDGFRB 1002–1014 Y1009 Beta platelet-derived growth factor receptor
PDGFRB 709–721 Y716 Beta platelet-derived growth factor receptor
PDGFRB 771–783 Y771, Y775, Y778 Beta platelet-derived growth factor receptor
PDGFRB 768–780 Y771, Y775, Y778 Beta platelet-derived growth factor receptor
PDGFRB 572–584 Y579, Y581 Beta platelet-derived growth factor receptor
FLT-1 (VEGFR1) 1326–1338 Y1327, Y1333 Vascular endothelial growth factor receptor 1
KDR (VEGFR2) 1168–1180 Y1175 Vascular endothelial growth factor receptor 2
KDR (VEGFR2) 989–1001 Y996 Vascular endothelial growth factor receptor 2
EPOR 361–373 Y368 Erythropoietin receptor
EPOR 419–431 Y426 Erythropoietin receptor
PECAM-1 706–718 Y713 Platelet endothelial cell adhesion molecule
PIK3R1 600–612 Y607 Phosphatidylinositol 3-kinase regulatory alpha subunit
EGFR 1190–1202 Y1197 Epidermal growth factor receptor
Cell adhesion, migration, and invasion
CALM1 95–107 Y100 Calmodulin
FES 706–718 Y713 Proto-oncogene tyrosine-protein kinase Fes/Fps
FER 707–719 Y714 Proto-oncogene tyrosine-protein kinase FER
LCK 387–399 Y394 Proto-oncogene tyrosine-protein kinase LCK
PXN 111–123 Y118 Paxillin
PXN 24–36 Y31/33 Paxillin
MST1R 1353–1365 Y1353, Y1360 Macrophage-stimulating protein receptor
CTTN 476–488 Y477, Y483 Src substrate protein p85
Cell survival and proliferation
CTNNB1 79–91 Y86 Beta-catenin
JAK1 1015–1027 Y1022, Y1023 Tyrosine-protein kinase JAK1
PDPK1 2–14 Y9 3-phosphoinositide dependent protein kinase 1
Other
CD247 116–128 Y123 T-cell surface glycoprotein CD3 zeta chain
CDK2 8–20 Y15, Y19 Cell division protein kinase 2
EPHA7 607–619 Y608, Y614 Ephrin type-A receptor 7
EPHB1 771–783 Y778 Ephrin type-B receptor 1
FRK 380–392 Y387 Tyrosine-protein kinase FRK
KRT6E 53–65 Y62 Keratin, type II cytoskeletal 6E
RET 1022–1034 Y1029 Proto-oncogene tyrosine-protein kinase receptor ret
a Substrate identities and common names are retrieved from UniProtKB/SwissProt [13]
b For each substrate, positions of the peptide sequence and the phosphorylation sites within the protein are indicated
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might be technical variation among 96-well array plates,
the analytical strategy of including a tyrosine kinase
inhibitor was attempted, to enable direct comparison of
substrate phosphorylation in its presence and absence on
the same array plate, and possibly diminishing plate-to-
plate variation [8]. Sunitinib is thoroughly characterized in
vitro and in vivo for inhibiting tyrosine kinase signaling
related to tumor hypoxia [16]. Whether other tyrosine
kinase inhibitors might have worked equally well for nor-
malization of basal kinase activity data in the clinical set-
ting of interest (primary tumor signaling and DTC status),
is not known.
Using this strategy, phosphorylation of 31 kinase sub-
strates by tumor sample lysates was found to be signiﬁ-
cantly more strongly inhibited by sunitinib in the DTC-
negative patients than in patients with positive DTC status.
As tumors outgrow their blood supply or are otherwise
deprived of oxygen, adaptive responses to the resulting
hypoxic conditions are initiated [17]. In this context, the
transcription factors hypoxia-inducible factor types 1a and
2a have emerged as key regulators of a range of target
genes that induce angiogenesis, including genes encoding
platelet-derived growth factor, vascular endothelial growth
factor, and erythropoietin [1]. In this study, components of
hypoxia-driven signaling were identiﬁed in the 31-peptide
panel demonstrating differential response to sunitinib
inhibition in patients with negative and positive DTC sta-
tus, which included receptors for these ligands; ﬁve of six
PDGFR type b substrates, three of ten VEGFR substrates
(one VEGFR1 and two VEGFR2), and both EPOR sub-
strates on the array. The observed ex vivo regulation of
phosphorylation of these particular substrates was not
unexpected, since sunitinib has been noted to inhibit
several receptor tyrosine kinases, among which members
of the VEGFR and PDGFR families are predominant tar-
gets [16].
Signaling initiated by VEGFR and PDGFR is funda-
mental for the angiogenic response [1, 5, 6], which comprises
proliferation and invasion of endothelial cells and also for-
mation of pericyte coverage of vascular sprouts for stabil-
ization of the newly formed vessel walls. In this process,
PDGFR-dependent signaling is required for pericyte differ-
entiation directed by the tissue stroma [18]. It is tempting to
speculate that the strong ex vivo sunitinib inhibition of the
PDGFR array substrate phosphorylation generated by tumor
samples from DTC-negative patients in this study reﬂects
high pericyte signaling activity of mature tumor vessel that
are less permeable for metastasizing tumor cells [19].
However, it cannot be ignored that among the 23 pep-
tides identiﬁed as angiogenesis-related in this study, ten
substrates were not correlated with the patients’ DTC sta-
tus, including seven of ten VEGFR substrates. Regulation
of tumor angiogenesis is a complex phenomenon. In
colorectal cancer, this complexity has recently been high-
lighted by the observation that anti-angiogenic therapy
(bevacizumab) that has proven efﬁcacious in metastatic
colorectal cancer, failed to meet the endpoint of prolonged
disease-free survival in randomized phase III trials in the
adjuvant setting [20, 21]. Interestingly, studies in experi-
mental models have indicated that mature pericytes protect
endothelial cells against VEGFR-directed therapies [22,
23]. The recent demonstration that tumor cells are able to
induce pericyte maturation of the neovasculature during
early formation of micrometastatic foci [24] might provide
one explanation for the lack of efﬁcacy of bevacizumab in
eradicating occult metastatic disease in colorectal cancer.
Fig. 3 Ex vivo sunitinib inhibition proﬁles from 23 angiogenesis-
related kinase substrates. Patient tumor samples along horizontal axis,
annotated by negative (-) or positive (?) status for disseminated
tumor cells to bone marrow, and phosphosubstrates along vertical
axis. Red corresponds to stronger and blue to weaker inhibition of
substrate phosphorylation. Left panel Substrate identities. For each
substrate, the position of phosphorylation sites within the protein is
indicated. (Color ﬁgure online)
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The panel of 31 differentially inhibited phosphopeptides
also included EPOR, the receptor for erythropoietin, which
is expressed in many non-hematopoietic tissues, including
endothelial cells and colorectal cancer [25], and has been
associated with angiogenic responses in experimental
tumor models [26]. Furthermore, this panel comprised
other candidate angiogenic regulators, such as PECAM-1
(platelet endothelial cell adhesion molecule-1), PIK3R1
(the PI3 K regulatory subunit a), and EGFR [27–29], as
well as the ephrin receptor types A7 and B1. Although
experimental studies suggest that several types of ephrin
receptors are activated in tumor vascularization [30], the
function of many subgroups is incompletely understood,
and in the current analyses, we therefore chose to exclude
ephrin receptors from the angiogenesis-related 23-peptide
panel.
The bone marrow compartment represents an important
site for hematogenous micrometastatic spread in breast and
prostate cancer, and clinical data has provided evidence for
an association between tumor cells detected in bone mar-
row at the time of tumor resection and postoperative met-
astatic relapse in these cancer types [14]. The presence of
systemically disseminated tumor cells has also been pro-
posed as biomarker of metastatic recurrence risk in colo-
rectal cancer [31]. In a study by Flatmark and co-workers
[11], the immunomagnetic selection method was used to
determine DTC status in 275 patients with primarily
resectable colorectal cancer, and recent update of the
clinical data shows that the presence of DTC was also
associated with poor long-term outcome in this patient
cohort [9]. In the present LARC-RRP study, using the same
method to examine bone marrow aspirates, absence of
DTC at the time of diagnosis was predictive of good short-
term metastasis-free survival after radical treatment of the
pelvic cavity. At the present stage of follow-up (median of
42 months), a non-signiﬁcant trend towards the same
association was found with overall survival. The overall
frequency of DTC-positive samples was higher in the
present study (60%) than in Flatmark’s study (17%), which
might be anticipated from the more locally advanced dis-
ease stage.
In summary, within a cohort of LARC patients, tumor
phenotypes deﬁned by tyrosine kinase activities that
appeared to correlate with weak ex vivo inhibition by
sunitinib, particularly related to angiogenic signaling, were
associated with early systemic dissemination. These
patients were also noted to have heightened risk of devel-
oping metastatic disease following the course of radical
treatment of the pelvic cavity. This novel strategy for
studying the functional tumor kinome in early metastatic
progression of rectal cancer may be used to improve our
understanding of the angiogenic response in metastasis.
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Table 1  The 102 array substrates included in the sunitinib inhibition profile
Peptide substratea Gene name – Common nameb Difference* P**
41_Y660 EPB41 - Protein 4.1 0.103 0.239 
ACHD_Y383/Y390 CHRND - Acetylcholine receptor subunit delta 0.098 0.150 
AMPE_Y12 ENPEP - Glutamyl aminopeptidase 0.014 0.840 
ANXA1_Y21 ANXA1 - ANXA1 protein   0.078 0.265 
ANXA2_Y24 ANXA2 - Annexin A2 0.198 0.060 
ART_YAAPFAKKKXC Artificial peptide 0.197 0.062 
C1R_Y204/Y210 C1R - Complement C1r subcomponent -0.008 0.881 
CALM_Y100 CALM1 - Calmodulin 0.174 0.012 
CBL_Y700 CBL - CBL E3 ubiquitin protein ligase 0.064 0.321 
CD3Z_Y153 CD247 - T-cell surface glycoprotein CD3 zeta chain 0.280 0.018 
CDK2_Y15/Y19 CDK2 - Cell division protein kinase 2 0.282 0.025 
CDK7_Y169 CDK7 - Cell division protein kinase 7 0.020 0.796 
CTNB1_Y86 Beta-catenin - CTNNB1 0.193 0.011 
DCX_Y112 DCX - Neuronal migration protein doublecortin 0.097 0.290 
DDR1_Y513 DDR1 - Epithelial discoidin domain receptor 1 0.216 0.055 
DYR1A_Y319/Y321 DYRK1A - Dual-specificity tyrosine-phosphorylation regulated kinase 1A 0.067 0.361 
EGFR_Y1110 EGFR - Epidermal growth factor receptor  0.145 0.110 
EGFR_Y1172 EGFR - Epidermal growth factor receptor  0.051 0.315 
EGFR_Y1197 EGFR - Epidermal growth factor receptor  0.101 0.036 
EPHA1_Y781 EPHA1 - Ephrin type-A receptor 1 0.222 0.051 
EPHA2_Y772 EPHA2 - Ephrin type-A receptor 2 0.205 0.078 
 2
EPHA4_Y596 EPHA3 - Ephrin type-A receptor 3 0.009 0.904 
EPHA7_Y608/Y614 EPHA7 - Ephrin type-A receptor 7 0.236 0.033 
EPHB1_Y778 EPHB1 - Ephrin type-B receptor 1 0.250 0.015 
EPHB4_Y590 EPHB4 - Ephrin type-B receptor 4 0.008 0.866 
EPOR_Y368 EPOR - Erythropoietin receptor 0.259 0.008 
EPOR_Y426 EPOR - Erythropoietin receptor 0.265 0.013 
ERBB2_Y1248 ERBB2 - Receptor tyrosine-protein kinase erbB-2 0.131 0.053 
ERBB2_Y877 ERBB2 - Receptor tyrosine-protein kinase erbB-2 0.094 0.214 
ERBB4_Y1284 ERBB4 - Receptor tyrosine-protein kinase erbB-4 0.073 0.240 
FAK1_Y570/Y576/Y577 PTK2 - Focal adhesion kinase 1 0.100 0.130 
FAK2_Y573/Y579/Y580 PTK2B - Focal adhesion kinase 2 beta 0.115 0.151 
FER_Y714 FER - Proto-oncogene tyrosine-protein kinase FER 0.215 0.031 
FES_Y713 FES - Proto-oncogene tyrosine-protein kinase Fes/Fps 0.261 0.025 
FGFR1_Y766 FGFR1 - Basic fibroblast growth factor receptor 1 0.054 0.324 
FGFR2_Y769 FGFR2 - Fibroblast growth factor receptor 2 0.095 0.135 
FGFR3_Y760 FGFR3 - Fibroblast growth factor receptor 3 0.066 0.274 
FRK_Y387 FRK - Tyrosine-protein kinase FRK 0.248 0.040 
INSR_Y1355 INSR - Insulin receptor -0.059 0.298 
INSR_Y992/Y999 INSR - Insulin receptor 0.050 0.304 
JAK1_Y1022/Y1023 JAK1 - Tyrosine-protein kinase JAK1 0.173 0.030 
JAK2_Y570 JAK2 - Tyrosine-protein kinase JAK2 0.160 0.052 
K2C6E_Y62 KRT6E - Keratin, type II cytoskeletal 6E 0.173 0.042 
KSYK_Y525/Y526 SYK - Tyrosine-protein kinase SYK 0.087 0.071 
LAT_Y200 LAT - Linker for activation of T cells 0.075 0.143 
LAT_Y255 LAT - Linker for activation of T cells 0.123 0.101 
LCK_Y394 LCK - Proto-oncogene tyrosine-protein kinase LCK 0.152 0.017 
MBP_Y203 MBP - Myelin basic protein 0.032 0.700 
MBP_Y261/Y268 MBP - Myelin basic protein 0.020 0.705 
MBP_Y268 MBP - Myelin basic protein 0.060 0.338 
MET_Y1230/Y1234/Y1235 MET - Hepatocyte growth factor receptor 0.133 0.142 
MK01_Y187 MAPK1 - Mitogen-activated protein kinase 1 0.051 0.460 
MK07_Y220 MAPK7 - Mitogen-activated protein kinase 7 0.087 0.321 
MK10_Y223 MAPK10 - Mitogen-activated protein kinase 10 0.104 0.156 
MK12_Y185 MAPK12 - Mitogen-activated protein kinase 12 -0.014 0.758 
NCF1_Y324 NCF1 - Neutrophil cytosol factor 1 0.008 0.921 
NPT2_Y511 SLC34A1 - Renal sodium-dependent phosphate transport protein 2 0.020 0.784 
NTRK1_Y496 NTRK1 - High affinity nerve growth factor receptor -0.105 0.055 
NTRK2_Y702/Y706/Y707 NTRK2 - BDNF/NT-3 growth factors receptor 0.160 0.059 
ODBA_Y345 BCKDHA - 2-oxoisovalerate dehydrogenase alpha subunit, mitochondrial 0.085 0.319 
P2AB_/Y307
PPP2CB - Serine/threonine protein phosphatase 2A, catalytic subunit, beta 
isoform 0.029 0.597 
P85A_Y607 PIK3R1 - Phosphatidylinositol 3-kinase regulatory alpha subunit 0.300 0.014 
PAXI_Y118 PXN - Paxillin 0.252 0.025 
PAXI_Y31/Y33 PXN - Paxillin 0.260 0.020 
PDGFB_Y1021 PDGFRB - Beta platelet-derived growth factor receptor 0.111 0.058 
PDPK1_Y373/Y376 PDPK1 - 3-phosphoinositide dependent protein kinase 1 0.117 0.169 
PDPK1_Y9 PDPK1 - 3-phosphoinositide dependent protein kinase 2 0.212 0.016 
 3
PECA1_Y713 PECAM1- Platelet endothelial cell adhesion molecule 0.272 0.021 
PGFRB_Y1009 PDGFRB - Beta platelet-derived growth factor receptor 0.241 0.002 
PGFRB_Y579/Y581 PDGFRB - Beta platelet-derived growth factor receptor 0.223 0.044 
PGFRB_Y716 PDGFRB - Beta platelet-derived growth factor receptor 0.179 0.029 
PGFRB_Y771/Y775/Y778 PDGFRB - Beta platelet-derived growth factor receptor 0.182 0.020 
PGFRB_Y771/Y775/Y778 PDGFRB - Beta platelet-derived growth factor receptor 0.177 0.036 
PLCG1_Y771/775 
PLCG1 - 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
gamma 1 0.233 0.050 
PRGR_Y795 PGR - Progesterone receptor 0.108 0.122 
PRRX2_Y208/Y214 PRRX2 -Paired mesoderm homeobox protein 2 0.111 0.105 
PTN11_Y546/551  PTPN11 - Tyrosine-protein phosphatase, non-receptor type 11 0.086 0.199 
RAF1_Y340/Y341 RAF1 - RAF proto-oncogene serine/threonine-protein kinase 0.088 0.297 
RASA1_Y460 RASA1 - Ras GTPase-activating protein 1 0.171 0.086 
RB_Y805/Y813 RB1 - Retinoblastoma-associated protein 0.066 0.402 
RET_Y1029 RET - Proto-oncogene tyrosine-protein kinase receptor ret 0.250 0.035 
RON_Y1353 MST1R - Macrophage-stimulating protein receptor  0.133 0.177 
RON_Y1353/Y1360 MST1R - Macrophage-stimulating protein receptor  0.154 0.017 
SRC8_Y477 CTTN - Src substrate protein p85 0.091 0.201 
SRC8_Y477/Y483 CTTN - Src substrate protein p86 0.297 0.021 
SRC8_Y479/486/489 CTTN - Src substrate protein p87 0.149 0.227 
TEC_Y513/519 TEC - Tyrosine-protein kinase Tec 0.132 0.078 
TNNT1_Y9 TNNT1 - TNNT1 protein  0.020 0.809 
TYRO3_Y681/685/686 TYRO3 - Tyrosine-protein kinase receptor TYRO3 0.049 0.430 
VEGFR1_Y1048 FLT1 - Vascular endothelial growth factor receptor 1 0.106 0.164 
VEGFR1_Y1053 FLT1 - Vascular endothelial growth factor receptor 1 0.055 0.445 
VEGFR1_Y1242 FLT1 - Vascular endothelial growth factor receptor 1 -0.020 0.707 
VEGFR1_Y1327/Y1333 FLT1 - Vascular endothelial growth factor receptor 1 0.156 0.042 
VEGFR2_Y1054/Y1059 KDR - Vascular endothelial growth factor receptor 2 0.063 0.268 
VEGFR2_Y1063 KDR - Vascular endothelial growth factor receptor 2 0.068 0.340 
VEGFR2_Y1175 KDR - Vascular endothelial growth factor receptor 2 0.122 0.023 
VEGFR2_Y951 KDR - Vascular endothelial growth factor receptor 2 0.035 0.605 
VEGFR2_Y996 KDR - Vascular endothelial growth factor receptor 2 0.250 0.025 
VGFR3_Y1063/Y1068 FLT4 - Vascular endothelial growth factor receptor 3 0.018 0.749 
VINC_Y822 VCL - Vinculin 0.033 0.587 
ZAP70_Y492/Y493 ZAP70 - Tyrosine-protein kinase ZAP-70 0.153 0.087 
ZBT16_Y630 ZBTB16 - Zinc finger and BTB domain containing protein 16 0.032 0.617 
a Substrate names from the Tyrosine Kinase PamChip96 Array (PamGene International 
B.V,‘s-Hertogenbosch, The Netherlands). For each substrate, position of phosphorylation 
sites within the protein is indicated 
b Gene names and common names, retrieved from UniProtKB/SwissProt 
(http://au.expasy.org/sprot)
* Calculated as mean log2 inhibition in patients positive for disseminated tumor cells to bone 
 4
marrow minus mean log2 inhibition in negative patients 
** By two-sample t-test 
Fig. 1 Distribution of the score of the first principal component of the 102 peptide substrates 
among the groups of patients with different histomorphologic tumor regression grade (TRG).
P = 0.049
TRG 1–2, good responders; TRG 3, intermediate responders; TRG 4, poor responders
Boxes, 25th, 50th, and 75th percentiles; bars, 10th and 90th percentiles; crosses, outlier values
 5
Fig. 2 Distribution of the score of the first principal component of the 102 peptide substrates 
among patients with positive and negative status for disseminated tumor cells (DTC) to bone 
marrow. P = 0.042 
DTC 0, negative DTC status; DTC 1, positive DTC status 
Boxes, 25th, 50th, and 75th percentiles; bars, 10th and 90th percentiles; crosses, outlier values 
 6
Fig. 3 Distribution of the score of the first principal component of the 23 angiogenesis-
related peptide substrates among patients with positive and negative status for disseminated 
tumor cells (DTC) to bone marrow. P = 0.019 
DTC 0, negative DTC status; DTC 1, positive DTC status 
Boxes, 25th, 50th, and 75th percentiles; bars, 10th and 90th percentiles; crosses, outlier values 
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Radiosensitization by the histone deacetylase
inhibitor vorinostat under hypoxia and with
capecitabine in experimental colorectal
carcinoma
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Abstract
Background: The histone deacetylase inhibitor vorinostat is a candidate radiosensitizer in locally advanced rectal
cancer (LARC). Radiosensitivity is critically influenced by hypoxia; hence, it is important to evaluate the efficacy of
potential radiosensitizers under variable tissue oxygenation. Since fluoropyrimidine-based chemoradiotherapy (CRT)
is the only clinically validated regimen in LARC, efficacy in combination with this established regimen should be
assessed in preclinical models before a candidate drug enters clinical trials.
Methods: Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in
one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively.
Radiosensitizing effects of vorinostat in combination with capecitabine were assessed by evaluation of tumor
growth delay in two colorectal carcinoma xenografts models.
Results: Under hypoxia, radiosensitization by vorinostat was demonstrated in vitro in terms of decreased
clonogenicity and in vivo as inhibition of tumor growth. Adding vorinostat to capecitabine-based CRT increased
radiosensitivity of xenografts in terms of inhibited tumor growth.
Conclusions: Vorinostat sensitized colorectal carcinoma cells to radiation under hypoxia in vitro and in vivo and
improved therapeutic efficacy in combination with capecitabine-based CRT in vivo. The results encourage
implementation of vorinostat into CRT in LARC trials.
Keywords: Rectal cancer, Vorinostat, Fluoropyrimidine, Hypoxia, Radiation
Background
In locally advanced rectal cancer (LARC), neoadjuvant
chemoradiotherapy (CRT) is given to obtain tumor down-
staging to allow complete surgical removal, and single-
agent fluoropyrimidine in combination with fractionated
pelvic radiation remains the standard regimen [1]. Treat-
ment responses vary considerably, and this may be par-
ticularly important in large T4 tumors that depend greatly
on the effect of neoadjuvant CRT for preoperative down-
staging [2]. Other potential radiosensitizing agents have
been evaluated for their ability to further enhance local
tumor response, but improvement has so far not been
achieved, warranting the continued search for novel radio-
sensitizers [3-6]. Histone deacetylase (HDAC) inhibitors
have emerged as a new class of drugs that has been shown
to sensitize tumors to radiation in experimental models.
We have previously assessed the radiosensitizing ability of
the HDAC inhibitor vorinostat in experimental colorectal
carcinoma models, demonstrating reduced in vitro clono-
genicity upon radiation exposure and delayed tumor
growth of xenografts exposed to fractionated radiation [7].
In a recent clinical phase I study, we reported a favorable
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toxicity profile of vorinostat in combination with pelvic
palliative radiotherapy [8,9].
As recently highlighted in guidelines from the NCRI
Clinical and Translational Radiotherapy Research Work-
ing Group [10], novel radiosensitizers must be ad-
equately evaluated in relevant preclinical models in
order to justify exposing patients to the risks of adding a
new drug to radiotherapy or CRT. Since human solid
tumors, including rectal carcinomas, often contain a
substantial fraction of hypoxic cells that are intrinsically
more resistant to radiotherapy, a drug’s ability to radio-
sensitize tumor cells under hypoxia should be taken into
account when investigating new CRT candidates [11].
Furthermore, since fluoropyrimidine-based CRT is the
established regimen in LARC, potential interaction be-
tween a new drug and the standard treatment should be
investigated to reveal possible antagonistic or synergistic
effects. In the present work, radiosensitizing effects of
vorinostat were assessed under hypoxic conditions in
four colorectal carcinoma models in vitro and in one
xenograft model. Moreover, radiosensitizing properties
of vorinostat in combination with the fluoropyrimidine
capecitabine were investigated in two colorectal carcin-
oma xenograft models.
Methods
Experimental treatments
Ionizing radiation (IR) was delivered to cell lines in cul-
ture at a rate of 1.0 Gy/min by Faxitron Cabinet X-ray
system (model 43855 F with CP 160 Option; Faxitron
Bioptics, Lincolnshire, IL). Control cells were simultan-
eously placed in room temperature. To tumor xenografts,
IR was delivered in daily 2-Gy fractions using a 6-MV
photon beam from a linear accelerator (Varian Clinac
2100 CD; Varian, San Diego, CA), at a dose rate of
2.6 Gy/min. Control mice were anaesthetized and
brought to the radiation room. Vorinostat (Alexis
Biochemicals, Lausen, Switzerland) and capecitabine
(Roche, Basel, Switzerland) were prepared and stored as
previously described [7].
In experiments involving hypoxia, the following
single agent and combination treatments were given:
C (control) =NO (normoxia), HO (hypoxia), IR-NO (IR
under normoxia), IR-HO (IR under hypoxia), VOR-NO
(vorinostat under normoxia), VOR-HO (vorinostat under
hypoxia), VOR-IR-NO (vorinostat and IR under nor-
moxia), and VOR-IR-HO (vorinostat and IR under
hypoxia). For experiments involving combination of vor-
inostat and capecitabine, the following treatments were
given: C (control), VOR (vorinostat), CAP (capecitabine),
IR, VOR-IR (vorinostat and IR), CAP-IR (capecitabine
and IR), and VOR-CAP-IR (vorinostat, capecitabine,
and IR).
Cell lines and in vitro experiments
Human colorectal carcinoma cell lines HCT116, HT29,
and SW620 (ATCC, Manassas, VA) and KM20L2 (kindly
provided by Dr. M. R. Boyd, National Cancer Institute,
Frederick, MD) were used. The cell lines were free from
mycoplasma infection and cell line identity was validated
by short tandem repeat analysis. Culturing conditions
were previously described [7]. Vorinostat (1 or 2 μM)
was added to the cell cultures for an incubation period
of 18 h. In vitro hypoxia (1% O2) was generated using an
Invivo2 200 Hypoxic Workstation (Ruskinn, Bridgend,
UK). Cell cultures were incubated under these condi-
tions for 18 h before sealing the flasks using non-filter
caps and transferring them to an x-ray unit. After IR ex-
posure, culture flasks were transferred to normoxic con-
ditions. Control cell cultures were kept under normoxic
conditions at all times. Clonogenicity was performed as
previously described [7] with the main modification
being that cells were grown in T-25 flasks (Nunc, Ros-
kilde, Denmark) to allow generation of hypoxia. Plating
efficiencies determined from control experiments were
0.63 ± 0.07 for HCT116, 0.84 ± 0.19 for HT29, 0.61 ± 0.14
for SW620, and 0.78 ± 0.08 for KM20L2. Surviving frac-
tions (SF) were calculated relative to the relevant
control.
For analysis of HIF-1α induction, HCT116 cells were
seeded in cell culture flasks and exposed to HO or NO
as previously described or treated with 100 μM CoCl2
for 4 h to generate a positive control for HIF-1α expres-
sion (Sigma Aldrich, St Louis, MO). Whole cells lysates
were generated as previously described [12] and stored
at - 80°C until analysis. Separation of 7.5 μg of protein
was performed using 4-12% NuPAGEW Novex Bis-Tris
Gels (Invitrogen, Carlsbad, CA) in MES buffer and
transferred to Immobilon-P membranes (Millipore, Bed-
ford, MA). Membranes were blocked for 1 h at room
temperature in Tris-buffered saline with 0.1% Tween-20
(TBST) and 5% non fat dry milk and incubated over night
at 4°C with mouse anti-HIF-1α antibody (# 610958; BD
Transduction Laboratories, Franklin Lakes, NJ) or goat
anti-actin antibody (sc-1616; Santa Cruz Biotechnology,
Santa Cruz, CA). After washing, the membranes were
incubated for 1 h at room temperature with appropriate
horseradish peroxidase conjugated secondary antibody,
and bands were visualized using Super Signal West
Dura Extended Duration Substrate (Thermo Scientific,
Waltham, MA).
Animal models
Locally bred female and male athymic Balb/c mice 6–
8 weeks old were used. For one experiment (vorinostat,
capecitabine, and IR– in vivo tumor growth, HCT116
xenografts) Balb/c nude (nu/nu) mice from Harlan La-
boratories (Rossdorf, Germany) were purchased, as our
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animal facility had reduced availability of inbred mice
due to relocation of the department. The mice were
maintained under specific pathogen-free conditions, and
food and water were supplied ad libitum. Housing and
all procedures involving animals were performed according
to protocols approved by the Animal Care and Use Com-
mittee, in compliance with the National Committee for
Animal Experiment’s guidelines on animal welfare. Xeno-
grafts were established as previously described [7] on the
thigh (hypoxia experiments) or on the rear flank (capecita-
bine experiments) and tumor volumes were calculated
using the following formula: volume= (п/6) × a×b2, in
which a and b were the largest and the smallest perpen-
dicular tumor diameters, respectively. The mice were sacri-
ficed when tumors reached a diameter of 15 mm (thigh) or
20 mm (flank), or if the animal failed to thrive.
In vivo experiments
In vivo tumor hypoxia was achieved by placing a heavy
clamp over the proximal thigh of anesthetized mice dur-
ing irradiation [13]. The tumors were clamped for
3.5 min before and during IR exposure (to a total period
of 5.0 min). In experiments involving hypoxia, the mice
were randomized by tumor volume into groups of 5–6
animals and were treated with vorinostat concomitantly
to irradiation for four consecutive days. Vorinostat
(100 mg/kg) or vehicle was given daily by intraperitoneal
(i.p.) injections three hours before radiation. Tumor
blood supply to clamped xenografts was examined by
measuring tumor radioactivity after injection of I125 and
used as a measure of acute hypoxia. I125 (Hartmann
Analytic, Braunschweig, Germany) in the form of an
iodinated antibody and with an activity of 2.85 MBq/ml,
was administered by tail vein injection (100 μL, mean
activity of 10 kBq/g) to four anesthetized mice (tumor
volume 91.3 ± 34.3 mm3; mean ± standard deviation).
After 5 min, the mice were sacrificed and tumors were
dissected and clamped and unclamped tumors were ana-
lyzed by a gamma counter (COBRA II Auto-Gamma;
Packard Canberra, Meriden, CT). The ratio of I125 activ-
ity (i.e., activity in clamped tumor divided by activity in
unclamped tumor on the same mouse) was 0.03 ± 0.01
(mean ± standard deviation), indicating a substantial re-
duction of blood flow to clamped tumors (p < 0.001).
In experiments involving capecitabine, the mice were
randomized by tumor volume into treatment groups of 6–
9 mice and treated with vorinostat concomitantly to irradi-
ation for five consecutive days. Vorinostat (100 mg/kg) or
vehicle was given daily by i.p. injections three hours before
radiation. Capecitabine (359 mg/kg) or vehicle was given
daily by oral gavage immediately after administration of
vorinostat. Relative tumor volumes (RTV) were calculated
relative to the tumor volume on the day of treatment initi-
ation. For each tumor, tumor doubling time (T2x) relative
to the Day 1 tumor volume was determined. Tumor
growth delay (TGD2x) was calculated by subtracting the
mean T2x of the vehicle-treated tumors from the T2x for
each treated xenograft.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Inc., Chicago, IL). Differences between groups were
analyzed using the two-sided Student t test under con-
ditions of normality and a non-parametric test (Mann–
Whitney rank-sum test) under other conditions. p values
less than 0.05 were considered statistically significant.
Results
Vorinostat, hypoxia, and IR – in vitro clonogenicity
In initial experiments on HCT116 cells, clonogenicity
was not influenced by hypoxia (SF for HO cells was
0.97 ± 0.08; mean ± standard error of the mean, com-
pared to C). Likewise, the survival of VOR-NO cells and
VOR-HO cells was similar (SF were 0.35 ± 0.04 and
Table 1 In vitro clonogenicity - mean surviving fractions (SEM) after treatment with ionizing radiation (IR, 5 Gy),
vorinostat and hypoxia
HCT116 HT29 SW620 KM20L2
SF p SF p SF p SF p
Monotherapy (relative to control)
IR 0.029 (0.04) <0.001 0.33 (0.02) <0.001 0.079 (0.02) <0.001 0.11 (0.002) <0.001
HO 0.97 (0.08) 0.7 0.98 (0.03) 0.6 0.62 (0.28) 0.3 0.92 (0.01) 0.01
VOR 0.35 (0.04) <0.001 0.78 (0.07) 0.05 0.84 (0.04) 0.07 0.66 (0.04) 0.04
Combination therapy
IR-HO (relative to HO) 0.13 (0.03) <0.001 0.51 (0.05) 0.002 0.36 (0.10) 0.02 0.20 (0.02) <0.001
VOR-HO (relative to HO) 0.41 (0.05) <0.001 0.88 (0.09) 0.3 0.68 (0.14) 0.1 0.68 (0.03) 0.08
VOR-IR (relative to VOR) 0.011 (0.004) <0.001 0.18 (0.03) <0.001 0.026 (0.02) <0.001 0.066 (0.02) <0.001
VOR-IR-HO (relative to VOR-HO) 0.020 (0.005) <0.001 0.24 (0.02) <0.001 0.052 (0.03) <0.001 0.040 (0.006) <0.001
SF = surviving fractions; HO= hypoxia; VOR = vorinostat; IR-HO= IR under hypoxia;
VOR-HO= vorinostat under hypoxia; VOR-IR = vorinostat and IR; VOR-IR-HO= vorinostat and IR under hypoxia.
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0.41 ± 0.05, respectively). The presence of hypoxia was
verified by western immunoblot analysis, showing induc-
tion of HIF-1α after exposure to in vitro hypoxia. In
contrast, IR-HO cells were less sensitive to a radiation
dose of 5 Gy than IR-NO cells (SF were 0.13 ± 0.03 and
0.029 ± 0.004, respectively; p = 0.002). Notably, vorinostat
enhanced the 5-Gy radiation effects of both hypoxic and
normoxic cells (SF for VOR-IR-HO cells was
0.020 ± 0.005; p = 0.003; SF for VOR-IR-NO cells was
0.011 ± 0.004; p = 0.006). The experiments were also per-
formed applying 2-Gy radiation doses, and although the
effects of hypoxia and vorinostat treatment exhibited the
same trends as for the 5-Gy dose, the differences were
not statistically significant (Table 1, Figure 1).
In subsequent experiments, a radiation dose of 5 Gy
was used. Hypoxia alone did not substantially influence
clonogenicity in any of the models. The cytotoxic effect
of vorinostat alone varied among the cell lines (SF 0.66-
0.88), but was not significantly different for VOR-HO
cells compared to VOR-NO cells. Clonogenicity of
IR-HO cells was higher than for the respective IR-NO
counterparts (for HT29, SF 0.51 ± 0.05 versus 0.33 ± 0.02;
p = 0.02; for SW620, SF 0.36 ± 0.10 versus 0.079 ± 0.02;
p = 0.049; for KM20L2, SF 0.20 ± 0.02 versus 0.11 ±
0.002; p = 0.02). Again, in VOR-IR-HO cells compared
to IR-HO cells, vorinostat caused radiosensitization (for
HT29, SF 0.24 ± 0.02 versus 0.51 ± 0.05; p = 0.005; for
SW620, SF 0.052 ± 0.03 versus 0.36 ± 0.10; p = 0.04;
for KM20L2, SF 0.040± 0.006 versus 0.20± 0.02; p =
0.002). Under normoxia (VOR-IR-NO), HT29 and
KM20L2 were radiosensitized by vorinostat, while the ef-
fect was not statistically significant for SW620.
Vorinostat, hypoxia, and IR – in vivo tumor growth
In a pilot experiment, radiation exposure inhibited
growth of normoxic SW620 xenografts but not of hyp-
oxic tumors. 5–6 mice were randomized to each treat-
ment group (control, C; hypoxia, HO: ionizing radiation
under normoxia, IR-NO; ionizing radiation under hyp-
oxia, IR-HO). Experimental treatments were started
17 days after establishment of SW620 xenografts at
tumor volumes of 192.7 ± 112 mm3 (mean ± standard
deviation). Of 23 mice included in the experiment, one
IR-NO animal was excluded from analysis as it was
sacrificed early (day 4) due to anesthesia-related compli-
cations. Untreated xenografts had a T2x of 5.33 ± 2.6 days.
The TGD2x of HO tumors was unchanged compared to
C (TGD2x 0.27 ± 1.9 days; p = 0.74). The IR exposure
inhibited growth of normoxic xenografts as IR-NO
tumors were growth inhibited (TGD2x 5.47 ± 1.9 days;
p < 0.001), while the growth rate of IR-HO tumors was
not significantly different from C (TGD2x 2.33 ± 3.0;
p = 0.09) (Table 2, Figure 2).
A subsequent experiment was undertaken to specific-
ally investigate the effects of vorinostat under hypoxia,
involving four treatment groups: C, IR-NO, IR-HO, or
VOR-IR-HO. Experimental treatments were started
13 days after establishment of SW620 xenografts at
tumor volumes of 51.1 ± 35 mm3 (mean± standard devi-
ation). Of 23 mice included in the experiment, four mice
were excluded from analysis as they were sacrificed early
(days 1–2) for the following reasons: anesthesia-related
complications (n= 3; two VOR-IR-HO and one IR-NO)
and failure to thrive (n= 1; VOR-IR-HO), leaving three
animals for analysis in the VOR-IR-HO group. For un-
treated xenografts T2x was 9.60 ± 7.7 days. Similarly to
the pilot findings, radiation exposure inhibited growth
under normoxia but not under hypoxia (for IR-NO
TGD2x was 7.83 ± 5.9 days; p = 0.016 compared to C); for
IR-HO tumors TGD2x was −1.43 ± 3.6; p = 0.40 com-
pared to C)). Importantly, vorinostat enhanced radiosen-
sitivity under hypoxia as growth of the VOR-IR-HO
xenografts was inhibited compared to IR-HO xenografts
(TGD2x was 6.07 ± 2.5 versus −1.43 ± 3.6; p = 0.015).
(See figure on previous page.)
Figure 1 Vorinostat, hypoxia, and ionizing radiation (IR) – in vitro clonogenicity and HIF-1α expression. (A) HCT116, (B) HT29, KM20L2
and SW620 cells were treated with IR under normoxia (IR-NO), IR under hypoxia (IR-HO), vorinostat and IR under normoxia (VOR-IR-NO) or
vorinostat and IR under hypoxia (VOR-IR-HO). Surviving fractions are shown as mean, and bars represent SEM. * Indicates significant difference
between IR-NO and IR-HO. ** Indicates significant difference between VOR-IR-NO and IR-NO. *** Indicates significant difference between VOR-IR-
HO and IR-HO. (C) Western immunoblot analysis of HIF-1α expression in HCT116 cells exposed to normoxia (NO) or hypoxia (HO). Cells were
treated with CoCl2 as a positive control and actin was used as protein loading control.
Table 2 Vorinostat, hypoxia, and ionizing radiation -
tumor growth delay
Treatment
groups
TGD2x
(days)
Compared
to (group)
p-value
SW620 Pilot
HO 0.27 ± 1.9 C 0.7
IR-NO 5.47 ± 1.9 C <0.001
IR-HO 2.33 ± 3.0 C 0.09
SW620 Main
experiment
IR-NO 7.83 ± 5.9 C 0.02
IR-HO −1.43 ± 3.6 C 0.4
VOR-IR-HO 6.07 ± 2.5 IR-HO 0.02
TGD2x = tumor growth delay at 2-fold increase of relative tumor volume;
C = control; HO= hypoxia; IR-NO= IR under normoxia; IR-HO= IR under hypoxia;
VOR-IR-HO= vorinostat and IR under hypoxia.
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Vorinostat, capecitabine, and IR – in vivo tumor growth
To assess the effect of adding vorinostat to
fluoropyrimidine-based CRT, two xenograft models,
SW620 and HCT116, were used. The experimental setup
included seven groups of mice receiving C, VOR, CAP,
IR, VOR-IR, CAP-IR, or the full combination of VOR-
CAP-IR. Experimental treatments were initiated 10 days
(SW620) or 14 days (HCT116) after establishment of
xenografts at tumor volumes of 100.8 ± 86 mm3 and
77.0 ± 57 mm3 (mean ± standard deviation), respectively.
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Figure 2 Vorinostat, hypoxia, and ionizing radiation (IR) – in vivo tumor growth. (A) Mice bearing SW620 xenografts were treated with
vehicle (control, C), hypoxia (HO), IR under normoxia (IR-NO) and IR under hypoxia (IR-HO). (B) Mice bearing SW620 xenografts were treated with
vehicle (control, C), IR under normoxia (IR-NO), IR under hypoxia (IR-HO), or vorinostat and IR under hypoxia (VOR-IR-HO). Relative tumor volumes
(mean± SEM) presented as function of time after start of treatments.
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Of 53 mice included in each experiment, five mice were
sacrificed early (days 1–4) because of anesthesia-related
complications (n= 3; SW620) or failure to thrive (n= 2;
HCT116), and were excluded from analysis. Further-
more, due to ulceration of the tumors, three xenografts
did not reach T2x and one vehicle xenograft grew abnor-
mally (HCT116) and were removed from the study
(Table 3, Figure 3).
For untreated xenografts T2x was 4.13 ± 0.9 days for
HCT116 and 4.30 ± 1.3 days for SW620. While IR inhib-
ited growth of HCT116 (TGD2x was 5.68 ± 8.5 days;
p = 0.025 compared to C), growth inhibition of SW620
was not statistically significant (TGD2x was
1.40 ± 2.2 days, p = 0.061 compared to C). Single-agent
therapy with CAP delayed tumor growth compared to C
for HCT116 (TGD2x was 2.68 ± 2.4 days, p = 0.001), but
not for SW620 (TGD2x was 0.14 ± 1.8 days, p = 0.8).
Single-agent therapy with VOR did not alter tumor
growth (for HCT116, TGD2x was 0.24 ± 1.9 days, p = 0.7
compared to C, respectively; for SW620, TGD2x was
0.88 ± 1.9 days, p = 0.2 compared to C. Tumor growth
delay of VOR-IR xenografts was observed for HCT-116
(TGD2x of VOR-IR was 20.06 ± 15.1 days compared to
TGD2x of IR which was 5.68 ± 8.5 days, p = 0.01), while
for SW620 tumor growth was not significantly delayed,
although a similar trend was observed (TGD2x of VOR-
IR was 2.78 ± 2.6 days compared to TGD2x of IR which
was 1.40 ± 2.2 days, p = 0.2). Only minor, non-significant
changes of radiosensitivity was obtained by adding cape-
citabine to IR (CAP-IR) (for HCT116, TGD2x of CAP-IR
was 5.46 ± 6.1 days compared to TGD2x of IR of
5.68 ± 8.5 days, p = 0.9; for SW620, TGD2x of CAP-IR
was 2.53 ± 3.1 days compared to TGD2x of IR of
1.40 ± 2.2 days, p = 0.2). Notably, vorinostat in combin-
ation with capecitabine improved radiation efficacy in
both models as TGD2x of VOR-CAP-IR xenografts were
significantly increased compared to TGD2x of CAP-IR
xenografts (for HCT116, TGD2x of VOR-CAP-IR was
18.99 ± 7.3 days compared to TGD2x of 5.46 ± 6.1 days
for CAP-IR, p <0.001; for SW620, TGD2x of VOR-CAP-
IR was 5.78 ± 3.9 days compared to TGD2x of
2.53 ± 3.1 days for CAP-IR, p = 0.03).
Discussion
Exposure to hypoxic conditions during radiation made
the cells in our in vitro models more radioresistent, in
line with theories of classical radiobiology stating that
hypoxia increases the resistance of cancer cells to radi-
ation treatment. In vivo, a similar effect of short-term
acute hypoxia was observed, as clamped tumors were
more resistant to treatment with fractionated radiation
than unclamped tumors. Vorinostat enhanced radiosen-
sitivity of cells exposed to hypoxia during radiation in all
colorectal carcinoma cell lines in vitro, almost counter-
balancing hypoxia-induced radioresistance. In line with
these results, vorinostat demonstrated radiosensitizing
effects in xenografts exposed to acute hypoxia, as tumor
volumes of vorinostat-treated mice irradiated under hyp-
oxia were similar to the tumor volumes of mice irra-
diated under normoxia, reversing the radioresistent
hypoxic phenotype.
Response to cancer treatment is strongly influenced
by the tumor microenvironment, and specifically, the
most important determinant of radiotherapy response
is tissue oxygenation. Colorectal tumors are often
large, and analysis of hypoxia biomarkers in patient
samples has revealed that most tumors exhibit a mo-
lecular phenotype consistent with varying hypoxia [11].
Moreover, in a recent report, expression of the
hypoxia-associated protein carbonic anhydrase IX was
negatively associated with CRT response in patients
with rectal cancer [14]. Hence, a likely explanation for
variable CRT response in rectal cancer is variable
tumor oxygenation, and in this perspective, the ability
to overcome hypoxia-related radioresistance would be
an advantageous property of a radiosensitizing drug. In
other tumor forms, a small number of drugs (such as
gemcitabine, irinotecan, and the poly(ADP-ribose)
polymerase-inhibitor velaparib) [15-17] have been eval-
uated in combination with radiotherapy under hypoxic
conditions. Considering the importance of tissue oxy-
genation for radiotherapy efficacy, the scarcity of ex-
perimental data exploring radiosensitizers under
hypoxia in LARC is remarkable. One reason for this
Table 3 Vorinostat, capecitabine, and ionizing radiation -
tumor growth delay
Treatment
groups
TGD2x
(days)
Compared
to (group)
p-value
HCT116
IR 5.68 ± 8.5 C 0.03
CAP 2.68 ± 2.4 C 0.001
VOR 0.24 ±1.9 C 0.7
CAP-IR 5.46 ± 6.1 IR 0.9
VOR-IR 20.06 ± 15.1 IR 0.01
VOR-CAP-IR 18.99 ± 7.3 CAP-IR <0.001
SW620
IR 1.40 ± 2.2 C 0.06
CAP 0.14 ± 1.8 C 0.8
VOR 0.88 ± 1.9 C 0.2
CAP-IR 2.53 ± 3.1 IR 0.3
VOR-IR 2.8 ± 2.6 IR 0.2
VOR-CAP-IR 5.78 ± 3.9 CAP-IR 0.03
TGD2x = tumor growth delay at 2-fold increase of relative tumor volume;
IR = ionizing radiation;
C = control; CAP = capecitabine; VOR= vorinostat; CAP-IR = capecitabine and IR;
VOR-IR = vorinostat and IR; VOR-CAP-IR = vorinostat, capecitabine and IR.
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could be related to difficulties in selecting appropriate
models for mimicking clinical hypoxia when evaluating
radiosensitizing drugs. This challenge was also appar-
ent in our experiments, as the impact of hypoxia on
radioresistance was less pronounced in the pilot than
in the main experiment (Figure 2). This illustrates bio-
logical variation which may be partially explained by
the introduction of a tighter set of hypoxia clamps in
the second experimental series than in the pilot. There
is also some controversy regarding how to conduct
in vivo experiments, particularly when fractionating the
radiation. Although the clamping technique has been
shown to be relevant for this purpose [18], it has been
questioned whether this strategy truly reflects radio-
sensitivity under hypoxia [19]. In this context, our ap-
proach of administering vorinostat prior to short-term
hypoxia and irradiation is interesting, as our experi-
ments represent an important attempt to evaluate a
novel radiosensitizer under tumor hypoxia. However,
such experiments should be repeated in larger series
of animals, and with the paucity of data describing the
use of conventional radiosensitizing agents in LARC
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Figure 3 Vorinostat, capecitabine, and ionizing radiation (IR) – in vivo tumor growth. Mice bearing (A) SW620 and (B) HCT116 xenografts
were treated with vehicle (control, C), vorinostat (VOR), capecitabine (CAP), IR, capecitabine and IR (CAP-IR), vorinostat and IR (VOR-IR), or
vorinostat, capecitabine and IR (VOR-CAP-IR). Relative tumor volumes (mean± SEM) presented as function of time after start of treatments.
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under hypoxia, the therapeutic implication of vorino-
stat in this clinical setting is still elusive.
In LARC, fluoropyrimidine-based neoadjuvant CRT is
the established treatment regimen and any novel radio-
sensitizing agent must be evaluated in this context. In
the present study, in vivo addition of vorinostat to cape-
citabine and fractionated radiation enhanced treatment
efficacy in terms of inhibited tumor growth in two colo-
rectal xenograft models. Vorinostat has recently been
shown to synergize with fluoropyrimidine-based chemo-
therapy in preclinical colorectal carcinoma models
[20,21], but radiosensitizing properties of the combin-
ation has to our knowledge not been evaluated. Applying
radiation in combination with vorinostat or capecitabine
alone, we observed trends towards enhanced radiosensi-
tivity, although the reduction of tumor volume was not
statistically significant. In our previous experiments,
both these drugs were potent radiosensitizers in experi-
mental colorectal carcinoma models [7,22]. The variable
effects on radiosensitivity could be explained by the lim-
ited total treatment doses possible to administer in the
experimental setting, in addition to variation associated
with the biological complexity of animal models. Similar
limitations were also present in the combination group
and in this context, the enhanced radiosensitivity
observed when combining vorinostat and capecitabine is
noteworthy, and adds to the preclinical evidence sup-
porting vorinostat as radiosensitizer in LARC [7,23].
Conclusion
Although preclinical evidence [7,23] and clinical safety
data [8,9] both support the use of vorinostat as radiosen-
sitizer in LARC, more extensive preclinical examination
was necessary prior to recommending vorinostat as an
additional component of CRT in LARC trials. Hence, we
expanded our in vitro and in vivo models by studying
radiosensitizing effects of vorinostat under hypoxic con-
ditions and in combination with capecitabine. Import-
antly, the results from the present study indicate that
vorinostat is a radiosensitizer under hypoxic conditions
and also interacts favorably with capecitabine in experi-
mental models of colorectal carcinoma. Recognizing the
important role of hypoxia in LARC, particularly in large
T4 tumors, as well as the requirement that novel drugs
should be compatible with fluoropyrimidine-based
standard CRT, our results encourage the implementation
of vorinostat in next-generation clinical CRT trials in
LARC.
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Abstract 
 
Background: Following the demonstration that histone deacetylase inhibitors enhanced 
experimental radiation-induced clonogenic suppression, the Pelvic Radiation and Vorinostat 
(PRAVO) phase 1 study, combining fractionated radiotherapy with daily vorinostat for pelvic 
carcinoma, was designed to evaluate both clinical and novel biomarker endpoints, the latter 
relating to pharmacodynamic indicators of vorinostat action in clinical radiotherapy. 
 
Patients and Methods: Potential biomarkers of vorinostat radiosensitizing action, not 
simultaneously manifesting molecular perturbations elicited by the radiation itself, were 
explored by gene expression array analysis of study patients’ peripheral blood mononuclear 
cells (PBMC), sampled at baseline (T0) and on-treatment two and 24 hours (T2 and T24) 
after the patients had received vorinostat. 
 
Results: This strategy revealed 1,600 array probes that were common for the comparisons T2 
versus T0 and T24 versus T2 across all of the patients, and furthermore, that no significantly 
differential expression was observed between the T0 and T24 groups. Functional annotation 
analysis of the array data showed that a significant number of identified genes were 
implicated in gene regulation, the cell cycle, and chromatin biology. Gene expression was 
validated both in patients’ PBMC and in vorinostat-treated human carcinoma xenograft 
models, and transient repression of MYC was consistently observed. 
 
Conclusion: Within the design of the PRAVO study, all of the identified genes showed rapid 
and transient induction or repression and therefore, in principle, fulfilled the requirement of 
being pharmacodynamic biomarkers of vorinostat action in fractionated radiotherapy, 
possibly underscoring the role of MYC in this therapeutic setting. 
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Introduction 
 
Modern radiation oncology will require a synergy between high-precision 
radiotherapy protocols and innovative approaches for biological optimization of radiation 
effect. From a clinical perspective, new insights into molecular radiobiology will provide a 
unique opportunity for combining systemic targeted therapeutics with radiotherapy [1]. One 
example is the use of histone deacetylase (HDAC) inhibitors as potentially radiosensitizing 
drugs. Inhibition of HDAC enzymes leads to acetylation of histone and non-histone proteins, 
and the resultant changes in gene transcription cause alterations in key molecules that 
orchestrate a wide range of cellular functions, including cell cycle progression, DNA damage 
signaling and repair, and cell death by apoptosis and autophagy [2–5]. 
Following the demonstration that HDAC inhibitors enhanced radiation-induced 
clonogenic suppression of experimental in vitro and in vivo colorectal carcinoma models [6–9], 
but independently of the actual histone acetylation level at the time of radiation exposure [7,8], 
we conducted the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study [10,11]. This trial, 
undertaken in sequential patient cohorts exposed to escalating dose levels of the HDAC inhibitor 
vorinostat combined with pelvic palliative radiotherapy for advanced gastrointestinal 
malignancy, was the first to report on the therapeutic use of an HDAC inhibitor in clinical 
radiotherapy. It was designed to demonstrate a number of key questions; whether the 
investigational agent reached the specific target (detection of tumor histone acetylation), the 
applicability of non-invasive tumor response assessment (using functional imaging), and 
importantly, that the combination of an HDAC inhibitor and radiation was safe and tolerable. 
The ultimate goal of a first-in-human therapy trial is to conclude with a recommended 
treatment dose for follow-up expanded trials, and in achieving this, a phase 1 study typically 
is designed to determine treatment toxicity and tolerability (in terms of dose-limiting toxicity 
and maximum-tolerated dose (MTD), respectively) [12,13]. For molecularly targeted agents, 
the dose that results in a relevant level of target modulation may differ greatly from the MTD, 
and generally, we do not have a good understanding of the relationship between the MTD and 
the dose required to achieve the desired therapeutic effect [1]. An optimum biological dose 
may be the dose that is associated with pharmacodynamic biomarkers reflecting the 
mechanism of drug action. In the setting of fractionated radiotherapy, this would ideally 
represent a radiosensitizing molecular event occurring at each radiation fraction, or in other 
words, a biological indicator with a transient and periodic expression profile. Importantly, 
tumor specimens for this particular purpose cannot be sampled after the patient has 
commenced the radiation treatment. Any signaling activity in on-treatment tumor samples 
would reflect the combined effect of radiation and the systemic drug, and the contribution of 
the latter would probably be indistinguishable from the effect of the actual accumulated 
radiation dose. Instead, the study can be designed to collect non-irradiated surrogate tissue 
both before the commencement of study treatment and on-treatment at time points reflecting 
the timing of administration of the systemic drug with regard to the fractionated radiotherapy 
protocol. In addition, as a general rule, biomarkers that have been previously established for 
single-agent therapy will require reevaluation in a first-in-human clinical trial combining a 
molecularly targeted compound with radiotherapy. 
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Within this context, i.e., that the possible mechanism of radiosensitizing action of the 
molecularly targeted agent should be regarded a main objective in a combined-modality study 
with radiotherapy, the present study reports on a correlative analytical strategy for identifying 
possible biomarkers of HDAC inhibitor activity, using peripheral blood mononuclear cells 
(PBMC) from the PRAVO phase 1 study patients receiving pelvic palliative radiotherapy as 
an easily accessible surrogate tissue for vorinostat exposure [14]. Gene expression array 
analysis identified PBMC genes that from experimental models are known to be implicated in 
biological processes governed by HDAC inhibitors, and might be further developed as 
pharmacodynamic biomarkers of vorinostat activity in the setting of fractionated 
radiotherapy. 
 
Materials and Methods 
Ethics Statement 
Both of the protocols for the PRAVO study (ClinicalTrials ID NCT00455351) and the 
phase 2, non-randomized study for patients with locally advanced rectal cancer (LARC) 
given neoadjuvant chemoradiotherapy (ClinicalTrials ID NCT00278694) were approved by 
the Institutional Review Board and the Regional Committee for Medical and Health Research 
Ethics South-East Norway (REC South-East, Permit Number S-06289 and S-05059, 
respectively), and were performed in accordance with the Declaration of Helsinki. Written 
informed consent was required for participation. Housing and all procedures involving 
animals were performed according to protocols approved by the Animal Care and Use 
Committee at Department of Comparative Medicine, Oslo University Hospital (Permit 
Number 885-2616-2919-2928-3688), in compliance with the Norwegian National Committee 
for Animal Experiments’ guidelines on animal welfare. 
 
PRAVO Study Patients and Objectives 
The patient population was enrolled between February 2007 and May 2009. The 
principal eligibility criterion was histologically confirmed pelvic carcinoma scheduled to 
receive palliative radiation to 30 Gy in 3-Gy daily fractions. Other details on eligibility are 
given in the initial report [10]. This phase 1 dose-escalation study adopted a standard 3+3 
expansion cohort design [12], where patients with advanced gastrointestinal carcinoma were 
enrolled onto four sequential dose levels of vorinostat (Merck & Co., Inc., Whitehouse 
Station, NJ, USA), starting at 100 mg daily with dose escalation in increments of 100 mg 
[10]. The primary objective was to determine tolerability of vorinostat, defined by dose-
limiting toxicity and MTD, when administered concomitantly with palliative radiation to 
pelvic target volumes. Secondary objectives were to assess the biological activity of 
vorinostat, including the identification of possible biomarkers of HDAC inhibitor activity, 
and to monitor radiological response when given with pelvic radiotherapy. The study data on 
patient treatment tolerability, tumor histone acetylation following vorinostat administration, 
and treatment-induced changes in tumor volume and apparent distribution coefficient, as 
assessed by magnetic resonance imaging, have been reported in detail previously [10,11]. 
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Patient Blood Sampling and RNA Isolation 
As depicted by Figure 1, peripheral blood, drawn on PAXgene Blood RNA Tubes 
(Qiagen Norge, Oslo, Norway), was collected at baseline (before commencement of study 
treatment; termed T0) and on-treatment the third treatment day, two and 24 hours after the 
patient had received the preceding daily dose of vorinostat (termed T2 and T24), respectively. 
A full set of three samples (T0, T2, and T24) was obtained from 14 of the 16 evaluable study 
patients (Table 1). The tubes were stored at –70 C until analysis. Total PBMC RNA was 
isolated using PAXgene Blood RNA Kit (Qiagen), following the manufacturer’s protocol. 
RNA concentration and quality were assessed using NanoDrop 1000 and Agilent 2100 
Bioanalyzer (Thermo Fisher Scientific Norway, Oslo, Norway), respectively. 
 
 
 
 
 
Figure 1. Treatment schedule for the Pelvic Radiation and Vorinostat phase 1 study. This study 
combined pelvic palliative radiotherapy (30 Gy in 3-Gy daily fractions; administered at 12 noon) with 
the histone deacetylase inhibitor vorinostat (given once daily at 9 a.m.) for advanced gastrointestinal 
malignancy. Arrows indicate administration of therapy. Study patients’ peripheral blood mononuclear 
cells (PBMC) were sampled before commencement of treatment (T0) and on active therapy, two 
hours (T2; at 11 a.m. on day 3) and 24 hours (T24; at 9 a.m. on day 3) after the previous dose of 
vorinostat. 
 
 
Gene Expression Array Analysis 
This analysis was performed by the Norwegian Genomics Consortium (Oslo, 
Norway). Briefly, cRNA synthesis, amplification, and hybridization to Illumina Human WG-
6 v3 Expression BeadChip arrays (Illumina, Inc., San Diego, CA, USA), containing 48,000 
probes, were carried out as per manufacturer’s instructions. Signal intensities were extracted 
by the BeadArray Reader Software (Illumina), and raw data were imported into the 
GenomeStudio v2010.1 Software, Gene Expression module v1.6.0 (Illumina). The primary 
array data are available in the Gene Expression Omnibus data repository (GEO accession 
number GSE46703). 
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Statistical and Functional Annotation Analyses of Array Data 
Analysis was performed using Bioconductor vR2.11.1 and the Bioconductor packages 
lumi 1.14.0, linear models for microarray data (limma) 3.4.4, and 
illuminaHumanv3BeadID.db 1.6.0 (www.bioconductor.org). Following quality control and 
pre-processing, the data were log2-transformed, and differential gene expression between the 
sample groups T0, T2, and T24 was determined by applying a Benjamin and Hochberg false 
discovery rate-adjusted P-value cut-off of 0.05. The total number of probes that were 
identified as differentially expressed was analyzed using the Database for Annotation, 
Visualization and Integrated Discovery, DAVID v6.7 [15,16]. Enriched biological processes 
and pathways were identified using the GOTERM_BP_FAT and KEGG_PATHWAY 
algorithms, applying a P-value cut-off of 0.01. Differential expression analysis of the array 
data was also performed using a P-value of 0.01 and a log2-fold change cut-off of 1.0 in order 
to identify genes whose expression changes could have potentially high biological 
significance. 
 
Experimental Human Colorectal Carcinoma Models 
The HCT116 and SW620 colorectal carcinoma cell lines were originally purchased 
from American Type Culture Collection (Manassas, VA, USA), and the identities of our 
laboratory’s versions were confirmed by short tandem repeat analysis (Table S1). The LoVo-
92 colorectal carcinoma cell line was kindly provided by Dr. Paul Noordhuis (VU Medical 
Centre, Amsterdam, The Netherlands) [17]. The cell lines were cultured as previously 
described [8,17]. Xenografts were established by subcutaneous injections of HCT116 or 
SW620 cell suspensions (2 × 106 cells) bilaterally on the flanks of locally bred female 
BALB/c nude (nu/nu) or Athymic Nude-Foxn1nu mice, 6–8 weeks of age. Vorinostat 
(Cayman Chemical, Ann Arbor, MI, USA; 100 mg/kg, dissolved in dimethyl sulfoxide to a 
concentration of 100 mg/ml immediately before use) or vehicle was given by intraperitoneal 
injection 13 days (HCT116) or 20 days (SW620) after establishment of xenografts. Three and 
12 hours after administration, the tumors were extirpated, snap-frozen in liquid nitrogen, and 
stored at –70°C. The xenografts were sectioned using a cryostat microtome prior to RNA 
extraction using TRIzol® Reagent (Invitrogen Dynal AS, Oslo, Norway). RNA concentration 
was assessed using the RNA/DNA calculator Gene Quent II (Pharmacia Biotech, Piscataway, 
NJ, USA). 
 
Tumor Samples from LARC Patients 
Primary tumor biopsies were sampled at the time of diagnosis from LARC patients 
enrolled onto a phase 2 study on neoadjuvant chemoradiotherapy (Table S2). The biopsy 
samples were snap-frozen in liquid nitrogen and stored at –70°C, and sectioned on the 
cryostat microtome, essentially as previously reported [18], before RNA was extracted. 
 
Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR) Analysis 
cDNA was synthesized from total RNA using the qScript™ cDNA Synthesis Kit 
(Quanta BioSciences, Inc., Gaithersburg, MD, USA). The qPCR was run in Perfecta qPCR 
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Supermix (Quanta), on iCycler (Bio-Rad Laboratories Norway, Oslo, Norway) and with all 
reactions in parallel. Primers were designed using ProbeFinder Assay Design Software 
(www.roche-applied-science.com/sis/rtpcr/upl/ezhome.html), and were obtained from the 
Universal ProbeLibrary collection (Roche Applied Sciences, Oslo, Norway). Primer 
sequences are listed in Table S3. Amplified cDNA generated from the reference cell line 
(LoVo-92) was included on all PCR plates for relative quantification purposes (correction of 
plate-to-plate variation). Data were normalized to the expression levels of two reference 
genes; YARS, encoding tyrosyl-tRNA synthetase, and TBP, encoding the TATA box-binding 
protein. When tested in the patient samples, the reference genes had equal expression per ng 
of cDNA, independent of patient treatment (vorinostat dose and time after administration). 
The data were analyzed using the GeneExpression Analysis for iCycler iQ® Real-Time PCR 
Detection System Software (BioRad), and were calculated relative to the level in the 
reference cell line and subsequently log2-transformed. 
 
Statistical Analysis of qPCR Data 
Analysis was performed using Predictive Analytics SoftWare Statistics version 19.0 
(SPSS Inc., Chicago, IL, USA). Q-Q plots were applied to test whether the data were 
normally distributed or not, before differences between groups were analyzed using two-
sided Student t-test for the PBMC samples and Mann-Whitney U test for xenograft samples. 
P-values less than 0.05 were considered statistically significant. 
 
Results 
PBMC Transcriptional Response to Vorinostat – Biological Processes and Pathways 
Table 1 gives study patient baseline characteristics; the full study data on treatment 
tolerability and response have been reported previously [10,11]. Of the 14 patients that 
provided a full set of PBMC samples (T0, T2, and T24), one patient was treated at vorinostat 
100 mg once daily and three patients at the 200 mg dose level, whereas four and six patients 
received the medication at 300 or 400 mg once daily, respectively.  
Importantly, as vorinostat-induced tumor histone acetylation had been observed at all 
dose levels [10], the array data from all patient samples at each time point (T0, T2, and T24) 
were pooled, irrespective of the vorinostat dose administered to the patients. This was done to 
increase the statistical power of the testing on analysis of differential gene expression 
between the individual time points. As shown by Figure 2, approximately 2,100 probes were 
differentially expressed both at two hours of vorinostat exposure (T2 versus T0) and on the 
T24 versus T2 comparison when applying the P-value cut-off of 0.05. Of these, 1,602 
transcripts were found to be altered in both comparisons, and furthermore, no significantly 
differential expression was observed when comparing the T0 and T24 groups. Hence, all of 
the 1,602 mutual probes that were identified had a transient change in expression level from 
T0, with approximately one half found to be up-regulated and thus, the other half down-
regulated at T2, followed by the opposite directional change to baseline expression at T24 
(data not shown). 
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Table 1. Study patients. 
 
Vorinostat dose 
(mg daily) 
Age 
(years) Gender Comment 
100 77 Female   
200 49 Female 
200 64 Female 
200 66 Female   
300 47 Female PBMC a not available 
300 66 Female 
300 77 Male 
300 81 Female 
300 82 Male 
300 87 Female PBMC a not available 
400 45 Female 
400 55 Male 
400 62 Male 
400 75 Female 
400 83 Female 
400 85 Female   
 aPeripheral blood mononuclear cells. 
 
        
                                        
Figure 2. Venn diagram illustrating differentially expressed genes. Study patients’ peripheral 
blood mononuclear cells were sampled at baseline (T0) and on-treatment two and 24 hours after 
administration of the daily dose of the study medication vorinostat (T2 and T24, respectively). Gene 
expression was analyzed by Illumina Human WG-6 v3 Expression BeadChip arrays. The array data 
from all patient samples at each time point (T0, T2, and T24) were pooled for the analysis. Probes 
with false discovery rate-adjusted P-values less than 0.05 were considered differentially expressed 
and subjected to Venn analysis, comparing by pairs T2 versus T0, T24 versus T2, and T24 versus T0. 
The figures represent numbers of probes in common for the various conditions. 
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Functional annotation analysis of the differentially expressed genes in patients’ 
PBMC identified several enriched biological processes. Comparison of the baseline PBMC 
transcription profile with that obtained two hours after vorinostat administration (T2 versus 
T0) showed that 69 biological processes were over-represented, whereas the corresponding 
comparison of T24 versus T2 transcriptional profiles identified 106 processes (Table S4). As 
seen from Table 2, displaying the top-ten Gene Ontology terms for each of the two 
comparisons, seven out of the ten biological processes were present in both, with 
transcription being the most significant. In addition, the analysis identified enrichment of 
genes involved in catabolic processes, the cell cycle, RNA processing, chromatin 
modification, and chromosome organization. The top-three pathway networks for each of the 
two comparisons, in common for both, comprised signaling factors of the cell cycle, 
including the p53 pathway (Table 3). 
 
Vorinostat Activity in PBMC – Verification of Selected Biomarkers 
Next, by introducing a log2-fold change cut-off of 1.0 while decreasing the P-value to 
0.01 in order to identify gene expression changes with presumably high biological 
significance, the list of differentially expressed probes, all with a biphasic pattern of 
regulation from T0 through T2 and T24, was reduced to 38 candidates (Table 4). Within this 
panel, two genes had duplicate array probes, whereas no reference sequence could be 
identified for three other probes, leaving 33 known genes as transcriptionally regulated by 
vorinostat following this stringent statistical analysis of the array data. 
 
 
Table 2. Enriched biological processes in patients’ peripheral blood mononuclear cells during 24 
hours of vorinostat treatment. 
 
Biological process a n (%) P-value Selected transcripts b 
T2 versus T0 c 
GO:0006350 transcription 253 (17) 5.1 × 10-14 MYC, DDIT3 
GO:0044265 cellular macromolecule 
catabolic process 107 (7.2) 8.2 × 10
-11 MYC, BARD1 
GO:0044257 cellular protein catabolic 
process 93 (6.3) 1.7 × 10
-10 BARD1 
GO:0007049 cell cycle 111 (7.5) 2.3 × 10-10 MYC, MSH6, BARD1, DDIT3 
GO:0051603 proteolysis involved in 
cellular protein catabolic process 92 (6.2) 2.9 × 10
-10 BARD1 
GO:0019941 modification-dependent 
protein catabolic process 89 (6.0) 3.4 × 10
-10 BARD1 
GO:0009057 macromolecule catabolic 
process 111 (7.5) 3.4 × 10
-10 MYC, BARD1 
GO:0030163 protein catabolic process 94 (6.6) 3.9 × 10-10 BARD1 
GO:0006396 RNA processing 84 (5.6) 1.8 × 10-9 
GO:0045449 regulation of transcription 276 (19) 5.0 × 10-9 MYC, DDIT3 
T24 versus T2 c 
GO:0006350 transcription 260 (17) 8.3 × 10-16 MYC, DDIT3 
GO:0007049 cell cycle 114 (7.5) 2.6 × 10-11 MYC, MSH6, BARD1, DDIT3 
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GO:0045449 regulation of transcription 286 (19) 5.4 × 10-11 MYC, DDIT3 
GO:0016568 chromatin modification 55 (3.6) 1.3 × 10-10 
GO:0006396 RNA processing 86 (5.6) 3.7 × 10-10 
GO:0044265 cellular macromolecule 
catabolic process 104 (6.8) 8.8 × 10
-10 MYC, BARD1 
GO:0051276 chromosome organization 78 (5.1) 9.6 × 10-10 MSH6 
GO:0022402 cell cycle process 85 (5.6) 4.1 × 10-9 MYC, MSH6, BARD1, DDIT3 
GO:0044257 cellular protein catabolic 
process 89 (5.8) 4.3 × 10
-9 BARD1 
GO:0009057 macromolecule catabolic 
process 107 (7.0) 6.4 × 10
-9 MYC, BARD1 
 
aGene Ontology (GO) terms in bold: present in both comparisons. 
bVerified by reverse transcriptase quantitative polymerase chain reaction analysis. 
cT0 represents baseline peripheral blood mononuclear cells (PBMC) samples; T2 and T24 represent 
PBMC samples collected two and 24 hours, respectively, after the patients had received the daily 
dose of vorinostat. 
 
 
 
Table 3. Enriched biological pathways in patients’ peripheral blood mononuclear cells during 24 hours 
of vorinostat treatment. 
 
Biological pathway n (%) P-value Genes a 
hsa04130 SNARE interactions 
in vesicular transport 10 (0.85) 1.6 × 10
-4 STX6, STX5, STX1A, STX12, STX16, USE1, BET1, BET1L, GOSR1, VAMP1  
hsa04115 p53 signaling 
pathway 13 (1.1) 2.7 × 10
-4 
 PMAIP1, RRM2B, SESN2, CDK4, CDK2, 
CCNE2, CCNE1, PPM1D, TNFRSF10B, 
RCHY1, APAF1, GADD45B, GADD45A 
hsa04110 cell cycle 17 (1.5) 0.0012 
 CCNH, ANAPC13, CDC23, CDK7, 
PTTG1, CDK4, ZBTB17, TGFB1, WEE1, 
CDK2, CCNE2, CCNE1, YWHAG, 
CDKN2D, GADD45B, GADD45A, MYC 
 
aGenes in bold: verified by reverse transcriptase quantitative polymerase chain reaction analysis. 
 
 
Table 4. Differentially expressed genes in patients’ peripheral blood mononuclear cells during 24 
hours of vorinostat treatment. a 
 
Accession no. Gene b Gene name 
T2 versus T0 c 
(log2-fold 
change) 
T24 versus T2 c 
(log2-fold 
change) 
NM_005627 SGK1 serum/glucocorticoid regulated kinase 1 –1.58 1.65 
NM_016478 ZC3HC1 zinc finger, C3HC-type containing 1 –1.43 1.39 
NM_175571 GIMAP8 GTPase, IMAP family member 8 –1.23 1.34 
NM_206938 MS4A7 
membrane-spanning 4-
domains, subfamily A, member 
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–1.21 1.06 
NM_002467 MYC v-myc myelocytomatosis viral oncogene homolog (avian) –1.20 1.09 
NM_001024938 SLC2A11 
solute carrier family 2 
(facilitated glucose 
transporter), member 11 
–1.16 1.17 
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NM_004843 IL27RA interleukin 27 receptor, alpha –1.14 1.05 
NM_000104 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 –1.13 1.26 
NM_207007 CCL4L2 chemokine (C-C motif) ligand 4-like 2 –1.04 1.26 
NM_014167 CCDC59 coiled-coil domain containing 59 –1.02 1.00 
NM_005346 HSPA1B heat shock 70kDa protein 1B 1.82 –2.02 
NM_153812 PHF13 PHD finger protein 13 1.80 –1.95 
NM_001564 ING2 inhibitor of growth family, member 2 1.59 –1.71 
NM_001564 ING2 inhibitor of growth family, member 2 1.56 –1.56 
NM_001001870 none None 1.42 –1.28 
NM_016639 TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 1.40 –1.33 
NM_152339 SPATA2L spermatogenesis associated 2-like 1.38 –1.46 
NM_025079 ZC3H12A zinc finger CCCH-type containing 12A 1.36 –1.29 
NM_015675 GADD45B growth arrest and DNA-damage-inducible, beta 1.30 –1.17 
NM_013368 SERTAD3 SERTA domain containing 3 1.24 –1.30 
NM_004219 PTTG1 pituitary tumor-transforming 1 1.23 –1.35 
NM_014711 CP110 CP110 protein 1.20 –1.21 
NM_005341 ZBTB48 zinc finger and BTB domain containing 48 1.14 –1.03 
NM_000179 MSH6 mutS homolog 6 (E. coli) 1.13 –1.23 
NM_153358 ZNF791 zinc finger protein 791 1.13 –1.07 
NM_006494 ERF Ets2 repressor factor 1.12 –1.06 
NR_002734 PTTG3P pituitary tumor-transforming 3, pseudogene 1.11 –1.18 
NM_016605 FAM53C family with sequence similarity 53, member C 1.07 –1.13 
NM_004219 PTTG1 pituitary tumor-transforming 1 1.07 –1.13 
not available none transcribed locus Hs.559604 1.07 –1.08 
NM_000024 ADRB2 adrenergic, beta-2-, receptor, surface 1.07 –1.07 
XM_926814 none None 1.05 –1.19 
NM_006806 BTG3 BTG family, member 3 1.05 –1.04 
NM_031212 SLC25A28 
solute carrier family 25 
(mitochondrial iron 
transporter), member 28 
1.05 –1.00 
NM_000465 BARD1 BRCA1 associated RING domain 1 1.02 –1.23 
NM_004083 DDIT3 DNA-damage-inducible transcript 3 1.02 –1.08 
NM_052901 SLC25A25 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier), member 25 
1.02 –1.06 
NM_024954 UBTD1 ubiquitin domain containing 1 1.01 –1.01 
 
aLog2-fold change higher than 1.0; P-value less than 0.01. 
bGenes in bold: chosen for validation of expression in the study patients’ peripheral blood 
mononuclear cells (PBMC) samples and human colorectal carcinoma xenograft models. 
cT0 represents baseline PBMC samples; T2 and T24 represent PBMC samples collected two and 24 
hours, respectively, after the patients had received the daily dose of vorinostat. 
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Selection of genes for verification analysis by RT-qPCR was based on both the 
relevance in the DNA damage response, which is recognized as a significant mechanism 
contributing to clinical radiation sensitivity [19], and previous indication of regulation by 
HDAC inhibitors. Five of the 33 genes were found to fulfill both criteria: MYC [20,21] 
among the ten genes repressed at T2 and correspondingly, GADD45B [22], MSH6 [23,24], 
BARD1 [25,26], and DDIT3 [27,28] among the 23 induced genes; mean PBMC expression 
levels at T0 relative to reference cell line expression are given in Table S5. These genes were 
present within the enriched biological processes and pathways identified by the functional 
annotation analysis of the differentially expressed genes (Table 2 and Table 3), and the 
biphasic pattern of regulation in PBMC through T2 and T24 was confirmed with significant 
time-dependent changes (P < 0.01) for all of the five genes (Figure 3). 
 
Vorinostat Activity in Experimental Tumors – Validation of Selected Biomarkers 
We have previously shown histone hyperacetylation in vorinostat-treated human 
colorectal carcinoma xenograft models (HCT116 and SW620), peaking three hours after 
vorinostat administration and with restored baseline levels of histone acetylation three to six 
hours later, without accumulative effect following repeat daily administration [8]. Hence, 
expression of the five selected genes was further assessed by RT-qPCR in HCT116 and 
SW620 xenografts, three and 12 hours after administering vorinostat to tumor-bearing mice; 
median control expression levels relative to reference cell line expression are given in Table 
S5. In the HCT116 model, a significant change (P < 0.05) in vorinostat-induced expression 
was found for MYC only. A similar transient MYC repression, but without statistically 
significant differences in expression levels through the time points, was seen in the SW620 
tumors (Figure 3). 
 
LARC – Primary Tumor MYC Expression 
On identifying MYC repression as a possible biomarker of HDAC inhibitor activity 
from the strategy of analyzing, firstly, PRAVO study patients’ PBMC, and secondly, 
vorinostat-treated colorectal carcinoma xenografts, and additionally recognizing this drug as 
a rational approach for biological optimization of radiation effect in pelvic gastrointestinal 
carcinoma [10], we investigated whether MYC might be expressed in the target tissue of a 
well-established pelvic radiotherapy protocol. In 27 LARC patients receiving neoadjuvant 
chemoradiotherapy [18], MYC expression was detected in all primary tumor samples, though 
at highly variable levels (median expression value was 0.47 (range 0.020–4.9) relative to 
reference cell line expression), but was essentially not associated with patient characteristics 
or treatment outcome in this small cohort (Table S2). 
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Figure 3. Validation of vorinostat-regulated expression of selected genes. Study patients’ 
peripheral blood mononuclear cells (PBMC) were sampled at baseline (T0) and on-treatment two (T2) 
and 24 (T24) hours after administration of the daily dose of the study medication vorinostat, and 
expression of MYC, GADD45B, MSH6, BARD1, and DDIT3 was analyzed by reverse transcriptase 
quantitative polymerase chain reaction (RT-qPCR). Correspondingly, mice bearing HCT116 or 
SW620 xenografts were injected intraperitoneally with vehicle (control, C) or vorinostat, and 
xenografts were harvested three (T3) and 12 (T12) hours after injection for RT-qPCR analysis of MYC 
expression. Relative gene expression (log2-fold change) for each comparison is given as mean ± 
SEM of the PBMC sample values (n = 14) and as median and range of the values from control (n = 8 
for HCT116; n = 4 for SW620) and vorinostat-treated (n = 4 for HCT116; n = 2 for SW620) xenografts. 
The compared gene expression levels were significantly different within the PBMC (P < 0.01) and 
HCT116 (P < 0.05) sample groups, while the differences were non-significant for the SW620 tumors. 
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Discussion 
 
Within the design of the PRAVO phase 1 study (Figure 1), combining the HDAC 
inhibitor vorinostat with fractionated radiation to pelvic targets volumes for determination of 
treatment tolerability and response, gene expression array analysis was performed of study 
patients’ PBMC, sampled at baseline (T0) and on-treatment two and 24 hours (T2 and T24) 
after the patient had received the daily dose of vorinostat, in order to identify possible 
biomarkers of HDAC inhibitor activity. This strategy revealed 1,600 array probes with 
biphasic pattern of expression from T0 through T2 and T24 across all of the study patients. A 
significant number of these genes were found implicated in processes comprising gene 
regulation, the cell cycle, and chromatin biology. Applying stringent criteria for array data 
analysis, five genes were recognized both as players in the DNA damage response and targets 
for regulation by HDAC inhibitors, and were therefore selected for validation of expression 
pattern both in study patients’ PBMC and in human colorectal carcinoma xenograft models. 
Of these, only MYC consistently showed rapid and transient repression in all conditions that 
were tested. 
In the setting of fractionated radiotherapy, a synergistic drug should preferably elicit a 
radiosensitizing molecular event at each radiation fraction; hence, a pharmacodynamic 
biomarker should reflect the timing of drug administration with regard to radiation exposure 
in a periodic manner [1]. Importantly, in a prior preclinical in vivo study combining 
vorinostat and fractionated radiation, we observed that tumor histone acetylation, considered 
a biomarker of vorinostat activity in the radiotherapy target tissue, reached a maximum three 
hours after intraperitoneal vorinostat injection into the experimental animals and was restored 
to baseline acetylation level three to six hours later, but with a repetitive, transient induction 
of acetylation following repeat injections. Of note, tumor growth inhibition after fractionated 
radiation, representing a long-term phenotypic outcome of the experimental manipulations, 
was significantly enhanced both when radiation was delivered at peak and restored histone 
acetylation levels [8]. Consequently, tumor histone hyperacetylation did not seem to be 
required at the time of radiation exposure, leaving the question of the optimum temporal 
relationship between administration of the radiosensitizing drug and radiation delivery 
unaddressed. 
In the PRAVO study, one patient at each vorinostat dose level had both baseline 
(before commencement of study treatment) and repeat tumor biopsy two-and-a-half hours 
after administration of vorinostat (on day 3 of the treatment protocol). Histone 
hyperacetylation was observed in all on-treatment biopsy samples [10], confirming the 
presence of vorinostat in the target at the time of the daily radiation exposure. However, 
given that one of the objectives of the study was to determine mechanisms of the presumed 
radiosensitizing action of vorinostat that were not simultaneously manifesting molecular 
perturbations elicited by the radiation itself, non-irradiated surrogate tissue was collected for 
the purpose of identifying new biomarkers. Several investigators have demonstrated PBMC 
histone hyperacetylation on HDAC inhibitor treatment [14,29,30]. With these aspects in 
mind, PBMC were deemed to represent a relevant surrogate tissue for studying 
radiosensitizing effects of vorinostat in the context of this clinical trial. 
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Interestingly, using the study patients’ PBMC as surrogate tissue for vorinostat 
exposure, all of the 1,600 probes that were found to be common for the comparisons T2 
versus T0 and T24 versus T2 in principle represented pharmacodynamic biomarkers of the 
chosen timing of vorinostat administration in the fractionated radiotherapy protocol. The 
genes showed rapid and transient induction or repression, thus mirroring the kinetics of the 
histone acetylation response. This observation implies that the design of the PRAVO study, 
undertaken in patients with advanced gastrointestinal cancer, may not have provided the 
optimum context for detailed capture of molecular effects of vorinostat. Thus, ethical 
concerns may challenge the structure required within a clinical trial setting for evaluating 
novel biomarker endpoints. Nevertheless, in the PRAVO study, functional annotation 
analysis of the panel of 1,600 probes identified biological processes and pathways comprising 
gene regulation (transcription, RNA processing), cell cycle progression (including p53 
signaling, commonly involved in the DNA damage response), and chromatin biology. These 
findings are consistent with well-known cellular perturbations following exposure of 
experimental tumor models to HDAC inhibitors [2–5]. 
Investigation of biomarkers of HDAC inhibitor activity has been undertaken in a 
number of clinical therapy trials. These include the demonstration of increased histone 
acetylation in patients’ PBMC in the early trials [14,29,30] and the more recent confirmation 
of changes in tumor expression of acetylated histone and non-histone proteins [10,14,31,32], 
the HDAC2 enzyme [31] and HR23B protein [32,34], the latter been proposed as predictive 
biomarker [35], and of tumor proliferation index [36]. Plasma protein profiling has been done 
in glioblastoma patients receiving vorinostat in combination with an established cytotoxic 
regimen [37]. Furthermore, tumor gene expression array analysis has been performed in a 
study with the HDAC inhibitor panobinostat as single agent [38] and in one trial each of 
combining either vorinostat or valproate with other biologic agents (in non-small cell lung 
carcinoma and acute myeloid leukemia, respectively) [39,40]. To our knowledge, the present 
study is the first to report on gene expression array analysis as an attempt to identify 
pharmacodynamic biomarker(s) reflecting timing of HDAC inhibitor administration with 
regard to an established cytotoxic regimen. 
The criteria for selecting genes for validation were both their presumed relevance in 
the DNA damage response and previous indications of regulation by an HDAC inhibitor [22–
24,28,41], and additionally, in order to find ‘tumor-specific’ markers, omitting genes that 
typically might be associated with leukocyte biology. Four of the selected genes were 
induced by vorinostat in the study patients’ PBMC but did not show a similar response in the 
experimental tumor models. BARD1 encodes a nuclear factor with tumor suppressor activity 
[24], the stress response effectors encoded by GADD45B and DDIT3 are implicated in cell 
cycle arrest, DNA repair, and apoptosis [42,43], and MSH6 encodes a DNA mismatch repair 
protein [44]. To date, only three studies seem to have been published on their potential use as 
biomarkers of therapy response [45–47]. In contrast, the confirmation of MYC as the only one 
of the selected genes with rapid and transient change in expression in all tested conditions 
(i.e., both in the study patients’ PBMC and experimental tumor models) may point to a 
particular importance of myc in the therapeutic setting with fractionated radiation. Future 
investigations of vorinostat as possible radiosensitizing agent might be within a long-term 
curative radiotherapy protocol, for example as an additional component of neoadjuvant 
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chemoradiotherapy for LARC. The confirmed presence of MYC expression in the intended 
radiotherapy target tissue (primary rectal tumors) in LARC patients encourages future 
exploration of this proto-oncogene as a novel biomarker endpoint. 
The myc protein acts both as transcriptional activator and repressor, regulating a 
myriad of genes that collectively conduct cell cycle progression, apoptosis, angiogenesis, and 
genetic instability [48]. Specifically, it has been suggested that myc activates DNA damage 
repair genes [20], and interestingly, that myc in hypoxic tumors acts synergistically with the 
transcription factor hypoxia-inducible factor type 1 , HIF-1  [49,50]. Recent evidence 
indicates that HDAC inhibition suppresses HIF-1  activity [51,52]. Consequently, mitigation 
of DNA damage repair capacity through suppression of myc/HIF-1  synergy in hypoxic 
tumors [53,54], typically being resistant to radiation, provides an appealing explanation for 
the radiosensitizing effect of HDAC inhibitors. 
However, conflicting data have been presented as to how HDAC inhibition may 
influence the myc protein itself. Whereas inhibition of various HDAC enzymes has been 
shown to cause myc repression in a range of human cancer cell lines [21,55– 57], which 
corresponds well with the data in the present study, specific nuclear induction of myc to 
mediate HDAC inhibitor-induced apoptosis in glioblastoma cell lines has also been 
demonstrated [58]. Interestingly, in nasopharyngeal carcinoma cells that were resistant to 
radiation, myc was found to be essential through the transcriptional activation of cell cycle 
checkpoint kinases [59], which are signaling factors implicated in DNA damage repair, 
thereby facilitating tumor cell survival following radiation exposure. On the contrary, 
although radiosensitization was conferred by HDAC inhibition both in hypoxic and normoxic 
hepatocellular carcinoma cells, a lower level of myc expression was associated with the 
hypoxic and more radioresistant condition [60]. Of particular note, in the present study, the 
vorinostat-induced repression of MYC was found both in study patients’ PBMC, clearly 
representing normoxic tissue, and experimental tumors that also were tested under normoxic 
conditions. 
In conclusion, integral in the PRAVO study design was the collection of non-
irradiated surrogate tissue for the identification of biomarker(s) of vorinostat activity to 
reflect the timing of administration and also suggest the mechanism of action of the HDAC 
inhibitor. This objective was achieved by gene expression array analysis of study patients’ 
PBMC and as a consequence, the identification of genes that from experimental models are 
known to be implicated in biological processes and pathways governed by HDAC inhibitors. 
Importantly, all of the identified genes showed rapid and transient induction or repression and 
therefore, in principle, fulfilled the requirement of being pharmacodynamic biomarkers for 
this radiosensitizing drug in fractionated radiotherapy. Among the identified candidate genes, 
MYC repression was found in all patient samples and tested experimental conditions, possibly 
underscoring the impact of the myc proto-oncogene in this particular therapeutic setting. 
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Supplementary Table 2. The Locally Advanced Rectal Cancer – Radiation response 
Prediction (LARC-RRP) phase 2 study (ClinicalTrials NCT00278694) – patient and treatment 
characteristics 
 
N (%) 
At baseline 
Median age, years (range) 56 (30–70) 
Gender 
  Male 15 (55.6) 
  Female 12 (44.4) 
T-status 
  T3 12 (44.4) 
  T4 15 (55.6) 
N-status 
  N0 3 (11.1) 
  N1 2 (7.4) 
  N2 22 (81.5) 
M-status 
  M0 23 (85.2) 
  M1 4 (14.8) 
Radiological response 
yT-status 
  yT0 0 
  yT1 0 
  yT2 1 (3.7) 
  yT3 13 (48.1) 
  yT4 13 (48.1) 
yN-status 
  yN0 11 (40.2) 
  yN1 4 (14.8) 
  yN2 12 (44.4) 
Histological response 
ypT-status 
  ypT0 3 (11.1) 
  ypT1 0 
  ypT2 3 (11.1) 
  ypT3 12 (44.4) 
  ypT4 8 (29.6) 
  missing 1 (3.7) 
ypN-status 
  ypN0 13 (48.1) 
  ypN1 10 (37.0) 
  ypN2 3 (11.1) 
Tumor Regression Grade * 
  TRG 1 (ypT0) 3 (11.1) 
  TRG 2 (sparsely remaining tumor) 13 (48.1) 
  TRG 3 (intermediate response) 6 (22.2) 
 22 
  TRG 4 (poor response) 4 (14.8) 
  TRG 5 (poor response) 0 
  missing 1 (3.7) 
Clinical outcome 
  Development of metastatic disease ** 12 (52.2) 
 
 
 
The LARC-RRP study was conducted in patients with locally advanced rectal cancer 
receiving neoadjuvant chemoradiotherapy (CRT). Data from a subgroup of 27 study patients 
are presented here. This population was enrolled between July 2008 and March 2010. Patient 
eligibility criteria, evaluation procedures, study treatment, and review procedures of follow-up 
have been described in detail previously ***. Patients were treated with neoadjuvant 
fluoropyrimidine-/oxaliplatin-based chemotherapy and CRT, followed by surgery. Follow-up 
data was obtained from the clinical database and censored on August 31, 2012 **. Valid 
observations of the presence or absence of distant metastases required designated radiologic 
examination. Four patients with synchronous resectable liver metastases were excluded from 
analysis of metastasis-free survival **. Data analysis was performed using Predictive 
Analytics SoftWare Statistics version 16.0 (SPSS Inc., Chicago, IL). No association of tumor 
MYC expression (median value 0.47, range 0.020–4.9; mean value 0.70 ± 0.20) and patient 
characteristics or treatment outcome was found. 
 
* Histologic Tumor Regression Grading (TRG) of tumor CRT response was graded within one 
of five TRG categories, spanning from the absence of residual tumor cells in the surgical 
specimen (histologic complete response; TRG 1) to the lack of morphologic signs of tissue 
response to treatment (TRG 5). 
 
** Censored at a median period of 33 months (range 5–45) 
 
*** Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK et al. Prediction of response to 
preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J 
Radiat Oncol Biol Phys 2010; 78, 555–62 
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Supplementary Table 4. Gene Ontology (GO) enriched biological processes in patients’ 
peripheral blood mononuclear cells during 24 hours of vorinostat treatment 
 
Biological Process N % P-value 
 
T2 versus T0 
GO:0006350 transcription 253 17 5.1  10-14 
GO:0044265 cellular macromolecule catabolic process 107 7.2    8.2  10-10 
GO:0044257 cellular protein catabolic process 93 6.3 1.7  10-10 
GO:0007049 cell cycle 111 7.5 2.4  10-10 
GO:0051603 proteolysis involved in cellular protein catabolic 
process 92 6.2 2.9  10-10 
GO:0019941 modification-dependent protein catabolic 
process 89 6.0 3.4  10-10 
GO:0043632 modification-dependent macromolecule 
catabolic process 89 6.0 3.4  10-10 
GO:0009057 macromolecule catabolic process 111 7.5 3.4  10-10 
GO:0030163 protein catabolic process 94 6.3 4.0  10-10 
GO:0006396 RNA processing 84 5.7 1.8  10-9 
GO:0045449 regulation of transcription 276 19 5.0  10-9 
GO:0022402 cell cycle process 79 5.3 3.4  10-7 
GO:0008380 RNA splicing 48 3.2 5.4  10-7 
GO:0051276 chromosome organization 70 4.7 5.4  10-7 
GO:0006366 transcription from RNA polymerase II promoter 42 2.8 6.2  10-7 
GO:0016568 chromatin modification 46 3.1 1.2  10-6 
GO:0006351 transcription, DNA-dependent 48 3.2 1.2  10-6 
GO:0032774 RNA biosynthetic process 48 3.2 1.8  10-6 
GO:0016071 mRNA metabolic process 56 3.8 2.0  10-6 
GO:0000278 mitotic cell cycle 56 3.8 2.0  10-6 
GO:0006259 DNA metabolic process 69 4.6 5.0  10-6 
GO:0006397 mRNA processing 49 3.3 7.7  10-6 
GO:0006325 chromatin organization 55 3.7 8.3  10-6 
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GO:0045184 establishment of protein localization 93 6.3 1.6  10-5 
GO:0015031 protein transport 92 6.2 1.9  10-5 
GO:0006974 response to DNA damage stimulus 52 3.5 4.9  10-5 
GO:0006511 ubiquitin-dependent protein catabolic process 38 2.6 5.1  10-5 
GO:0022403 cell cycle phase 56 3.8 5.6  10-5 
GO:0008104 protein localization 101 6.8 6.1  10-5 
GO:0051726 regulation of cell cycle 47 3.2 7.6  10-5 
GO:0033554 cellular response to stress 69 4.6 1.8  10-4 
GO:0034660 ncRNA metabolic process 35 2.4 1.9  10-4 
GO:0034470 ncRNA processing 30 2.0 2.5  10-4 
GO:0010605 negative regulation of macromolecule metabolic 
process 84 5.7 2.8  10-4 
GO:0043933 macromolecular complex subunit organization 81 5.5 4.1  10-4 
GO:0010604 positive regulation of macromolecule metabolic 
process 94 6.3 5.0  10-4 
GO:0006281 DNA repair 39 2.6 6.7  10-4 
GO:0051301 cell division 40 2.7 7.1  10-4 
GO:0048285 organelle fission 33 2.2 8.2  10-4 
GO:0051252 regulation of RNA metabolic process 176 11 8.8  10-4 
GO:0000279 M phase 43 2.9 9.2  10-4 
GO:0065003 macromolecular complex assembly 75 5.1 9.5  10-4 
GO:0000087 M phase of mitotic cell cycle     32 2.2 0.001 
GO:0007067 mitosis 31 2.1 0.002 
GO:0000280 nuclear division 31 2.1 0.002 
GO:0016265 death 79 5.3 0.002 
GO:0006508 proteolysis 108 7.3 0.002 
GO:0006355 regulation of transcription, DNA-dependent 170 11 0.002 
GO:0008219 cell death 78 5.3 0.002 
GO:0070727 cellular macromolecule localization 49 3.3 0.003 
GO:0045941 positive regulation of transcription 63 4.2 0.003 
GO:0045934 negative regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 58 3.9 0.003 
GO:0045935 positive regulation of nucleobase, nucleoside, 
68 4.6 0.004 
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nucleotide and nucleic acid metabolic process 
GO:0010628 positive regulation of gene expression 64 4.3 0.004 
GO:0032268 regulation of cellular protein metabolic process 54 3.6 0.004 
GO:0034613 cellular protein localization 48 3.2 0.005 
GO:0051186 cofactor metabolic process 27 1.8 0.005 
GO:0051172 negative regulation of nitrogen compound 
metabolic process 58 3.9 0.005 
GO:0051248 negative regulation of protein metabolic process 26 1.8 0.005 
GO:0012501 programmed cell death 66 4.4 0.005 
GO:0046907 intracellular transport 70 4.7 0.006 
GO:0010629 negative regulation of gene expression 56 3.8 0.006 
GO:0032269 negative regulation of cellular protein metabolic 
process 25 1.7 0.006 
GO:0006461 protein complex assembly 56 3.8 0.006 
GO:0070271 protein complex biogenesis 56 3.8 0.006 
GO:0051173 positive regulation of nitrogen compound 
metabolic process 68 4.6 0.008 
GO:0006915 apoptosis 64 4.3 0.009 
GO:0016481 negative regulation of transcription 51 3.4 0.009 
GO:0031328 positive regulation of cellular biosynthetic 
process 71 4.8 0.010 
 
 
T24 versus T2 
 
GO:0006350 transcription 260 17 8.3  10-16 
GO:0007049 cell cycle 114 7.6 2.6  10-11 
GO:0045449 regulation of transcription 286 19 5.4  10-11 
GO:0016568 chromatin modification 55 3.7 1.3  10-10 
GO:0006396 RNA processing 86 5.7 3.7  10-10 
GO:0044265 cellular macromolecule catabolic process 104 6.9 8.8  10-10 
GO:0051276 chromosome organization 78 5.2 9.0  10-9 
GO:0022402 cell cycle process 85 5.7 4.0  10-9 
GO:0044257 cellular protein catabolic process 89 5.9 4.3  10-9 
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GO:0009057 macromolecule catabolic process 107 7.1 6.4  10-9 
GO:0051603 proteolysis involved in cellular protein catabolic 
process 88 5.9 7.4  10-9 
GO:0019941 modification-dependent protein catabolic 
process 85 5.7 8.8  10-9 
GO:0043632 modification-dependent macromolecule 
catabolic process 85 5.7 8.8  10-9 
GO:0030163 protein catabolic process 90 6.0 9.4  10-9 
GO:0006325 chromatin organization 62 4.1 3.0  10-8 
GO:0006259 DNA metabolic process 75 5.0 7.2  10-8 
GO:0000278 mitotic cell cycle 57 3.8 9.7  10-7 
GO:0006351 transcription, DNA-dependent 48 3.2 1.3  10-6 
GO:0006366 transcription from RNA polymerase II promoter 41 2.7 1.7  10-6 
GO:0032774 RNA biosynthetic process 48 3.2 1.9  10-6 
GO:0008380 RNA splicing 46 3.1 3.3  10-6 
GO:0016071 mRNA metabolic process 55 3.7 4.6  10-6 
GO:0006397 mRNA processing 48 3.2 1.7  10-6 
GO:0016570 histone modification 25 1.7 1.9  10-6 
GO:0016569 covalent chromatin modification 25 1.7 3.3  10-5 
GO:0033554 cellular response to stress 72 4.8 3.5  10-5 
GO:0045184 establishment of protein localization 91 6.1 4.8  10-5 
GO:0006974 response to DNA damage stimulus 52 3.5 5.1  10-5 
GO:0015031 protein transport 90 6.0 5.7  10-5 
GO:0006281 DNA repair 42 2.8 8.0  10-5 
GO:0043933 macromolecular complex subunit organization 84 5.6 9.9  10-5 
GO:0022403 cell cycle phase 55 3.7 1.1  10-4 
GO:0007050 cell cycle arrest 21 1.4 1.1  10-4 
GO:0006511 ubiquitin-dependent protein catabolic process 36 2.4 2.6  10-4 
GO:0034470 ncRNA processing 30 2.0 2.6  10-4 
GO:0051252 regulation of RNA metabolic process 180 12 2.8  10-4 
GO:0010605 negative regulation of macromolecule metabolic 
process 84 5.6 2.9  10-4 
GO:0051726 regulation of cell cycle 45 3.0 3.1  10-4 
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GO:0051338 regulation of transferase activity 49 3.3 3.3  10-4 
GO:0065003 macromolecular complex assembly 77 5.1 3.8  10-4 
GO:0008104 protein localization 97 6.5 3.9  10-4 
GO:0045859 regulation of protein kinase activity 46 3.1 3.9  10-4 
GO:0048285 organelle fission 34 2.3 4.0  10-4 
GO:0034660 ncRNA metabolic process 34 2.3 4.4  10-4 
GO:0043549 regulation of kinase activity 47 3.1 4.6  10-4 
GO:0006355 regulation of transcription, DNA-dependent 175 11 4.8  10-4 
GO:0016265 death 82 5.5 4.8  10-4 
GO:0008219 cell death 81 5.4 6.3  10-4 
GO:0070727 cellular macromolecule localization 52 3.5 6.6  10-4 
GO:0042325 regulation of phosphorylation 57 3.8 6.8  10-4 
GO:0051301 cell division 40 2.7 7.3  10-4 
GO:0042981 regulation of apoptosis 88 5.9 8.7  10-4 
GO:0000280 nuclear division 32 2.1 8.8  10-4 
GO:0007067 mitosis 32 2.1 8.8  10-4 
GO:0034613 cellular protein localization 51 3.4 9.8  10-4 
GO:0051174 regulation of phosphorus metabolic process 58 3.9 0.001 
GO:0019220 regulation of phosphate metabolic process 58 3.9 0.001 
GO:0043067 regulation of programmed cell death 88 5.9 0.001 
GO:0000087 M phase of mitotic cell cycle 32 2.1 0.001 
GO:0045941 positive regulation of transcription 65 4.3 0.001 
GO:0010941 regulation of cell death 88 5.9 0.001 
GO:0045934 negative regulation of nucleobase, nucleoside,  
nucleotide and nucleic acid metabolic process 60 4.0 0.001 
GO:0012501 programmed cell death 69 4.6 0.002 
GO:0006461 protein complex assembly 59 3.9 0.002 
GO:0070271 protein complex biogenesis 59 3.9 0.002 
GO:0006352 transcription initiation 16 1.1 0.002 
GO:0000279 M phase 42 2.8 0.002 
GO:0010628 positive regulation of gene expression 66 4.4 0.002 
 29 
GO:0010604 positive regulation of macromolecule metabolic 
process 91 6.1 0.002 
GO:0006399 tRNA metabolic process 20 1.3 0.002 
GO:0006473 protein amino acid acetylation 12 0.8 0.002 
GO:0051172 negative regulation of nitrogen compound 
metabolic process 60 4.0 0.002 
GO:0008033 tRNA processing 15 1.0 0.002 
GO:0006886 intracellular protein transport 46 3.1 0.002 
GO:0043065 positive regulation of apoptosis 51 3.4 0.003 
GO:0034621 cellular macromolecular complex subunit 
organization 44 2.9 0.003 
GO:0045935 positive regulation of nucleobase, nucleoside, 
nucleotide  
and nucleic acid metabolic process 69 4.6 0.003 
GO:0006915 apoptosis 67 4.5 0.003 
GO:0043068 positive regulation of programmed cell death 51 3.4 0.003 
GO:0051188 cofactor biosynthetic process 17 1.1 0.003 
GO:0010942 positive regulation of cell death 51 3.4 0.003 
GO:0006368 RNA elongation from RNA polymerase II 
promoter 11 0.7 0.003 
GO:0046907 intracellular transport 71 4.7 0.004 
GO:0000394 RNA splicing, via endonucleolytic cleavage and 
ligation 4 0.3 0.004 
GO:0006388 tRNA splicing, via endonucleolytic cleavage and 
ligation 4 0.3 0.004 
GO:0031327 negative regulation of cellular biosynthetic 
process 62 4.1 0.004 
GO:0009890 negative regulation of biosynthetic process 63 4.2 0.005 
GO:0031400 negative regulation of protein modification 
process 19 1.3 0.005 
GO:0051186 cofactor metabolic process 27 1.8 0.005 
GO:0006916 anti-apoptosis 28 1.9 0.005 
GO:0006354 RNA elongation 11 0.7 0.005 
GO:0051173 positive regulation of nitrogen compound 
metabolic process 69 4.6 0.005 
GO:0010557 positive regulation of macromolecule 
biosynthetic process 70 4.7 0.005 
 30 
GO:0032259 methylation 14 0.9 0.005 
GO:0006367 transcription initiation from RNA polymerase II 
promoter 13 0.9 0.006 
GO:0016481 negative regulation of transcription 52 3.5 0.006 
GO:0043543 protein amino acid acylation 12 0.8 0.006 
GO:0010558 negative regulation of macromolecule 
biosynthetic process 60 4.0 0.006 
GO:0022613 ribonucleoprotein complex biogenesis 25 1.7 0.006 
GO:0006732 coenzyme metabolic process 22 1.5 0.008 
GO:0042791 5S class rRNA transcription 4 0.3 0.008 
GO:0042797 tRNA transcription from RNA polymerase III 
promoter 4 0.3 0.008 
GO:0000079 regulation of cyclin-dependent protein kinase 
activity 11 0.7 0.008 
GO:0010629 negative regulation of gene expression 55 3.7 0.009 
GO:0006412 translation 39 2.6 0.010 
GO:0009891 positive regulation of biosynthetic process 72 4.8 0.010 
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